Iris Biotech

LINKEROLOGY®

Version: IB6_1

Empowering Peptide Innovation

With this guiding theme in mind, Iris Biotech's mission is to support researchers by supplying

- innovative technologies,
- rare compounds,
- as well as a broad portfolio on standard consumables,

available in flexible quantities from small scale to bulk quantities. To fulfill our dedication "Empowering Peptide Innovation", we are attending various conferences, symposia, and exhibitions each year. This allows us to remain in direct contact with scientists all over the world, both from academia and industry, to exchange knowledge, and to gather new ideas to tackle your current challenges.

Guided by our dedication to provide

- competent service,
- as well as novel substances and
- latest technologies,

Iris Biotech is your trusted partner for the world of peptides, while having strong expertise in associated disciplines. Thus, our portfolio comprises reagents and tools for the synthesis and purification of peptides, e.g. amino acids, resins and solvents but also for related technologies such as Drug Delivery and Linkerology® and Life Sciences.

Amino Acids ***Building Blocks*** ***Life Sciences*** ***Drug Delivery*** ***Reagents*** ***Resins*** ***Linkerology®*** ***Kits***

Owed to the growing demand for tailor-made compounds, our portfolio is fine-tuned by our Custom Synthesis Service at Iris Biotech Laboratories. Our skilled scientists offer profound expertise in

- *de novo* route development,
- upscaling towards larger scale production,
- as well as synthesis optimization for increased efficiency.

Examples are the synthesis of rare chiral building blocks, unnatural amino acid derivatives, sophisticated orthogonal protecting groups, heterocycles, building blocks for nucleotides, PEGs and PEG-analogues as well as specific linkers for controlled drug delivery and release.

Portfolio Overview

Peptide Synthesis, Modification and Purification

(Protected) Amino Acids

Standards such as Fmoc-D/L-AAA and Boc-D/L-AAA, variety of protecting groups (e.g. Pbf, Trt, ^{t}Bu, Bzl, Acm, Mob, SIT, Phacm, Allocam, Mmt), unusual amino acids, fluorinated derivatives, substituted prolines, arginine analogues

Building Blocks

Amino alcohols, amino aldehydes, diamines and hydrazines, (pseudoproline) dipeptides, polyamines and spermines, fatty acid derivatives

Reagents

Coupling reagents, solvents and scavengers, protecting groups

Resins

Preloaded resins (e.g. based on Trityl, TCP, TentaGel, Methoxybenzhydryl, Merrifield, PAM, Rink, Wang), scavenger resins, hydrazone resins

Kits

Chromatography-free peptide purification and modification by Peptide Easy Clean (PEC)

Linkerology ® and Drug Delivery

Linkers for Solid Phase Peptide Synthesis

Cleavable Linkers

Val-Ala based, Val-Cit based, disulfide based, Dde-helping hands

Photo-Activatable Linkers

Functionalized Linkers

Clickable linkers, trifunctional linkers, linkers with maleimide function, cross-linkers, selective N-term acylation and biotinylation

PROTACs

Ligands, linkers & modules

Fullerenes & Poly(2-oxazolines)

Poly-Amino Acids

Poly-Arg, Poly-Glu, Poly-Lys, Poly-Orn, Poly-Sar

PEGylation

Branched PEGylating reagents, (amino-)PEG-acids, PEG-amines & hydrazides & guanidines, reagents for Click-conjugation, Biotin-PEG-reagents, PEG-thiols, PEG-maleimides, other PEGylating reagents

Life Sciences

Carbohydrates

Galactose, Glucose, Maltose, Mannose, Xylose and others

Drug Metabolites

Peptides

Substrates & Inhibitors

E.g. protein kinase inhibitors, substrates for fusion (Halo/Snap/Clip)-tagged proteins

Natural Products

Dyes and Fluorescent Labels

E.g. ICG, AMC, DAPI

Maillard & Amadori Reaction Products

Large portfolio of derivatives useful as standards for food, pharma and cosmetics industry

Vitamins

Custom Synthesis

Your project requires a compound not listed in our portfolio?
Get in contact and inquire about our custom synthesis capabilities.

Our experienced scientists are excited to accept your synthetic challenge!
In such cases, your request undergoes the following stages:



Step-by-Step Analysis

- Customer's demands

Process Evaluation

- Detailed literature review
- Synthetic possibilities

Strategy Development

- Protocol development
- Method development and validation
- Customized synthesis

Quality Consistency

- Identity confirmation
- Purity verification

Our Service Promise

All our services are based on high standards, transparency & documentation, trust, honesty & confidentiality, as well as the required know-how.

High Standards

- Values: sustainability & responsibility
- State-of-the-art equipment & latest technologies
- High quality standards
- Qualified suppliers & regular audits

Transparency & Documentation

- Talk to our specialists – customer care
- Certificates of analysis & impurity profiling
- Analytical and process reports

Trust, Honesty & Confidentiality

- Intergenerational business valuing partnerships
- Meeting the customer's expectations
- Integrity towards our customers

Our Know-How

- One-step reactions & complex multi-step synthesis
- Scalability from mg to kg quantities
- Route scouting

Linkerology®

1. The Concept of Antibody-Drug Conjugation (ADC)

1.1. Technical and Market Background

Conjugating highly potent small molecules to vastly target specific biomolecules, like antibodies, has become a modern and sophisticated approach, particularly in the field of cancer therapy. The list of ADCs in clinics continues to grow, bolstered by the success of two pioneers in this field:

Adcetris® (Seattle Genetics) has been approved in 2011 for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma (ALCL) and reached $476.9 million sales per year in 2018. This drug is composed of a monoclonal antibody targeting CD30 conjugated to four molecules of monomethyl auristatin E *via* a self-immolative linkage (*Fig. 1*). Reduction of interchain disulfide bonds provides reactive cysteine residues, which are then conjugated with maleimide payload linker systems, yielding the final drug compound.



Fig. 1: Composition of Adcetris®, one of the first FDA-approved ADCs.

Kadcyla®, another pioneer in this field, has been approved in 2013 for the treatment of HER-2 positive metastatic breast cancer and reached $981 million sales per year in 2018. In this case, payloads are conjugated to surface accessible lysines resulting in a heterogeneous modification of the core antibody.

Reference:

→ *Antibody-drug conjugates in tumor therapy; B. Sammet, C. Steinkuhler, N. Sewald;* ***Pharm Pat Anal*** *2012; **1**: 65-73. https://doi.org/10.4155/ppa.12.4*

IC_{50}
Inhibitory Concentration
Concentration causing 50% of maximal inhibition of the desired activity.

EC_{50}
Effective Concentration
Concentration causing 50% of maximal response of the desired effect.

ED_{50}
Effective Dose
Dose causing the desired effect in 50% of individuals.

GI_{50}
Growth Inhibition
Concentration causing 50% inhibition of cell proliferation/cell growth.

TC_{50}
Toxic Concentration
Concentration causing a defined toxic effect in 50% of individuals.

TD_{50}
Toxic Dose
Dose causing a defined toxic effect in 50% of individuals.

CC_{50}
Cytotoxic Concentration
Concentration killing 50% of cells.

LC_{50}
Lethal Concentration
Concentration killing 50% of individuals.

LD_{50}
Lethal Dose
Dose killing 50% of individuals.

ADCs – Mode of Action

The typical mode of action of ADCs is shown in Figure 2. An ADC circulates in plasma until it reaches the target cell. The antibody portion of an ADC then nails to a cell-surface antigen that is ideally specific to a cancer cell. Upon binding, the ADC-antigen protein complex becomes internalized into the cancer cell. When the complex is degraded, it releases the cytotoxin which then binds to its target to cause cancer cell apoptosis. The linker between antibody and payload is typically either permanent or cleavable by hydrolases, such as the protease cathepsin B, by glucoronidases or through reductive conditions and the presence of glutathion.



Fig. 2: Mode of action of ADCs.

back to content ↑

This concept is a sophisticated approach combining the high specificity of antibodies with the high potency of (small) drug molecules. The disadvantages of antibodies, like low potency, as well as the drawbacks of small drug molecules, like low specificity accompanied by high toxicity through many side effects, are compensated by the advantages of the other counterpart. A smart synergistic combination of both elements significantly enlarges the narrow therapeutic window of a small drug molecule between minimum (efficacious) and maximum (toxic) dosage (*Fig. 3*). ADC drugs expand the therapeutic window, as they can increase efficacy and decrease toxicity in comparison to traditional chemotherapeutic cancer treatments. Targeted delivery to cancer cells increases the amount of dosed drug reaching the tumor, thus lowering the minimum effective dose (MED). The maximum tolerated dose (MTD) is increased, as less drug reaches healthy, non-target tissues.



Fig. 3: The therapeutic window is significantly enlarged using ADCs compared to small-molecule drugs.

References:

- *L. Anthony, (2019). ADC Landscape Review 2019 [PowerPoint slides]. Retrieved from http://worldadc-usa.com*
- *Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload; A. C. Tiberghien, J. N. Levy, L. A. Masterson, N. V. Patel, L. R. Adams, S. Corbett, D. G. Williams, J. A. Hartley, P. W. Howard;* ***ACS Med Chem Lett*** *2016;* ***7****: 983-987. https://doi.org/10.1021/acsmedchemlett.6b00062*
- *Recent advances of antibody drug conjugates for clinical applications; P. Zhao, Y. Zhang, W. Li, C. Jeanty, G. Xiang, Y. Dong;* ***Acta Pharmaceutica Sinica B*** *2020;* ***10(9)****: 1589-1600. https://doi.org/10.1016/j.apsb.2020.04.012*

In 2019, there were approximately 100 ADCs in various phases of clinical development, of which some 20 ADCs were carrying auristatins, PBD derivatives, and maytansines, respectively (*Fig. 4*).

YEAR	USA	EU & UK	JAPAN	CHINA
2011	ADCETRIS			
2012		ADCETRIS		
2013	Kadcyla	Kadcyla		
2014			ADCETRIS, Kadcyla	
2015				
2016				
2017	BESPONSA, MYLOTARC	BESPONSA		
2018	LUMOXITI	MYLOTARC		
2019	POLIVY, ENHERTU, PADCEV			
2020	TRODELVY, BLENREP	BLENREP, POLIVY	AKALUX, ENHERTU	ADCETRIS, Kadcyla
2021	Zynlonta, Tivdak	ENHERTU		Disitamab Vedotin

Fig. 4: Global Approved ADCs (2021).

While initially only small molecules or short peptides have been used as payloads, the panel of conjugates has opened to chelators for radioactive nuclides and larger biomolecules, such as toxic enzymes. Additional variations have been introduced on the antibody side by utilizing antibody fragment combinations or diabodies (*Fig. 5*).



Fig. 5: The concept of antibody-drug conjugation can be extended from conjugations of small cytotoxic molecules to conjugation with chelators for radionuclides, proteins or with antibody fragments.

Points of conjugation are typically the thiol groups of cysteines, the amino functions of lysines or the N-terminus of a monoclonal antibody. Due to the inherent heterogeneity of conjugation to the multiple amines or cysteines found in mAbs, significant research efforts are directed toward the production of discrete, homogeneous ADC products *via* site-specific conjugation. This may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally reactive functional handle such as an aldehyde, ketone, azido, or alkynyl tag. These site-specific approaches increase the homogeneity of ADCs and enable novel bioorthogonal chemistries which utilize, reactive moieties rather than thiols or amines. This broad diversity of applicable linkers can then be utilized leading to improved design in future generations of ADCs.

References:

→ *Site-specific antibody drug conjugates for cancer therapy; S. Panowski, S. Bhakta, H. Raab, P. Polakis, J. R. Junutula;* ***MAbs*** *2014;* ***6****: 34-45. https://doi.org/10.4161/mabs.27022*

→ *Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy; U. B. Hagemann, K. Wickstroem, S. Hammer, R. M. Bjerke, S. Zitzmann-Kolbe, O. B. Ryan, J. Karlsson, A. Scholz, H. Hennekes, D. Mumberg , A. S. Cuthbertson;* ***Cancer Biother Radiopharm*** *2020;* ***35(7)****: 497-510. https://doi.org/10.1089/cbr.2020.3568*

back to content ↑

1.2. Linker Design, Connectivity, Degradability, and Drug-Antibody Ratio (DAR)

Antibody-drug conjugates (ADCs), which combine the specificity, favorable pharmacokinetics, and biodistribution of a monoclonal antibody (mAb) with the cytotoxic potency of a drug are promising new therapeutics for cancer. Along with the development of monoclonal antibodies (mAbs) and cytotoxic drugs, the design of the linker is essential, as it impacts the efficacy and tolerability of ADCs. The linker needs to provide sufficient stability during systemic circulation while providing rapid and efficient release of the cytotoxic drug in its active state inside the tumor cells.

Antibody	Linker			Payload
Natural Connectivities: thiols (Cys) amines (Lys) 	Conjugation	Cleavable Part	Traceless Part	
	Chemically: maleimide disulfide acid/active ester Click tetrazine/TCO His-Tag specific acylation	***Hydrolases:*** Val-Ala Val-Cit Phe-Lys Gly-Phe-Leu-Gly Ala-Leu-Ala-Leu cyclobutyl-Ala cyclobutyl-Cit glucuronic acid		
Artificial Connectivities: azides and alkynes peptides (ligases) His-Tag	***Enzymatically:*** $(Gly)_3$-linker ligase substrate	***Oxidoreductases:*** $-CH_2-S-S-CH_2-$ $-CH_2-S-S-CHMe-$ $-CH_2-S-S-CMe_2-$		
		low pH: $-O-Si(iPr_2)-O-$		

Fig. 6: Conceptual overview of antibody-drug conjugation.



Fig. 7: Drug-antibody ratio (DAR) is an important parameter of an ADC. Low DAR could reduce the antitumor efficacy, while high DAR may affect antibody structure, stability, and antigen binding etc. therefore causing loss of activity. DAR values are also important for the therapeutic index of ADCs. In most ADC drug candidates, the DAR values were maintained at about 2-4. Hence, controlling DAR during ADC preparation is a key procedure. Figure provided by Glycotope.

The type of linkage between payload and biomolecule can basically either be permanent or cleavable under certain well-defined circumstances (*Fig. 6*). As payloads typically are highly cytotoxic, it would be fatal if they were released from their carrier during circulation in plasma. Hence, the linker part should be stable to conditions such as pH, redox potential, presence of proteases in plasma, and all other parameters of plasma. However, after internalization it is favorable that the linker is fragmenting in order to release the drug molecule, ideally in a traceless manner. Conjugations with the antibody can rather easily be achieved using active esters forming amide bonds with lysines, which are usually accessible in a high number on the surface. The resulting conjugate, hence, is rather heterogenic with different numbers of payloads attached at different positions. A more and well-defined drug-antibody ratio (DAR) can be achieved by utilizing the disulfide bridges between heavy and light chains of the antibody.

After reductive cleavage of the disulfide bonds, conjugation chemistry can be performed by different kinds of reactions like conventional maleimides or disulfide bond formation. Heterogeneity can be observed if heavy and light antibody chains do not recombine in the original manner.

A highly accurate and specific DAR with well-defined connectivity can be achieved, if unnatural amino acids, e.g., *p*-azidophenylalanine, can be introduced recombinantly. Click chemistry or other Diels-Alder type reactions can be used to introduce linkers and payloads. In a similar manner, certain peptide fragments can be added, which serve as substrates for ligases in order to conjugate to appropriate linker-payload conjugates.

Reference:

→ *Linker Technologies for Antibody–Drug Conjugates; B. Nolting;* ***Antibody-Drug Conjugates L. Ducry*** *2013;* ***1045****: 71-100. https://doi.org/10.1007/978-1-62703-541-5_5*

Cleavage Mechanisms



Fig. 8: Valyl-citrullyl dipeptide fragment serves as substrate for cathepsin and suffers cleavage by hydrolysis leading to a 1,6-elimination with fragmentation and traceless release of the drug molecule.

An ADC travels through plasma until it reaches the target cell. After internalization, the complex degrades and releases the payload even with a stable linker. However, release can be accelerated through implementation of moieties which fragmentize under certain conditions. One of the most commonly used spacers is the bifunctional *p*-aminobenzyl alcohol group, which is linked to the peptide through the amino group forming an amide bond, while amine containing cytotoxic drugs are attached through carbamate functionalities to the benzylic hydroxyl group of the linker. The resulting prodrugs are activated upon protease mediated hydrolysis and cleavage of the amide bond of citrulline to the *p*-aminobenzyl fragment, leading to a 1,6-elimination reaction releasing the unmodified drug, carbon dioxide, and remnants of the linker group (*Fig. 8*, *Fig. 9*).



Fig. 9: Glucuronic acid capped p-aminobenzyl will be cleaved by glucuronidases resulting in 1,6-elmination, fragmentation, and traceless release of the drug molecule.

In an extension of the peptide-based linker strategies to provide high ADC stability, β-glucuronic acid-based linkers were developed. Facile release of the active drug is realized through cleavage of the β-glucuronide glycosidic bond by the lysosomal enzyme β-glucuronidase. This enzyme is abundantly present in lysosomes and overexpressed in some tumor types, while its activity outside cells is low. The linker is hydrophilic, stable against circulation, and provides ADCs that are highly active both *in vitro* and *in vivo*.

back to content ↑



Fig. 10: Chinoidic variations of trimethyl locks are reduced to the corresponding diphenol followed by traceless release of a drug molecule via lacton formation.

Besides hydrolases, the presence of oxidoreductases in the lysosome is being utilized for the design of cleavable linkers. Cytochrome P450 oxidoreductase (CPR), nitroquinone oxidoreductase 1 (NQO1), and cellular reductants such as glutathione (GSH) transform reducible fragments like chinone or disulfide to self-immolative intermediates.

Trimethyl Lock

The sterical demand of three closely positioned methyl groups (*Fig. 10*) favors the cleavage of a carbonyl bond by lacton formation. The acidity of the phenol is sufficient to accelerate lactonization at neutral pH and any residue carrying a hydroxyl or amino function will be unlocked, i.e. tracelessly released. The hydroxy group of phenol can be protected and released by a variety of methodologies. This reaction usually requires no elevated temperature. Hence, it will work nicely at physiological conditions.

Product details

RL-2960 Acetyl-Trimethyl-Lock

3-(2-Acetoxy-4,6-dimethylphenyl)-3-methylbutyric acid

CAS-No.	134098-68-3
Formula	$C_{15}H_{20}O_4$
Mol. weight	264,14 g/mol



RL-2950 Fourmethyl-Lock

3-(2,4-dimethyl-3,6-dioxocyclohexa-1,4-dienyl)-3-methylbutanoic acid

CAS-No.	133544-77-1
Formula	$C_{13}H_{16}O_4$
Mol. weight	236,26 g/mol



RL-2940 Fivemethyl-Lock

3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanoic acid

CAS-No.	40662-29-1
Formula	$C_{14}H_{18}O_4$
Mol. weight	250,29 g/mol



RL-2970 Photo-Trimethyl-Lock

3-(2-Nitroveratryl-4,6-dimethylphenyl)-3-methylbutyric acid

CAS-No.	2095134-25-9
Formula	$C_{22}H_{27}NO_7$
Mol. weight	417,45 g/mol



FAA7190 Fmoc-Spr(oNB)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-beta,beta-dimethyl-(2,4-dimethyl-6-(2-nitrobenzyloxy)phenyl) alanine (rac.)

CAS-No.	1032400-98-8
Formula	$C_{35}H_{34}N_2O_7$
Mol. weight	594,66 g/mol



FAA7200 Fmoc-Spr(oNv)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-beta,beta-dimethyl-(2-methyl-6-(2-nitroveratryl)phenyl)alanine (rac.)

CAS-No.	1228829-20-6
Formula	$C_{36}H_{36}N_2O_9$
Mol. weight	640,68 g/mol



References:

- *Trimethyl lock: A trigger for molecular release in chemistry, biology, and pharmacology; M. N. Levine, R. T. Raines;* ***Chem. Sci.*** *2012;* ***3****: 2412-2420. https://doi.org/10.1039/C2SC20536J*
- *Photo-triggered fluorescent labelling of recombinant proteins in live cells; D. Jung, K. Sato, K. Min, A. Shigenaga, J. Jung, A. Otaka, Y. Kwon;* ***Chem Commun*** *2015;* ***51****: 9670-3. https://doi.org/10.1039/C2SC20536J*
- *Detection of DT-diaphorase Enzyme with a ParaCEST MRI Contrast Agent; I. Daryaei, K. M. Jones, M. D. Pagel;* ***Chemistry*** *2017;* ***23****: 6514-6517. https://doi.org/10.1002/chem.201700721*
- *Syntheses and kinetic studies of cyclisation-based self-immolative spacers; S. Huvelle, A. Alouane, T. Le Saux, L. Jullien, F. Schmidt;* ***Org Biomol Chem*** *2017;* ***15****: 3435-3443. https://doi.org/10.1039/c7ob00121e*
- *Invention of stimulus-responsive peptide-bond-cleaving residue (Spr) and its application to chemical biology tools; A. Shigenaga, J. Yamamoto, T. Kohiki, T. Inokuma, A. Otaka;* ***J Pept Sci*** *2017;* ***23****: 505-513. https://doi.org/10.1002/psc.2961*
- *Trimethyl Lock: A Multifunctional Molecular Tool for Drug Delivery, Cellular Imaging, and Stimuli-Responsive Materials; O. A. Okoh, P. Klahn;* ***ChemBioChem*** *2018;* ***19****: 1668-1694. https://doi.org/10.1002/cbic.201800269*

back to content ↑

Disulfide Linkers

Disulfide linkers (*Fig. 11*) are likely first degraded in the lysosome to generate a cysteine-disulfide catabolite followed by disulfide reduction in the cytosol by cellular reductants such as GSH. The kinetics of reduction can be tailored by neighboring one to four methyl groups next to both sulfurs.



Fig. 11: Mechanism of disulfide bond cleavage in lysosomal compartments.

References:

- → *Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers; T. H. Pillow, M. Schutten, S. F. Yu, R. Ohri, J. Sadowsky, K. A. Poon, W. Solis, F. Zhong, G. Del Rosario, M. A. T. Go, J. Lau, S. Yee, J. He, L. Liu, C. Ng, K. Xu, D. D. Leipold, A. V. Kamath, D. Zhang, L. Masterson, S. J. Gregson, P. W. Howard, F. Fang, J. Chen, J. Gunzner-Toste, K. K. Kozak, S. Spencer, P. Polakis, A. G. Polson, J. A. Flygare, J. R. Junutula;* ***Mol. Cancer. Ther.*** *2017;* ***16****: 871-878. https://doi.org/10.1158/1535-7163.MCT-16-0641*
- → *Mechanisms of drug release in nanotherapeutic delivery systems; P. T. Wong, S. K. Choi;* ***Chem Rev*** *2015;* ***115****: 3388-432. https://doi.org/10.1021/cr5004634*
- → *Expanded Utility of the beta-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents; S. C. Jeffrey, J. De Brabander, J. Miyamoto, P. D. Senter;* ***ACS Med Chem Lett*** *2010;* ***1****: 277-80. https://doi.org/10.1021/ml100039h*

Multiple Payloads with one self-immolative Linker

p-Hydroxy- and *p*-amino-benzyl fragments will release payloads by a 1,6-elimination cascade, resulting in chinoide intermediates. Under physiological conditions, they readily add water to reform the aromatic ring structure. In case appropriate carbamate substitutions are also placed on position 2 and 2', a fragmentation will occur in a similar manner as by a 1,4-elimination and release any molecules at these positions (*Fig. 12*).



Fig. 12: Mechanism of multiple traceless release.

One of the major challenges related to anticancer chemotherapy is resistance against anticancer drugs. A strategy to revert the resistance of tumor cells is the combined use of different anticancer drugs.

References:

- *A novel connector linkage applicable in prodrug design; P. L. Carl, P. K. Chakravarty, J. A. Katzenellenbogen; **J. Med. Chem.** 1981; **24**: 479-80. https://doi.org/10.1021/jm00137a001*
- *The azaquinone-methide elimination: comparison study of 1,6- and 1,4-eliminations under physiological conditions; R. Erez, D. Shabat; **Org Biomol Chem** 2008; **6**: 2669-72. https://doi.org/10.1039/b808198k*
- *Dendritic chain Dendritic chain reaction: responsive release of hydrogen peroxide upon generation and enzymatic oxidation of methanol; M. Avital- Shmilovici, D. Shabat; **Bioorg Med Chem** 2010; **18**: 3643-7. https://doi.org/10.1016/j.bmc.2010.02.038*
- *ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal; C. H. Choi; **Cancer Cell Int** 2005; **5**: 30. https://doi.org/10.1186/1475-2867-5-30*

It has been reported that payload release can be supported by introducing a *N,N'*-dimethylethane-1,2-diamine bridge between carbamate and payload. After release of carbon dioxide, it will cyclize and form 1,3-dimethylimidazolidin-2-one and liberate the payload from the linker construction (*Fig. 13*).



Fig. 13: Mechanism of assisted traceless release by N,N'-dimethylethane-1,2-diamine.

Besides the benzyl system, other moieties have been used for fragmentation reactions. In *Fig. 14* different methods are summarized, which have been studied and published. PG is the protecting group and LG the leaving group belonging to the payload to be released. X needs to be a strong electron-donating group, such as O, X or NH, in order to initiate the elimination cascade. While the 1,6-elimination of a benzyl system tends to be the most common system, *ortho*-benzyl undergoing a 1,4-elimination can alternatively be used, as well as styrene fragments (1,8-elimination). However, neither naphthalene rings nor biphenyl structures (1,10-elimination) work, even with a strongly donating amino group.

back to content ↑



Fig. 14: Possible fragments enabling traceless release of payloads.

References:

- *Self-immolative spacers: kinetic aspects, structure-property relationships, and applications; A. Alouane, R. Labruere, T. Le Saux, F. Schmidt, L. Jullien;* ***Angew Chem Int Ed*** *2015;* ***54****: 7492-509. https://doi.org/10.1002/anie.201500088*
- *Cleavable linkers in chemical biology; G. Leriche, L. Chisholm, A. Wagner;* ***Bioorg Med Chem*** *2012;* ***20****: 571-82. https://doi.org/10.1016/j.bmc.2011.07.048*

Diisopropylsilylether Linker



Fig. 15: Diisopropylsilylethers are stable in plasma conditions and hydrolyze at acidic pH releasing alcohol terminated payloads.

Silyl ether linkers (*Fig. 15*) provide the option to modify a different functional handle of the parent payload compared to the hydrazone, disulfide, thioether and peptide bonds commonly used in bioconjugations. Silyl ether linkers also provide an alternative mechanism of release compared to peptide and disulfide linkers and have more stability than hydrazone linkers. Both of these factors contribute to making silyl ethers a flexible tool for ADC development. Silyl ether-based acid-cleavable ADC show a plasma half- life of greater than 7 days, while the stability can be further improved by introducing PHB. The resulting ADC exhibits improved stability, effective release of payload, appropriate efficacy *in vitro* and *in vivo*, and controlled therapeutic toxicity. This strategy may deepen the cognition of acid-cleavable linker and provide a new conjugating model for amine terminated payloads.

References:

- *Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy; Y. Wang, S. Fan, D. Xiao, F. Xie, W. Li, W. Zhong, X. Zhou;* ***Cancers (Basel)*** *2019;* ***11****: 957. https://doi.org/10.3390/cancers11070957*
- *A versatile acid-labile linker for antibody–drug conjugates; M. C. Finniss, K. S. Chu, C. J. Bowerman, J. C. Luft, Z. A. Haroon, J. M. DeSimone;* ***Med. Chem. Commun.*** *2014;* ***5****: 1355-1358. https://doi.org/10.1039/c4md00150h*
- *Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy; S. J. Moon, S. V. Govindan, T. M. Cardillo, C. A. D'Souza, H. J. Hansen, D. M. Goldenberg;* ***J. Med. Chem.*** *2008;* ***51****: 6916-26. https://doi.org/10.1021/jm800719t*
- *Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia; P. R. Hamann, L. M. Hinman, I. Hollander, C. F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H. R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D. A. Flowers, I. Bernstein;* ***Bioconjug Chem*** *2002;* ***13****: 47-58. https://doi.org/10.1021/bc010021y*
- *Development of potent monoclonal antibody auristatin conjugates for cancer therapy; S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. Chace, R. L. DeBlanc, R. P. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. Wahl, D. L. Meyer, P. D. Senter;* ***Nat Biotechnol*** *2003;* ***21****: 778-84. https://doi.org/10.1038/nbt832*

back to content ↑

2. Permanent Linkers

2.1. PEG-Based Spacer Molecules

This class of linkers is considered non-cleavable, meaning linker cleavage and payload release do not depend on the differential properties between plasma and cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC *via* antigen-mediated endocytosis and delivery to lysosomal compartments, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation. This process releases a drug derivative, formed by the cytotoxic drug, the linker, and the amino acid residue to which the linker was covalently attached.

The following section displays examples of hetero-bifunctional PEG-based spacer molecules. As payloads are quite often rather hydrophobic, PEG fragments help to solubilize the linker-payload conjugate, which is essential to perform successful conjugation to the antibody. It further helps to increase the solubility in physiological media and to improve the pharmacokinetic properties of the whole ADC construct.

Two of the latest approved ADCs, Trodelvy and Zynlonta, were developed with PEG spacers als part of their linkers to improve solubility and stability *in vivo*.

		Product details
PEG4885 HOOC-dPEG™(2)-COOH **Ethyleneglycol-bis(propionic acid)** CAS-No. 19364-66-0 Formula $C_8H_{14}O_6$ Mol. weight 206,19 g/mol		
PEG4120 NHS-PEG(2)-NHS **3,6-Dioxaoctandioic acid bissuccinimidyl ester** CAS-No. 65869-63-8 Formula $C_{16}H_{20}N_2O_{10}$ Mol. weight 400,34 g/mol		
PEG1365 H_2N-PEG(2)-CO-OtBu **3-(2-(2-Aminoethoxy)ethoxy)propanoic acid t-butyl ester** CAS-No. 756525-95-8 Formula $C_{11}H_{23}NO_4$ Mol. weight 233,3 g/mol		

PEG4980 H_2N-PEG(2)-N_3*TosOH

2-[2-(2-Azidoethoxy)ethoxy]ethanaminium tosylat

CAS-No.	2173092-98-1
Formula	$C_7H_{14}N_4O_2$*$C_7H_8O_3S$
Mol. weight	174,20*172,20 g/mol



PEG4960 Boc-NH-PEG(2)-N_3

1-(t-Butyloxycarbonyl-amino)-3,6-dioxa-8-octaneazide

CAS-No.	950683-55-3
Formula	$C_{11}H_{22}N_4O_4$
Mol. weight	274,32 g/mol



PEG1555 mal-PEG(2)-COOH

3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy) propanoic acid

CAS-No.	756525-98-1
Formula	$C_{14}H_{20}N_2O_7$
Mol. weight	328,32 g/mol



PEG1560 mal-PEG(2)-NHS

3-(2-(2-(3-Maleimidopropanamido)ethoxy)ethoxy) propanoic acid succinimidyl ester

CAS-No.	955094-26-5
Formula	$C_{18}H_{23}N_3O_9$
Mol. weight	425,39 g/mol



PEG2035 DOODA

3,6-Dioxaoctanedioic acid

CAS-No.	23243-68-7
Formula	$C_6H_{10}O_6$
Mol. weight	178,14 g/mol



PEG2030 TUDA

3,6,9-Trioxaundecandioic acid

CAS-No.	13887-98-4
Formula	$C_8H_{14}O_7$
Mol. weight	222,19 g/mol



back to content ↑

Product details

BNN1016 Boc-DOOA

1-(t-Butyloxycarbonyl-amino)-3,6-dioxa-8-octaneamine, liq.



CAS-No.	153086-78-3
Formula	$C_{11}H_{24}N_2O_4$
Mol. weight	248,32 g/mol

FNN1007 Fmoc-DOOA*HCl

1-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxa-8-octaneamine hydrochloride



CAS-No.	868599-73-9
Formula	$C_{21}H_{26}N_2O_4$*HCl
Mol. weight	370,45*36,45 g/mol

PEG5180 Fmoc-DOOA-DIG-OH

2-(2-(2-(2-((9-Fluorenylmethyloxycarbonyl)amino) ethoxy)ethoxy)ethylamino)-diglycolic acid



CAS-No.	669073-64-7
Formula	$C_{25}H_{30}N_2O_8$
Mol. weight	486,51 g/mol

FAA5730 Fmoc-TTD-DIG-OH

[N_1-(9-Fluorenylmethoxycarbonyl)-1,13-diamino-4,7,10-trioxatridecan-diglycolic acid



CAS-No.	916585-44-9
Formula	$C_{29}H_{38}N_2O_9$
Mol. weight	558,62 g/mol

PEG2420 H-O_2Oc-OH

[2-(2-aminoethoxy)ethoxy]acetic acid



CAS-No.	134978-97-5
Formula	$C_6H_{13}NO_4$
Mol. weight	163,17 g/mol

PEG7940 H-O_2Oc-OH*HCl

8-amino-3,6-dioxaoctanoic acid hydrochloride



CAS-No.	134979-01-4
Formula	$C_6H_{13}NO_4$*HCl
Mol. weight	163,17*36,45 g/mol

PEG2430 H-O_2Oc-OtBu*HCl

[2-(2-aminoethoxy)ethoxy]acetic acid tert-butyl ester*HCl

CAS-No.	2098500-69-5
Formula	$C_{10}H_{21}NO_4$*HCl
Mol. weight	219,28*36,45 g/mol



AAA1905 Aloc-O_2Oc-OH*DCHA

8-(Allyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine

CAS-No.	560088-74-6
Formula	$C_{10}H_{17}NO_6$*$C_{12}H_{23}N$
Mol. weight	247,11*181,32 g/mol



PEG8080 Boc-O_2Oc-OH

(2-(2-(t-Butyloxycarbonylamino)ethoxy)ethoxy)acetic acid

CAS-No.	108466-89-3
Formula	$C_{11}H_{21}NO_6$
Mol. weight	263,29 g/mol



BAA1466 Boc-O_2Oc-OH*DCHA

8-(t-Butyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylammonium salt

CAS-No.	560088-79-1
Formula	$C_{11}H_{21}NO_6$*$C_{12}H_{23}N$
Mol. weight	263,29*181,32 g/mol



DAA1016 Dde-O_2Oc-OH

8-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-amino]-3,6-dioxaoctanoic acid, {2-[2-(Dde-amino) ethoxy]ethoxy}acetic acid

CAS-No.	1263045-93-7
Formula	$C_{16}H_{25}NO_6$
Mol. weight	327,37 g/mol



FAA1435 Fmoc-O_2Oc-OH

8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid

CAS-No.	166108-71-0
Formula	$C_{21}H_{23}NO_6$
Mol. weight	385,42 g/mol



back to content ↑

Product details

FAA6020 Fmoc-O_2Oc-PFP

8-(9-Fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid pentafluorophenyl ester

CAS-No. 1263044-39-8
Formula $C_{27}H_{22}F_5NO_6$
Mol. weight 551,5 g/mol



PEG4870 Mal-O_2Oc-OH

{2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy] ethoxy}acetic acid

CAS-No. 173323-23-4
Formula $C_{10}H_{13}NO_6$
Mol. weight 243,21 g/mol



PEG4650 Mtt-O_2Oc-OH*DEA

N-(4-Methyltrity)-8-amino-3,6-dioxaoctanoic acid diethylamine

CAS-No. 2098500-66-2
Formula $C_{26}H_{29}NO_4*C_4H_{11}N$
Mol. weight 419,51*73,14 g/mol



PEG2780 N_3-O_2Oc-OH*CHA

[2-(2-azidoethoxy)ethoxy]acetic acid cyclohexylamine salt

CAS-No. 2098500-94-6
Formula $C_6H_{11}N_3O_4*C_6H_{13}N$
Mol. weight 189,17*99,17 g/mol



PEG7950 N_3-AEEA-OK

Potassium 8-azido-3,6-dioxaoctanoate

CAS-No. 882518-90-3 net
Formula $C_6H_{10}KN_3O_4$
Mol. weight 39,10*188,16 g/mol



PEG5390 N_3-O_2Oc-OtBu

8-Azido-3,6-dioxaoctanoic acid t-butyl ester

CAS-No. 251564-45-1
Formula $C_{10}H_{19}N_3O_4$
Mol. weight 245,28 g/mol



Product details

PEG5000 N_3-TFBA-O_2Oc

{2-[2-(4-Azido-2,3,5,6-tetrafluorobenzoyl-amino)ethoxy] ethoxy}acetic acid

CAS-No. 1993119-45-1
Formula $C_{13}H_{12}F_4N_4O_5$
Mol. weight 380,25 g/mol



PAA1050 Poc-O_2Oc-OH*DCHA

8-(Popargylyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine

Formula $C_{10}H_{15}NO_6$*$C_{12}H_{23}N$
Mol. weight 245,23*181,32 g/mol



ZAA1186 Z-O_2Oc-OH*DCHA

8-(Benzyloxycarbonyl-amino)-3,6-dioxaoctanoic acid dicyclohexylamine

CAS-No. 560088-84-8
Formula $C_{14}H_{19}NO_6$*$C_{12}H_{23}N$
Mol. weight 297,31*181,32 g/mol



PEG1810 Fmoc-AEEP

3-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy) ethoxy)propanoic acid

CAS-No. 872679-70-4
Formula $C_{22}H_{25}NO_6$
Mol. weight 399,44 g/mol



PEG4970 Fmoc-Ebes

N-[8-(9-Fluorenylmethyloxycarbonyl)amino-3,6-dioxaoctyl]succinamic acid

CAS-No. 613245-91-3
Formula $C_{25}H_{30}N_2O_7$
Mol. weight 470,51 g/mol



FAA1568 Fmoc-TTDS-OH

[N_1-(9-Fluorenylmethoxycarbonyl)-1,13-diamino-4,7,10-trioxatridecan-succinamic acid

CAS-No. 172089-14-4
Formula $C_{29}H_{38}N_2O_8$
Mol. weight 542,63 g/mol



back to content ↑

Product details

PEG4900 N_3-EEEt-OH

2-[2-(2-Azidoethoxy)ethoxy]ethanol

CAS-No.	86520-52-7
Formula	$C_6H_{13}N_3O_3$
Mol. weight	175,19 g/mol



PEG5400 N_3-AEEEA*CHA

11-Azido-3,6,9-trioxaundecanoic acid cyclohexylamine

CAS-No.	172531-37-2 net
Formula	$C_8H_{15}N_3O_5$*$C_6H_{13}N$
Mol. weight	233,22*99,17 g/mol



PEG5370 Fmoc-AEEE

2-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy) ethoxy)ethanol

CAS-No.	560088-66-6
Formula	$C_{21}H_{25}NO_5$
Mol. weight	371,43 g/mol



PEG7010 Trt-S-EEE

S-Trityl-2-(2-(2-mercaptoethoxy)ethoxy)ethanol

CAS-No.	728033-15-6
Formula	$C_{25}H_{28}O_3S$
Mol. weight	408,55 g/mol



BNN1028 Boc-TOTA

1-(t-Butyloxycarbonyl-amino)-4,7,10-trioxa-13-tri-decanamine, liq.

CAS-No.	194920-62-2
Formula	$C_{15}H_{32}N_2O_5$
Mol. weight	320,43 g/mol



FNN1011 Fmoc-TOTA*HCl

1-(9-Fluorenylmethyloxycarbonyl-amino)-4,7,10-tri-oxa-13-tridecanamine hydrochloride

CAS-No.	868599-75-1
Formula	$C_{25}H_{34}N_2O_5$*HCl
Mol. weight	442,56*36,45 g/mol



Product details

BNN1150 N_3-TOTA

1-Azido-4,7,10-trioxa-13-tridecanamine



CAS-No. 1162336-72-2
Formula $C_{10}H_{22}N_4O_3$
Mol. weight 246,31 g/mol

PEG5170 N_3-TOTA-Suc

1-Azido-4,7,10-trioxa-13-tridecaneamine succinamic acid



CAS-No. 1993176-74-1
Formula $C_{14}H_{26}N_4O_6$
Mol. weight 346,38 g/mol

PEG1745 Z-TOTA

1-Benzyloxycarbonyl-4,7,10-trioxa-13-tridecaneamine



CAS-No. 220156-99-0
Formula $C_{18}H_{30}N_2O_5$
Mol. weight 354,44 g/mol

PEG7860 Boc2-AEEEE

2-(2-(2-(2-(Di-(t-butylmethyloxycarbonyl))aminoethoxy) ethoxy)ethoxy)ethanol



CAS-No. 2389064-37-1
Formula $C_{18}H_{35}NO_8$
Mol. weight 393,47 g/mol

PEG5385 Boc,Z-AEEEE

2-(2-(2-(2-(Benzyloxycarbonyl-tert-Butylmethyloxycarbonyl)aminoethoxy)ethoxy)ethoxy)ethanol



CAS-No. 2389064-46-2
Formula $C_{21}H_{33}NO_8$
Mol. weight 427,49 g/mol

PEG5380 Fmoc-AEEEE

2-(2-(2-(2-(9-Fluorenylmethyloxycarbonyl)aminoethoxy)ethoxy)ethoxy)ethanol



CAS-No. 868594-41-6
Formula $C_{23}H_{29}NO_6$
Mol. weight 415,48 g/mol

back to content ↑

Product details

PEG6730 Trt-S-EEEE

S-Trityl-2-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy) ethanol

CAS-No. 125607-10-5
Formula $C_{27}H_{32}O_4S$
Mol. weight 452,61 g/mol



PEG4875 HOOC-dPEG™(3)-COOH

Diethyleneglycol-bis(propionic acid)

CAS-No. 96517-92-9
Formula $C_{10}H_{18}O_7$
Mol. weight 250,25 g/mol



PEG4130 NHS-PEG(3)-NHS

3,6,9-Trioxaundecandioic acid bissuccinimidyl ester

CAS-No. 1314378-16-9
Formula $C_{18}H_{24}N_2O_{11}$
Mol. weight 444,39 g/mol



PEG1485 mal-dPEG(3)-mal

Bis-(1,13-(3-maleimidopropionyl)amido)-4,7,10-trioxatridecane

CAS-No. 756525-89-0
Formula $C_{24}H_{34}N_4O_9$
Mol. weight 522,55 g/mol



PEG7870 Boc-NH-PEG(3)-NH_2

1-(t-Butyloxycarbonyl)amino-3,6,9-trioxa-undecan-11-amine

CAS-No. 101187-40-0
Formula $C_{13}H_{28}N_2O_5$
Mol. weight 292,37 g/mol



PEG7190 Bromoacetamido-PEG(3)-N_3

Bromoacetamido-tri(ethylene glycol)-azide

CAS-No. 940005-81-2
Formula $C_{10}H_{19}BrN_4O_4$
Mol. weight 339,19 g/mol



PEG4370 Fmoc-NH-PEG(3)-COOH

12-(9-Fluorenylmethyloxycarbonylamino)-4,7,10-trioxa-dodecanoic acid



CAS-No.	867062-95-1
Formula	$C_{24}H_{29}NO_7$
Mol. weight	443,49 g/mol

TCO1050 TCO-PEG(3)-mal

trans-Cyclooctene-PEG(3)-maleimide



CAS-No.	1609659-01-9
Formula	$C_{26}H_{41}N_3O_8$
Mol. weight	523,62 g/mol

PEG3760 N_3-PEG(3)-OH

alpha-Azido-omega-hydroxy tetra(ethylene glycol)



CAS-No.	86770-67-4
Formula	$C_8H_{17}N_3O_4$
Mol. weight	219,24 g/mol

PEG3060 H_2N-PEG(3)-N_3

1-Amino-11-azido-3,6,9-trioxaundecane



CAS-No.	134179-38-7
Formula	$C_8H_{18}N_4O_3$
Mol. weight	218,25 g/mol

PEG5320 N_3-PEG(4)-NH_2

14-Azido-3,6,9,12-tetraoxatetradecan-1-amine



CAS-No.	951671-92-4
Formula	$C_{10}H_{22}N_4O_4$
Mol. weight	262,31 g/mol

PEG1221 H-O_2Oc-O_2Oc-OH

17-Amino-10-oxo-3,6,12,15-tetraoxa-9-azaheptadecan-1-oic acid



CAS-No.	1143516-05-5
Formula	$C_{12}H_{24}N_2O_7$
Mol. weight	308,33 g/mol

back to content ↑

Product details

BAA1485 Boc-O_2Oc-O_2Oc-OH

17-(t-Butyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid



CAS-No.	1069067-08-8
Formula	$C_{17}H_{32}N_2O_9$
Mol. weight	408,45 g/mol

FAA1787 Fmoc-O_2Oc-O_2Oc-OH

17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid



CAS-No.	560088-89-3
Formula	$C_{27}H_{34}N_2O_9$
Mol. weight	530,58 g/mol

PEG2790 N_3-O_2Oc-O_2Oc-OH

8-(8-Azido-3,6-dioxaoctanoylamido)-3,6-dioxaoctanoic acid



CAS-No.	1254054-60-8
Formula	$C_{12}H_{22}N_4O_7$
Mol. weight	334,33 g/mol

FAA6790 Fmoc-O_2Oc-O_2Oc-PFP

17-(9-Fluorenylmethyloxycarbonyl-amino)-9-aza-3,6,12,15-tetraoxa-10-on-heptadecanoic acid pentafluorophenyl ester



Formula	$C_{33}H_{33}F_5N_2O_9$
Mol. weight	696,61 g/mol

PEG2770 H-O_2Oc-O_2Oc-O_2Oc-OH

26-amino-10,19-dioxo-3,6,12,15,21,24-hexaoxa-9,18-diazahexacosan-1-oic acid



Formula	$C_{18}H_{35}N_3O_{10}$
Mol. weight	453,48 g/mol

PEG8060 H-O2Oc-O2Oc-O2Oc-O2Oc-OH

8-amino-3,6-dioxaoctanoic acid tetramer



Formula	$C_{24}H_{46}N_4O_{13}$
Mol. weight	598,64 g/mol

Product details

PEG1320 H_2N-PEG(4)-OH

2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethanol



CAS-No.	86770-74-3
Formula	$C_8H_{19}NO_4$
Mol. weight	193,24 g/mol

PEG1335 H_2N-dPEG(4)-NHNH-Boc

15-Amino-4,7,10,13-tetraoxa-pentadecanoyl-N'-(t-butyloxycarbonyl)-hydrazid



CAS-No.	1263047-17-1
Formula	$C_{16}H_{33}N_3O_7$
Mol. weight	379,45 g/mol

PEG1805 Fmoc-NH-dPEG(4)-NHNH-Boc

15-(9-Fluorenylmethyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoyl-N'-(t-butyloxycarbonyl)hydrazid



CAS-No.	1263044-77-4
Formula	$C_{31}H_{43}N_3O_9$
Mol. weight	601,69 g/mol

PEG7880 Boc-NH-PEG(4)-NH_2

1-(t-Butyloxycarbonyl)amino-3,6,9,12-tetraoxatetradecan-14-amine



CAS-No.	811442-84-9
Formula	$C_{15}H_{32}N_2O_6$
Mol. weight	336,42 g/mol

PEG1915 Boc-NH-PEG(4)-OH

2-(2-(2-(2-(t-Butyloxycarbonylamino)ethoxy)ethoxy)ethoxy)ethanol



CAS-No.	106984-09-2
Formula	$C_{13}H_{27}NO_6$
Mol. weight	293,36 g/mol

PEG1535 HO-dPEG(4)-CO-OtBu

15-Hydroxy-4,7,10,13-tetraoxa-pentadecanoic acid t-butyl ester



CAS-No.	518044-32-1
Formula	$C_{15}H_{30}O_7$
Mol. weight	322,39 g/mol

back to content ↑

Product details

PEG7220 HO-PEG(4)-TFP

Hydroxy-tetra(ethylene glycol)-propionyl 2,3,5,6-tetrafluorophenyl ester

Formula $C_{17}H_{22}F_4O_7$
Mol. weight 414,35 g/mol



PEG4880 HOOC-dPEG™(4)-COOH

Tetraethyleneglycol-bis(propionic acid)

CAS-No. 31127-85-2
Formula $C_{12}H_{22}O_8$
Mol. weight 294,30 g/mol



PEG1370 H_2N-dPEG(4)-COOH

15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid

CAS-No. 663921-15-1
Formula $C_{11}H_{23}NO_6$
Mol. weight 265,3 g/mol



PEG1375 H_2N-dPEG(4)-CO-OtBu

15-Amino-4,7,10,13-tetraoxa-pentadecanoic acid t-butyl ester

CAS-No. 581065-95-4
Formula $C_{15}H_{31}NO_6$
Mol. weight 321,41 g/mol



PEG1920 Boc-NH-PEG(4)-COOH

15-t-Butyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid

CAS-No. 756525-91-4
Formula $C_{16}H_{31}NO_8$
Mol. weight 365,42 g/mol



PEG2145 Dnp-NH-PEG(4)-COOH

1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid

CAS-No. 858126-76-8
Formula $C_{17}H_{25}N_3O_{10}$
Mol. weight 431,39 g/mol



PEG2150 Dnp-NH-PEG(4)-NHS

1-(2,4-Dinitrophenylamino)-3,6,9,12-tetraoxapentadecanoic acid succinimidyl ester



CAS-No.	858126-78-0
Formula	$C_{21}H_{28}N_4O_{12}$
Mol. weight	528,47 g/mol

PEG4410 Fmoc-NH-dPEG™(4)-NHS

15-(9-Fluorenylmethyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid succinimidyl ester



CAS-No.	1314378-14-7
Formula	$C_{30}H_{36}N_2O_{10}$
Mol. weight	584,24 g/mol

PEG7810 Fmoc-NH-dPEG™(4)-TFP

15-(9-Fluorenylmethyloxycarbonyl)amino-4,7,10,13-tetraoxa-pentadecanoic acid (2,3,5,6-tetrafluorophenyl) ester



Formula	$C_{32}H_{33}F_4NO_8$
Mol. weight	635,6 g/mol

PEG2161 Mtt-NH-PEG(4)-COOH*TEA

1-(*p*-Methytritylamino)-3,6,9,12-tetraoxapentadecanoic acid triethylamionium salt



CAS-No.	1310680-33-1 (net)
Formula	$C_{31}H_{39}NO_6*C_6H_{15}N$
Mol. weight	$C_{31}H_{39}NO_6*C_6H_{15}N$ g/mol

PEG2230 OPSS-PEG(4)-NHS

N-[3-(o-Pyridyldisulfido)propanoyl]-15-amino-4,7,10,13-tetraoxa-pentadecanoyl succinimidyl ester



CAS-No.	1334177-95-5
Formula	$C_{23}H_{33}N_3O_9S_2$
Mol. weight	559,65 g/mol

PEG5080 Phth-NO-dPEG™(4)-NHS

1-Phthalimidoxy-3,6,9,12-tetraoxapentadecan-15-oic acid succinimdyl ester



Formula	$C_{23}H_{28}N_2O_{11}$
Mol. weight	508,48 g/mol

back to content ↑

Product details

PEG1495 Z-NH-dPEG(4)-COOH

15-Benzyloxycarbonylamino-4,7,10,13-tetraoxa-pentadecanoic acid



CAS-No. 756526-00-8
Formula $C_{19}H_{29}NO_8$
Mol. weight 399,44 g/mol

PEG5420 Alkyne-PEG(4)-COOH

Alkyne-PEG(4)-acid



CAS-No. 1245823-51-1
Formula $C_{14}H_{24}O_7$
Mol. weight 304,34 g/mol

PEG5410 Alkyne-PEG(4)-NHS

Alkyne-PEG(4)-succinimidyl ester



CAS-No. 1393330-40-9
Formula $C_{18}H_{27}NO_9$
Mol. weight 401,41 g/mol

PEG5430 Alkyne-PEG(4)-NH_2

Alkyne-PEG(4)-amine



CAS-No. 1013921-36-2
Formula $C_{11}H_{21}NO_4$
Mol. weight 231,29 g/mol

PEG5440 Alkyne-PEG(4)-mal

Alkyne-PEG(4)-maleimide



CAS-No. 1609651-90-2
Formula $C_{18}H_{26}N_2O_7$
Mol. weight 382,41 g/mol

TCO1040 TCO-PEG(4)-COOH

trans-Cyclooctene-PEG(4)-Acid



Formula $C_{20}H_{35}NO_8$
Mol. weight 417,49 g/mol

TCO1010 TCO-PEG(4)-NHS

trans-Cyclooctene-PEG(4)-carboxy succinimidyl ester

CAS-No. 1621096-79-4
Formula $C_{24}H_{38}N_2O_{10}$
Mol. weight 514,57 g/mol



RL-2510 DBCO-PEG(4)-OH

Dibenzoazacyclooctyne-tetra(ethylene glycol)

CAS-No. 1416711-60-8
Formula $C_{29}H_{36}N_2O_6$
Mol. weight 508,61 g/mol



RL-2420 DBCO-PEG(4)-NH_2*TFA

Dibenzoazacyclooctyne-tetra(ethylene glycol)-amine trifluoro acetic acid salt

CAS-No. 1255942-08-5 net
Formula $C_{29}H_{37}N_3O_6*C_2F_3HO_2$
Mol. weight 523,62*114,02 g/mol



RL-2421 DBCO-Sulfo-PEG(4)-NH_2

Dibenzoazacyclooctyne-tetra(ethylene glycol)amine

CAS-No. 2055198-05-3
Formula $C_{32}H_{42}N_4O_{10}S$
Mol. weight 674,76 g/mol



PEG1970 HS-dPEG(4)-COOH

15-Mercapto-4,7,10,13-tertaoxa-pentadecanoic acid

CAS-No. 749247-06-1
Formula $C_{11}H_{22}O_6S$
Mol. weight 282,35 g/mol



PEG1740 Mmt-S-dPEG(4)-COOH

15-(4-Methoxytrityl)thio-4,7,10,13-tertaoxa-pentadecanoic acid

CAS-No. 1263047-31-9
Formula $C_{31}H_{38}O_7S$
Mol. weight 554,69 g/mol



back to content ↑

Product details

PEG6710 Trt-S-PEG(4)-COOH*H2O

15-Tritylmercapto-4,7,10,13-tetraoxapentadecanoic acid monohydrate

CAS-No. 882847-05-4 net
Formula $C_{30}H_{36}O_6S*H_2O$
Mol. weight 524,67*18,01 g/mol



PEG3590 Lipoamide-dPEG™(4)-OMe

alpha-Lipoamide-omega-methoxy tetra(ethylene glycol)

CAS-No. 1334172-66-5
Formula $C_{17}H_{33}NO_5S_2$
Mol. weight 395,58 g/mol



PEG2345 N_3-PEG(4)-COOH

15-Azido-4,7,10,13-tetraoxa-pentadecanoic acid

CAS-No. 1257063-35-6
Formula $C_{11}H_{21}N_3O_6$
Mol. weight 291,3 g/mol



PEG1400 N_3-dPEG(4)-NHS

15-Azido-4,7,10,13-tetraoxa-pentadecanoic acid succinimidyl ester

CAS-No. 944251-24-5
Formula $C_{15}H_{24}N_4O_8$
Mol. weight 388,37 g/mol



PEG5300 N_3-PEG(4)-OH

2-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy) ethanol

CAS-No. 86770-68-5
Formula $C_{10}H_{21}N_3O_5$
Mol. weight 263,29 g/mol



RL-2310 MeTz-PEG(4)-COOH

Methyltetrazine-PEG(4)-acid

CAS-No. 1802907-91-0
Formula $C_{20}H_{28}N_4O_7$
Mol. weight 436,56 g/mol



Product details

RL-3480 8-Azido-octanoyl-OSu

8-Azidodooctanoic acid N-hydroxysuccinimide ester

CAS-No.	2576471-56-0
Formula	$C_{12}H_{18}N_4O_4$
Mol. weight	282,30 g/mol



RL-2330 MeTz-PEG(4)-NHS

Methyltetrazine-PEG(4)-propanoyl succinimidyl ester

CAS-No.	1802907-92-1
Formula	$C_{24}H_{31}N_5O_9$
Mol. weight	533,53 g/mol



RL-2340 MeTz-PEG(4)-mal

Methyltetrazine-PEG(4)-maleimide

CAS-No.	1802908-02-6
Formula	$C_{24}H_{30}N_6O_7$
Mol. weight	514,53 g/mol



Iris Biotech

Any Questions or Suggestions?

We are there for you – simply choose one of the numerous possibilities to get in touch!

+49 (0) 9231 97121-0
+49 (0) 9231 97121-99
info@iris-biotech.de
www.iris-biotech.de

back to content ↑

2.2. Hydrophobic Spacer Molecules

Product details

RL-3460 10-Undecynoyl-OSu

10-Undecynoic acid N-hydroxysuccinimide ester

CAS-No. 1006592-57-9
Formula $C_{15}H_{21}NO_4$
Mol. weight 279,34 g/mol



RL-2055 Alkyne-myristic acid

13-Tetradecynoic acid

CAS-No. 82909-47-5
Formula $C_{14}H_{24}O_2$
Mol. weight 224,34 g/mol



RL-2060 Alkyne-palmitic acid

15-Hexadecynoic acid

CAS-No. 99208-90-9
Formula $C_{16}H_{28}O_2$
Mol. weight 252,39 g/mol



RL-2065 Alkyne-stearic acid

17-Octadecynoic acid

CAS-No. 34450-18-5
Formula $C_{18}H_{32}O_2$
Mol. weight 280,45 g/mol



BNN1330 DETA(HBH)*2HCl

tert-butyl bis(2-aminoethyl)carbamate

CAS-No. 1914917-65-9
Formula $C_9H_{21}N_3O_2$*2HCl
Mol. weight 203,29*72,92 g/mol



BNN1340 DPTA(BHB)*HCl

di-tert-butyl (azanediylbis(propane-3,1-diyl))dicarbamate



CAS-No.	82409-03-8
Formula	$C_{16}H_{33}N_3O_4$*HCl
Mol. weight	331,46*36,46 g/mol

BNN1350 DETA(BHH*2HCl)

tert-butyl (2-((2-aminoethyl)amino)ethyl)carbamate dihydrochloride



CAS-No.	162279-67-6
Formula	$C_9H_{21}N_3O_2$*2HCl
Mol. weight	203,29*72,92 g/mol

HAA9300 H-Aca-Aca-OH

6-(6-Aminohexanamido)hexanoic acid



CAS-No.	2014-58-6
Formula	$C_{12}H_{24}N_2O_3$
Mol. weight	244,34 g/mol

BAA4870 Boc-Aca-Aca-OH

N-Boc-6-(6-Aminohexanamido)hexanoic acid



CAS-No.	14254-45-6
Formula	$C_{17}H_{32}N_2O_5$
Mol. weight	344,45 g/mol

RL-2980 N_3-Aca-OSu

6-Azidocaproic acid N-hydroxysuccinimidyl ester



CAS-No.	866363-70-4
Formula	$C_{10}H_{14}N_4O_4$
Mol. weight	254,24

HAA6990 N_3-Aca-Aca-OH

6-(6-azidohexanamido)hexanoic acid



CAS-No.	866363-71-5
Formula	$C_{12}H_{22}N_4O_3$
Mol. weight	270,33 g/mol

back to content ↑

Product details

AAA1970 N_3-Pen-OH

5-Azido-pentanoic acid

CAS-No.	79583-98-5
Formula	$C_5H_9N_3O_2$
Mol. weight	143,14 g/mol



AAA1960 N_3-Hx-OH

6-Azido-hexanoic acid

CAS-No.	79598-53-1
Formula	$C_6H_{11}N_3O_2$
Mol. weight	157,17 g/mol



RL-3480 8-Azido-octanoyl-OSu

8-Azidodooctanoic acid N-hydroxysuccinimide ester

CAS-No.	2576471-56-0
Formula	$C_{12}H_{18}N_4O_4$
Mol. weight	282,30 g/mol



RL-3170 11-Azido-undecanoyl-OSu

11-Azidoundecanoic acid N-hydroxysuccinimide ester

CAS-No.	850080-13-6
Formula	$C_{15}H_{24}N_4O_4$
Mol. weight	324,38 g/mol



RL-3200 11-Azidoundecanoic acid

11-Azido-undecanoic acid

CAS-No.	118162-45-1
Formula	$C_{11}H_{21}N_3O_2$
Mol. weight	227,30 g/mol



RL-3210 12-Azidododecanoic acid

12-Azido-dodecanoic acid

CAS-No.	80667-36-3
Formula	$C_{12}H_{23}N_3O_2$
Mol. weight	241,33 g/mol



RL-3220 12-Azido-dodecanoyl-OSu

12-Azidododecanoic acid N-hydroxysuccinimide ester

CAS-No. 2489524-00-5
Formula $C_{16}H_{26}N_4O_4$
Mol. weight 338,40 g/mol



RL-3230 14-Azido-myristic acid

14-azidotetradecanoic acid

CAS-No. 176108-61-5
Formula $C_{14}H_{27}N_3O_2$
Mol. weight 269,38 g/mol



RL-3240 16-Azido-palmitic acid

16-azidohexadecanoic acid

CAS-No. 112668-54-9
Formula $C_{16}H_{31}N_3O_2$
Mol. weight 297,44 g/mol



RL-3250 18-Azido-stearic acid

18-azidooctadecanoic acid

CAS-No. 1529763-58-3
Formula $C_{18}H_{35}N_3O_2$
Mol. weight 325,49 g/mol



BAA4240 14-(Boc-amino)-myristic acid

14-((t-Butyloxycarbonyl)amino)tetradecanoic acid

CAS-No. 2307778-46-5
Formula $C_{19}H_{37}NO_4$
Mol. weight 343,51 g/mol



FAA8160 14-(Fmoc-amino)-myristic acid

14-((9-Fluorenylmethyloxycarbonyl)amino)tetradecanoic acid

CAS-No. 1931109-55-5
Formula $C_{29}H_{39}NO_4$
Mol. weight 465,63 g/mol



back to content ↑

Product details

BAA3900 16-(Boc-amino)-palmitic acid

16-((t-Butyloxycarbonyl)amino)hexadecanoic acid



CAS-No.	135747-73-8
Formula	$C_{21}H_{41}NO_4$
Mol. weight	371,55 g/mol

FAA7460 16-(Fmoc-amino)-palmitic acid

16-((9-Fluorenylmethyloxycarbonyl)amino)hexadecanoic acid



CAS-No.	1356220-22-8
Formula	$C_{31}H_{43}NO_4$
Mol. weight	493,68 g/mol

BAA3910 18-(Boc-amino)-stearic acid

18-((t-Butyloxycarbonyl)amino)octadecanoic acid



Formula	$C_{23}H_{45}NO_4$
Mol. weight	399,61 g/mol

FAA7450 18-(Fmoc-amino)-stearic acid

18-((9-Fluorenylmethyloxycarbonyl)amino)octadecanoic acid



CAS-No.	1199580-37-4
Formula	$C_{33}H_{47}NO_4$
Mol. weight	521,73 g/mol

2.3. Permanent Linkers with Maleimide Function

Michael addition of a thiol to a maleimide is commonly used for numerous bioconjugations. Several commercial constructs like Brentuximab vedotin, Trastuzumab emtansine, and Cimzia contain a thiol-maleimide adduct. However, this reaction is reversible. During the journey of an appropriate thioether containing drug through physiological media, this bond can break, and fragments are released which might contribute to certain unwanted or even toxic reactions.



Fig. 16: Maleimides bind reversibly to thiols resulting in thioethers. This linkage turns stable once the maleimide ring is opened through hydrolysis.

However, if the succinimide moiety of a maleimide-thiol conjugate is hydrolyzed, the ring-opened product is fully stabilized towards cleavage (*Fig. 16*). The rates of ring-opening hydrolysis are greatly accelerated by electron withdrawing N-substituents and good nucleophiles in the proximity of the carbonyl functions. Thus, conjugates made with nucleophilic side chains and electron-withdrawing maleimides may be purposefully hydrolyzed to their ring-opened counterparts and ensure good *in vivo* stability.

References:

- *Covalent Modification of Biomolecules through Maleimide-Based Labeling Strategies; K. Renault, J. W. Fredy, P. Y. Renard, C. Sabot;* ***Bioconjug Chem*** *2018;* ***29****: 2497-2513. https://doi.org/10.1021/acs.bioconjchem.8b00252*
- *Optimisation of the dibromomaleimide (DBM) platform for native antibody conjugation by accelerated post-conjugation hydrolysis; M. Morais, J. P. M. Nunes, K. Karu, N. Forte, I. Benni, M. E. B. Smith, S. Caddick, V. Chudasama, J. R. Baker;* ***Org Biomol Chem*** *2017;* ***15****: 2947-2952. https://doi.org/10.1039/c7ob00220c*
- *Use of a next generation maleimide in combination with THIOMAB™ antibody technology delivers a highly stable, potent and near homogeneous THIOMAB™ antibody-drug conjugate (TDC); J. P. M. Nunes, V. Vassileva, E. Robinson, M. Morais, M. E. B. Smith, R. B. Pedley, S. Caddick, J. R. Baker, V. Chudasama;* ***RSC Advances*** *2017;* ***7****: 24828-24832. https://doi.org/10.1039/c7ra04606e*
- *Long-term stabilization of maleimide-thiol conjugates; S. D. Fontaine, R. Reid, L. Robinson, G. W. Ashley, D. V. Santi;* ***Bioconjug Chem*** *2015;* ***26****: 145-52. https://doi.org/10.1021/bc5005262*
- *Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates; R. P. Lyon, J. R. Setter, T. D. Bovee, S. O. Doronina, J. H. Hunter, M. E. Anderson, C. L. Balasubramanian, S. M. Duniho, C. I. Leiske, F. Li, P. D. Senter;* ***Nat Biotechnol*** *2014;* ***32****: 1059-62. https://doi.org/10.1038/nbt.2968*
- *Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy; L. N. Tumey, M. Charati, T. He, E. Sousa, D. Ma, X. Han, T. Clark, J. Casavant, F. Loganzo, F. Barletta, J. Lucas, E. I. Graziani;* ***Bioconjug Chem*** *2014;* ***25****: 1871-80. https://doi.org/10.1021/bc500357n*

Product details

RL-3000 Mal-Et-OH

N-(2-Hydroxyethyl)maleimide

CAS-No.	1585-90-6
Formula	$C_6H_7NO_3$
Mol. weight	141,12 g/mol



RL-2780 Mal-NH_2*HCl

2-Maleimidoethylamine hydrochloride

CAS-No.	134272-64-3
Formula	$C_6H_8N_2O_2$*HCl
Mol. weight	140,14*36,45 g/mol



back to content ↑

Product details

RL-2490 DBCO-mal

Dibenzoazacyclooctyne-maleimide

CAS-No. 1395786-30-7
Formula $C_{25}H_{21}N_3O_4$
Mol. weight 427,45 g/mol



RL-2500 DBCO-PEG(4)-mal

Dibenzoazacyclooctyne-tetra(ethylene glycol)-maleimide

CAS-No. 1480516-75-3
Formula $C_{36}H_{42}N_4O_9$
Mol. weight 674,74 g/mol



RL-2340 MeTz-PEG(4)-mal

Methyltetrazine-PEG(4)-maleimide

CAS-No. 1802908-02-6
Formula $C_{24}H_{30}N_6O_7$
Mol. weight 514,53 g/mol



MAA1020 Mal-beta-Ala-OSu

3-(Maleimido)propionic acid N-succinimidyl ester

CAS-No. 55750-62-4
Formula $C_{11}H_{10}N_2O_6$
Mol. weight 266,21 g/mol



RL-2640 Mal-Bu-NHS

4-Maleimidobutyric acid-NHS ester

CAS-No. 80307-12-6
Formula $C_{12}H_{12}N_2O_6$
Mol. weight 280,23 g/mol



RL-2670 Mal-Pen-NHS

5-Maleimidopentanoic acid-NHS ester

CAS-No. 103750-03-4
Formula $C_{13}H_{14}N_2O_6$
Mol. weight 294,26 g/mol



RL-2660 Mal-Hx-NHS

6-Maleimidohexanoic acid-NHS ester

CAS-No. 55750-63-5
Formula $C_{14}H_{16}N_2O_6$
Mol. weight 308,29 g/mol



RL-2690 Mal-PrHx-NHS

6-(3-Maleimidopropionylamino)-hexanoic acid-NHS ester

CAS-No. 367927-39-7
Formula $C_{17}H_{21}N_3O_7$
Mol. weight 379,36 g/mol



MAA1040 Mal-L-Dap(Boc)-OH*DCHA

N-alpha-MaleimidoN-beta-t-butyloxycarbonyl-L-2,3-di-aminopropionic acid dicyclohexylamine

CAS-No. 2004724-16-5
Formula $C_{12}H_{16}N_2O_6*C_{12}H_{23}N$
Mol. weight 284,27*181,32 g/mol



MAA1080 Mal-L-Dap(Boc)-OPfp

N-alpha-MaleimidoN-beta-t-butyloxycarbonyl-L-2,3-di-aminopropionic acid pentafluorophenolate

CAS-No. 1887132-90-2
Formula $C_{18}H_{15}F_5N_2O_6$
Mol. weight 450,31 g/mol



MAA1060 Mal-D-Dap(Boc)-OH*DCHA

N-alpha-MaleimidoN-beta-t-butyloxycarbo-nyl-D-2,3-diaminopropionic acid dicyclohexylamine

CAS-No. 2382651-11-6 net
Formula $C_{12}H_{16}N_2O_6*C_{12}H_{23}N$
Mol. weight 284,27*181,32 g/mol



MAA5400 Mal-AMCHC-OH

trans-4-(maleimidomethyl)cyclohexane-1-carboxylic acid

CAS-No. 69907-67-1
Formula $C_{12}H_{15}NO_4$
Mol. weight 237,25 g/mol



back to content ↑

Product details

MAA1000 Mal-AMCHC-OSu

trans-N-Succinimidyl 4-(maleimidomethyl)cyclohexane-1-carboxylate

CAS-No.	71875-81-5
Formula	$C_{16}H_{18}N_2O_6$
Mol. weight	334,33 g/mol



MAA1050 Sulfo-SMCC

4-(N-Maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt (cis/trans mixture)

CAS-No.	92921-24-9
Formula	$C_{16}H_{17}N_2NaO_9S$
Mol. weight	436,37 g/mol



RL-2650 Mal-cHxHx-NHS

6-[trans-4-(Maleimidomethyl)-cyclohexanoylamino]-hexanoic acid-NHS ester

CAS-No.	125559-00-4
Formula	$C_{22}H_{29}N_3O_7$
Mol. weight	447,48 g/mol



RL-2600 3-Mal-Bz-NHS

3-Maleimidobenzoic acid-NHS ester

CAS-No.	58626-38-3
Formula	$C_{15}H_{10}N_2O_6$
Mol. weight	314,25 g/mol



RL-2610 3-Mal-MBz-NHS

3-(Maleimidomethyl)-benzoic acid-NHS ester

CAS-No.	91574-36-6
Formula	$C_{16}H_{12}N_2O_6$
Mol. weight	328,28 g/mol



RL-2620 4-Mal-Bz-NHS

4-Maleimidobenzoic acid-NHS ester

CAS-No.	64191-06-6
Formula	$C_{15}H_{10}N_2O_6$
Mol. weight	314,25 g/mol



RL-2630 4-Mal-MBz-NHS

4-(Maleimidomethyl)-benzoic acid-NHS ester

CAS-No. 64987-84-4
Formula $C_{16}H_{12}N_2O_6$
Mol. weight 328,28 g/mol



RL-2680 Mal-PhBu-NHS

4-(4-Maleimidophenyl)-butyric acid-NHS ester

CAS-No. 79886-55-8
Formula $C_{18}H_{16}N_2O_6$
Mol. weight 356,33 g/mol



LS-3350 4-(N-Maleimido)benzophenone

1-(4-Benzoylphenyl)-1H-pyrrole-2,5-dione

CAS-No. 92944-71-3
Formula $C_{17}H_{11}NO_3$
Mol. weight 277,28 g/mol



RL-3380 (Mal-CH_2CH_2)$_2$-N-CH_2-COOH

bis(2-(maleinimido)ethyl)glycine

Formula $C_{14}H_{15}N_3O_6$
Mol. weight 321,29 g/mol



RL-3430 Mal-N-Boc-Aeg-NHS

N-(t-butoxycarbonyl)-N-(2-(maleinimido)ethyl)glycine
N-Hydroxysuccinimidyl ester

Formula $C_{17}H_{21}N_3O_8$
Mol. weight 395,37 g/mol



RL-3450 Mal-CH_2CH_2-N-(CH_2-COOH)$_2$

2,2'-((2-(maleinimido)ethyl)azanediyl)diacetic acid

CAS-No. 207612-92-8
Formula $C_{10}H_{12}N_2O_6$
Mol. weight 256,21 g/mol



back to content ↑

Product details

RL-3400 Mal-CH_2CH_2-N(Me)-CH_2-COOH

N-(2-(maleinimido)ethyl)-N-methylglycine

Formula	$C_9H_{12}N_2O_4$
Mol. weight	212,21 g/mol



MAA1100 Mal-AMCHC-N-Propargylamide

trans-4-[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl]-N-(prop-2-yn-1-yl)cyclohexane-1-carboxamide

CAS-No.	2027476-42-0
Formula	$C_{15}H_{18}N_2O_3$
Mol. weight	274,32 g/mol



2.4. Photoactivatable Linkers

Irradiation of diazirines with UV light (ca. 350-360 nm) yields a highly reactive carbene species that can undergo insertions into C–C, C–H, O–H, and X–H (X = heteroatom) bonds of neighboring molecules to irreversibly form a covalent bond (*Fig. 17*). The diazirine moiety is the smallest of all photophores, so introduction of a diazirine-bearing amino acid into a peptide or protein usually does not impair its biological activity. Further, advantages of diazirine crosslinkers are their stability at room temperature and their relative stability against nucleophiles as well as towards both acidic and basic conditions.



Fig. 17: Use of photo-phenylalanine for the identification of angiotensin-II receptor binding sites; ^{125}I is used as a radiotracer.

References:

- → *Protein-polymer conjugation via ligand affinity and photoactivation of glutathione S-transferase; E. W. Lin, N. Boehnke, H. D. Maynard;* ***Bioconjug Chem*** *2014;* ***25****: 1902-9. https://doi.org/10.1021/bc500380r*
- → *Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes; H. Shi, C. J. Zhang, G. Y. Chen, S. Q. Yao;* ***J Am Chem Soc*** *2012;* ***134****: 3001-14. https://doi.org/10.1021/ja208518u*
- → *Probing protein-protein interactions with a genetically encoded photo-crosslinking amino acid; H. W. Ai, W. Shen, A. Sagi, P. R. Chen, P. G. Schultz;* ***ChemBioChem*** *2011;* ***12****: 1854-7. https://doi.org/10.1002/cbic.201100194*

- *Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe; H. Shi, X. Cheng, S. K. Sze, S. Q. Yao;* ***Chem Commun*** *2011;* ***47****: 11306-8. https://doi.org/10.1039/c1cc14824a*
- *Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4; J. M. Janz, Y. Ren, R. Looby, M. A. Kazmi, P. Sachdev, A. Grunbeck, L. Haggis, D. Chinnapen, A. Y. Lin, C. Seibert, T. McMurry, K. E. Carlson, T. W. Muir, S. Hunt, 3rd, T. P. Sakmar;* ***J Am Chem Soc*** *2011;* ***133****: 15878-81. https://doi.org/10.1021/ja206661w*
- *Aliphatic diazirines as photoaffinity probes for proteins: recent developments; J. Das;* ***Chem Rev*** *2011;* ***111****: 4405-17. https://doi.org/10.1021/cr1002722*
- *Synthesis and application of photoproline - a photoactivatable derivative of proline; B. VanderMeijden, J. A. Robinson;* ***Arkivoc*** *2011;* ***2011****: 130-136. https://doi.org/10.3998/ark.5550190.0012.611*
- *Photo-crosslinking of proteins in intact cells reveals a dimeric structure of cyclooxygenase-2 and an inhibitor-sensitive oligomeric structure of microsomal prostaglandin E2 synthase-1; P. O. Hetu, M. Ouellet, J. P. Falgueyret, C. Ramachandran, J. Robichaud, R. Zamboni, D. Riendeau;* ***Arch Biochem Biophys*** *2008;* ***477****: 155-62. https://doi.org/10.1016/j.abb.2008.04.038*
- *Covalent capture of phospho-dependent protein oligomerization by site-specific incorporation of a diazirine photo-cross-linker; M. Vila-Perello, M. R. Pratt, F. Tulin and T. W. Muir;* ***J Am Chem Soc*** *2007;* ***129****: 8068-9. https://doi.org/10.1021/ja072013j*
- *Photo-leucine incorporation reveals the target of a cyclodepsipeptide inhibitor of cotranslational translocation; A. L. MacKinnon, J. L. Garrison, R. S. Hegde, J. Taunton;* ***J Am Chem Soc*** *2007;* ***129****: 14560-1. https://doi.org/10.1021/ja076250y*
- *Synthesis of photoactive analogues of a cystine knot trypsin inhibitor protein; T. Durek, J. Zhang, C. He, S. B. Kent;* ***Org Lett*** *2007;* ***9****: 5497-500. https://doi.org/10.1021/ol702461z*
- *Photo-leucine and photo-methionine allow identification of protein-protein interactions in living cells; M. Suchanek, A. Radzikowska, C. Thiele;* ***Nat Methods*** *2005;* ***2****: 261-7. https://doi.org/10.1038/nmeth752*

Product details

RL-2910 Photo-Butylamine

2-(3-methyl-3H-diazirin-3-yl)ethan-1-amine hydrochloride

CAS-No.	25055-95-2
Formula	$C_4H_9N_3$*HCl
Mol. weight	99,13*36,45 g/mol



RL-2890 Photo-Pentanoic acid

3-(3-methyl-3H-diazirin-3-yl)propanoic acid

CAS-No.	25055-86-1
Formula	$C_5H_8N_2O_2$
Mol. weight	128,13 g/mol



RL-2900 Photo-Hexanoic acid

4-(3-methyl-3H-diazirin-3-yl)butanoic acid

CAS-No.	16297-97-5
Formula	$C_6H_{10}N_2O_2$
Mol. weight	142,16 g/mol



back to content ↑

Product details

RL-2920 Photo-Benzoic acid

4-[3-(Trifluoromethyl)-3H-diazirin-3-yl]benzoic acid

CAS-No. 85559-46-2
Formula $C_9H_5F_3N_2O_2$
Mol. weight 230,14 g/mol



RL-2930 Photo-Benzylamine*HCl

4-[3-(Trifluoromethyl)-3H-diazirin-3-yl]benzylamine hydrochloride

CAS-No. 1258874-29-1
Formula $C_9H_8N_3F_3$*HCl
Mol. weight 215,18*36,45 g/mol



RL-3410 Photo-Click-Heptanoic acid

2-(3-(but-3-ynyl)-3H-diazirin-3-yl)acetic acid

CAS-No. 2049109-24-0
Formula $C_7H_8N_2O_2$
Mol. weight 152,15 g/mol



RL-2035 ATFB

4-Azido-2,3,5,6-tetrafluorobenzoic acid

CAS-No. 122590-77-6
Formula $C_7HF_4N_3O_2$
Mol. weight 235,1 g/mol



RL-2045 ATFB-NHS

N-Succinimidyl 4-azido-2,3,5,6-tetrafluorobenzoate

CAS-No. 126695-58-7
Formula $C_{11}H_4F_4N_4O_4$
Mol. weight 332,17 g/mol



PEG5000 N_3-TFBA-O_2Oc

{2-[2-(4-Azido-2,3,5,6-tetrafluorobenzoyl-amino)ethoxy] ethoxy}acetic acid

CAS-No. 1993119-45-1
Formula $C_{13}H_{12}F_4N_4O_5$
Mol. weight 380,25 g/mol



Find many more photoactivatable linkers in our Photo Chemistry brochure or visit our website:



back to content ↑

3. Cleavable Linkers

Peptidic bonds are expected to have a high serum stability, as lysosomal proteolytic enzymes show reduced activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood compared to lysosomes. This was confirmed by preclinical *in vivo* studies, which revealed half-lives of seven to ten days for peptide linkers. Release of a drug conjugated *via* a peptidyl linker to monoclonal antibodies (mAb) occurs specifically due to the action of lysosomal proteases (e.g., cathepsin and plasmin). These proteases may be present at elevated levels in certain tumor tissues. Therefore, peptide linkers combine greater systemic stability with rapid enzymatic release of the drug in the target cell. Besides Val-Ala, Val-Cit and Phe-Lys, other sequences have been reported as lysosomally cleavable peptides, like Gly-Phe-Leu-Gly and Ala-Leu-Ala-Leu.

References:

→ *Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect; M. Kovar, J. Strohalm, T. Etrych, K. Ulbrich, B. Rihova;* ***Bioconjug Chem*** *2002;* ***13****: 206-15. https://doi.org/10.1021/bc010063m*

→ *Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy; A. J. Versluis, E. T. Rump, P. C. Rensen, T. J. Van Berkel, M. K. Bijsterbosch;* ***Pharm Res*** *1998;* ***15****: 531-7. https://doi.org/10.1023/a:1011917508056*

→ *Influence of a peptide linker on biodistribution and metabolism of antibody-conjugated benzyl-EDTA. Comparison of enzymatic digestion in vitro and in vivo; M. Studer, L. A. Kroger, S. J. DeNardo, D. L. Kukis and C. F. Meares;* ***Bioconjug Chem*** *1992;* ***3****: 424-9. https://doi.org/10.1021/bc00017a012*



Fig. 18: Cyclobutane-1,1-dicarboxamide can replace valine in dipeptide linker systems, resulting in improved ADC selectivity.

Peptide-based ADC linkers, such as Val-Cit or Val-Ala, that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. However, the use of peptide-based linkers limits the ability to modulate protease specificity. Furthermore, if the linker can preferentially be hydrolyzed by tumor-specific proteases only, safety margin may improve. In this context, a cyclobutane-1,1-dicarboxamide-containing linker (*Fig. 18*) replacing valine in other sequences has been invented which is hydrolyzed predominantly by cathepsin B, while the typical valine-citrulline dipeptide linker is rather less. ADCs bearing the nonpeptidic linker are as efficacious and stable *in vivo* as those with the dipeptide linker. Hence, the application of the peptidomimetic linker presents new opportunities for improving the selectivity of ADCs.

Reference:

→ *Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity; B. Wei, J. Gunzner-Toste, H. Yao, T. Wang, J. Wang, Z. Xu, J. Chen, J. Wai, J. Nonomiya, S. P. Tsai, J. Chuh, K. R. Kozak, Y. Liu, S. F. Yu, J. Lau, G. Li, G. D. Phillips, D. Leipold, A. Kamath, D. Su, K. Xu, C. Eigenbrot, S. Steinbacher, R. Ohri, H. Raab, L. R. Staben, G. Zhao, J. A. Flygare, T. H. Pillow, V. Verma, L. A. Masterson, P. W. Howard, B. Safina;* ***J. Med. Chem.*** *2018;* ***61****: 989-1000.https://doi.org/10.1021/acs.jmedchem.7b01430*

3.1. Valine-Alanine-Based Enzymatically Cleavable Linkers

Product details

ADC1290 6-Azidohexanoyl-Val-Ala-PAB

6-azidohexanoyl-valyl-alanyl-(4-aminobenzyl alcohol)

Formula $C_{21}H_{32}N_6O_4$
Mol. weight 432,52 g/mol



ADC1300 6-Azidohexanoyl-Val-Ala-PAB-PNP

6-azidohexanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{28}H_{35}N_7O_8$
Mol. weight 597,62 g/mol



Reference:

→ *NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity; R. J. Anderson, B. J. Compton, C. W. Tang, A. Authier-Hall, C. M. Hayman, G. W. Swinerd, R. Kowalczyk, P. Harris, M. A. Brimble, D. S. Larsen, O. Gasser, R. Weinkove, I. F. Hermans, G. F. Painter;* ***Chem. Sci.*** *2015;* ***6****: 5120-5127. https://doi.org/10.1039/c4sc03599b*

Product details

ADC1330 Azido-PEG(4)-Val-Ala-PAB

azido-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl alcohol)

Formula $C_{26}H_{42}N_6O_8$
Mol. weight 566,65 g/mol



ADC1340 Azido-PEG(4)-Val-Ala-PAB-PNP

azido-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{33}H_{45}N_7O_{12}$
Mol. weight 731,75 g/mol



back to content ↑

Product details

ADC1310 4-Pentynoyl-Val-Ala-PAB

4-pentynoyl-valyl-alanyl-(4-aminobenzyl alcohol)



CAS-No. 1956294-75-9
Formula $C_{20}H_{27}N_3O_4$
Mol. weight 373,45 g/mol

ADC1320 4-Pentynoyl-Val-Ala-PAB-PNP

4-pentynoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



CAS-No. 1956294-76-0
Formula $C_{27}H_{30}N_4O_8$
Mol. weight 538,55 g/mol

Reference:

→ *Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation; N. Cox, J. R. Kintzing, M. Smith, G. A. Grant, J. R. Cochran;* ***Angew Chem Int Ed*** *2016;* ***55****: 9894-7. https://doi.org/10.1002/anie.201603488*

Product details

ADC1350 Alkyne-PEG(4)-Val-Ala-PAB

propargyl-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl alcohol)



Formula $C_{29}H_{45}N_3O_9$
Mol. weight 579,68 g/mol

ADC1360 Alkyne-PEG(4)-Val-Ala-PAB-PNP

propargyl-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{36}H_{48}N_4O_{13}$
Mol. weight 744,79 g/mol

References:

→ *Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents; J. Almaliti, B. Miller, H. Pietraszkiewicz, E. Glukhov, C. B. Naman, T. Kline, J. Hanson, X. Li, S. Zhou, F. A. Valeriote, W. H. Gerwick;* ***Eur J Med Chem*** *2019;* ***161****: 416-432. https://doi.org/10.1016/j.ejmech.2018.10.024*

→ *Design and synthesis of novel dual-cyclic RGD peptides for alphavbeta3 integrin targeting; J. Liu, X. Cheng, X. Tian, D. Guan, J. Ao, Z. Wu, W. Huang, Z. Le;* ***Bioorg Med Chem Lett*** *2019;* ***29****: 896-900. https://doi.org/10.1016/j.bmcl.2019.01.043*

Product details

ADC1040 Boc-Val-Ala-PAB

t-Butyloxycarbonyl-valyl-alanyl-4-aminobenzylalcohol

CAS-No.	1884577-99-4
Formula	$C_{20}H_{31}N_3O_5$
Mol. weight	393,48 g/mol



ADC1050 Boc-Val-Ala-PAB-PNP

t-Butyloxycarbonyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)carbonate

CAS-No.	1884578-00-0
Formula	$C_{27}H_{34}N_4O_9$
Mol. weight	558,58 g/mol



ADC1060 Fmoc-Val-Ala-PAB

9-Fluorenylmethyloxycarbonyl-valyl-alanyl-4-aminobenzylalcohol

CAS-No.	1394238-91-5
Formula	$C_{30}H_{33}N_3O_5$
Mol. weight	515,61 g/mol



ADC1070 Fmoc-Val-Ala-PAB-PNP

9-Fluorenylmethyloxycarbonyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)carbonate

CAS-No.	1394238-92-6
Formula	$C_{37}H_{36}N_4O_9$
Mol. weight	680,71 g/mol



ADC1410 Fmoc-Val-Ala-PAB-NMeCH$_2$CH$_2$NMe-Boc

9-Fluorenylmethyloxycarbonyl-valyl-alanyl-4-aminobenzyloxycarbonyl-((t-buytl methyl(2-methylamino)ethyl)carbamate)

CAS-No.	1691196-82-3
Formula	$C_{40}H_{51}N_5O_8$
Mol. weight	729,86 g/mol



back to content ↑

References:

- *Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin alphaV beta3; A. Raposo Moreira Dias, A. Pina, A. Dal Corso, D. Arosio, L. Belvisi, L. Pignataro, M. Caruso and C. Gennari;* ***Chemistry*** *2017;* ***23****: 14410-14415. https://doi.org/10.1002/chem.201703093*
- *Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers; A. Dal Corso, M. Caruso, L. Belvisi, D. Arosio, U. Piarulli, C. Albanese, F. Gasparri, A. Marsiglio, F. Sola, S. Troiani, B. Valsasina, L. Pignataro, D. Donati, C. Gennari;* ***Chemistry*** *2015;* ***21****: 6921-9. https://doi.org/10.1002/chem.201500158*
- *Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release; F. M. de Groot, W. J. Loos, R. Koekkoek, L. W. van Berkom, G. F. Busscher, A. E. Seelen, C. Albrecht, P. de Bruijn, H. W. Scheeren;* ***J Org Chem*** *2001;* ***66****: 8815-30. https://doi.org/10.1021/jo0158884*

Product details

ADC1270 MC-Val-Ala-PAB

6-maleimidohexanoyl-valyl-alanyl-(4-aminobenzyl alcohol)



CAS-No.	1870916-87-2
Formula	$C_{25}H_{34}N_4O_6$
Mol. weight	486,56 g/mol

ADC1280 MC-Val-Ala-PAB-PNP

6-maleimidohexanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



CAS-No.	1639939-40-4
Formula	$C_{32}H_{37}N_5O_{10}$
Mol. weight	651,66 g/mol

Reference:

- *Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research; D. Mondal, J. Ford, K. G. Pinney;* ***Tetrahedron Lett*** *2018;* ***59****: 3594-3599. https://doi.org/10.1016/j.tetlet.2018.08.021*

Product details

ADC1540 DTM-C6-Val-Ala-PAB

6-(3,4-bisphenylthiomaleimido)hexanoyl-valyl-alanyl-(4-aminobenzyl alcohol)



Formula	$C_{37}H_{42}N_4O_6S_2$
Mol. weight	702,88 g/mol

ADC1550 DTM-C6-Val-Ala-PAB-PNP

6-(3,4-bisphenylthiomaleimido)hexanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{44}H_{45}N_5O_{10}S_2$
Mol. weight 867,99 g/mol

References:

- *Next generation maleimides enable the controlled assembly of antibody-drug conjugates via native disulfide bond bridging; F. F. Schumacher, J. P. Nunes, A. Maruani, V. Chudasama, M. E. Smith, K. A. Chester, J. R. Baker, S. Caddick;* ***Org Biomol Chem*** *2014;* ***12****: 7261-9. https://doi.org/10.1039/c4ob01550a*
- *Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro; N. Aubrey, E. Allard-Vannier, C. Martin, F. Bryden, S. Letast, C. Colas, Z. Lakhrif, N. Collinet, I. Dimier-Poisson, I. Chourpa, M. C. Viaud-Massuard, N. Joubert;* ***Bioconjug Chem*** *2018;* ***29****: 3516-3521. https://doi.org/10.1021/acs.bioconjchem.8b00668*
- *Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates; F. Bryden, C. Martin, S. Letast, E. Lles, I. Vieitez-Villemin, A. Rousseau, C. Colas, M. Brachet-Botineau, E. Allard-Vannier, C. Larbouret, M. C. Viaud-Massuard, N. Joubert;* ***Org Biomol Chem*** *2018;* ***16****: 1882-1889. https://doi.org/10.1039/c7ob02780j*

ADC1080 Mal-Dap(Boc)-Val-Ala-PAB-PNP

N-alpha-Maleimido-N-beta-t-butyloxycarbonyl-L-2,3-diaminopropionyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{34}H_{40}N_6O_{12}$
Mol. weight 721,71 g/mol

References:

- *Linker Technologies for Antibody–Drug Conjugates; B. Nolting;* ***Antibody-Drug Conjugates L. Ducry*** *2013;* ***1045****: 71-100. https://doi.org/10.1007/978-1-62703-541-5_5*
- *Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates; R. P. Lyon, J. R. Setter, T. D. Bovee, S. O. Doronina, J. H. Hunter, M. E. Anderson, C. L. Balasubramanian, S. M. Duniho, C. I. Leiske, F. Li, P. D. Senter;* ***Nat Biotechnol*** *2014;* ***32****: 1059-62. https://doi.org/10.1038/nbt.2968*
- *Self-Stabilizing Linker Conjugate; Lyon R., Doronina S., Bovee T.; Seattle Genetics, Inc.; U.S. Patent No. 9,504,756, 2013*

back to content ↑

Product details

ADC1370 Mal-PEG(4)-Val-Ala-PAB

maleimido-tetraethyleneglycol-propanoyl-alanyl-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{33}H_{50}N_6O_{11}$
Mol. weight 706,78 g/mol



Reference:

→ *In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas; S. Cazzamalli, E. Figueras, L. Petho, A. Borbely, C. Steinkuhler, D. Neri, N. Sewald;* ***ACS Omega*** *2018; 3: 14726-14731. https://doi.org/10.1021/acsomega.8b02350*

Product details

ADC1390 Mal-beta-Ala-PEG(4)-Val-Ala-PAB

maleimido-beta-alanyl-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl alcohol)

Formula $C_{33}H_{49}N_5O_{11}$
Mol. weight 691,77 g/mol



ADC1400 Mal-beta-Ala-PEG(4)-Val-Ala-PAB-PNP

maleimido-beta-alanyl-tetraethyleneglycol-propanoyl-valyl-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

CAS-No. 2417003-94-0
Formula $C_{40}H_{52}N_6O_{15}$
Mol. weight 856,87 g/mol



ADC1580 Azido-cyclobutane-1,1-dicarboxamide-Ala-PAB

3-azidopropyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl alcohol)

Formula $C_{19}H_{26}N_6O_4$
Mol. weight 402,45 g/mol



ADC1590 Azido-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP

3-azidopropyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{26}H_{29}N_7O_8$
Mol. weight 567,55 g/mol



ADC1600 Propargyl-cyclobutane-1,1-dicarboxamide-Ala-PAB

propargyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl alcohol)



Formula $C_{19}H_{23}N_3O_4$
Mol. weight 357,40 g/mol

ADC1610 Propargyl-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP

propargyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{26}H_{26}N_4O_8$
Mol. weight 522,51 g/mol

ADC1620 DBCO-cyclobutane-1,1-dicarboxamide-Ala-PAB

dibenzoazacyclooctyne-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl alcohol)



Formula $C_{34}H_{34}N_4O_5$
Mol. weight 578,66 g/mol

ADC1630 DBCO-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP

dibenzoazacyclooctyne-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{41}H_{37}N_5O_9$
Mol. weight 743,76 g/mol

ADC1560 Mal-cyclobutane-1,1-dicarboxamide-Ala-PAB

5-maleimidopentyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl alcohol)



Formula $C_{25}H_{32}N_4O_6$
Mol. weight 484,54 g/mol

ADC1570 Mal-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP

5-maleimidopentyl-cyclobutane-1,1-dicarboxamide-alanyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



Formula $C_{32}H_{35}N_5O_{10}$
Mol. weight 649,65 g/mol

back to content ↑

Reference:

→ *Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity; B. Wei, J. Gunzner-Toste, H. Yao, T. Wang, J. Wang, Z. Xu, J. Chen, J. Wai, J. Nonomiya, S. P. Tsai, J. Chuh, K. R. Kozak, Y. Liu, S. F. Yu, J. Lau, G. Li, G. D. Phillips, D. Leipold, A. Kamath, D. Su, K. Xu, C. Eigenbrot, S. Steinbacher, R. Ohri, H. Raab, L. R. Staben, G. Zhao, J. A. Flygare, T. H. Pillow, V. Verma, L. A. Masterson, P. W. Howard, B. Safina;* ***J. Med. Chem.*** *2018;* ***61****: 989-1000. https://doi.org/10.1021/acs.jmedchem.7b01430*

3.2. Valine-Citrulline-Based Enzymatically Cleavable Linkers

Product details

ADC1120 6-Azidohexanoyl-Val-Cit-PAB

6-azidohexanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

CAS-No.	1613321-02-0
Formula	$C_{24}H_{38}N_8O_5$
Mol. weight	518,61 g/mol



ADC1130 6-Azidohexanoyl-Val-Cit-PAB-PNP

6-azidohexanoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

CAS-No.	1613321-01-9
Formula	$C_{31}H_{41}N_9O_9$
Mol. weight	683,71 g/mol



Reference:

→ *NKT cell-dependent glycolipid-peptide vaccines with potent anti-tumour activity; R. J. Anderson, B. J. Compton, C. W. Tang, A. Authier-Hall, C. M. Hayman, G. W. Swinerd, R. Kowalczyk, P. Harris, M. A. Brimble, D. S. Larsen, O. Gasser, R. Weinkove, I. F. Hermans, G. F. Painter;* ***Chem. Sci.*** *2015;* ***6****: 5120-5127. https://doi.org/10.1039/c4sc03599b*

Product details

ADC1160 Azido-PEG(4)-Val-Cit-PAB

azido-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

CAS-No.	2055024-64-9
Formula	$C_{29}H_{48}N_8O_9$
Mol. weight	652,74 g/mol



Product details

ADC1170 Azido-PEG(4)-Val-Cit-PAB-PNP

azido-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

CAS-No. 1869126-60-2
Formula $C_{36}H_{51}N_9O_{13}$
Mol. weight 817,84 g/mol



ADC1140 4-Pentynoyl-Val-Cit-PAB

4-pentynoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{23}H_{33}N_5O_5$
Mol. weight 459,54 g/mol



ADC1150 4-Pentynoyl-Val-Cit-PAB-PNP

4-pentynoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{30}H_{36}N_6O_9$
Mol. weight 624,64 g/mol



Reference:

→ *Integrin-Targeting Knottin Peptide–Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation. N. Cox, J. R. Kintzing, M. Smith, G. A. Grant, J. R. Cochran;* ***Angew. Chem. Int. Ed.*** *2016;* ***55(34)****: 9894-9897. https://doi.org/10.1002/anie.201603488*

Product details

ADC1180 Alkyne-PEG(4)-Val-Cit-PAB

propargyl-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{32}H_{51}N_5O_{10}$
Mol. weight 665,77 g/mol



ADC1190 Alkyne-PEG(4)-Val-Cit-PAB-PNP

propargyl-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{39}H_{54}N_6O_{14}$
Mol. weight 830,88 g/mol



back to content ↑

References:

→ *Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. J. Almaliti, B. Miller, H. Pietraszkiewicz, E. Glukhov, C. B. Naman, T. Kline, J. Hanson, X. Li, S. Zhou, F. A. Valeriote, W. H. Gerwick;* ***Eur J Med Chem.*** *2019;* ***161****: 416-432. https://doi.org/10.1016/j.ejmech.2018.10.024*

→ *Design and synthesis of novel dual-cyclic RGD peptides for αvβ3 integrin targeting. J. Liu, X. Cheng, X. Tian, D. Guan, J. Ao, Z. Wu, W. Huang, Z. Le;* ***Bioorg Med Chem Lett.*** *2019;* ***29(7)****: 896-900. https://doi.org/10.1016/j.bmcl.2019.01.043*

Product details

ADC1020 Boc-Val-Cit-PAB

t-Butyloxycarbonyl-valyl-citrullyl-4-aminobenzylalcohol

CAS-No.	870487-09-5
Formula	$C_{23}H_{37}N_5O_6$
Mol. weight	479,59 g/mol



ADC1010 Boc-Val-Cit-PAB-PNP

t-Butyloxycarbonyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)carbonate

CAS-No.	870487-10-8
Formula	$C_{30}H_{40}N_6O_{10}$
Mol. weight	644,67 g/mol



ADC1030 Fmoc-Val-Cit-PAB

9-Fluorenylmethyloxycarbonyl-valyl-citrullyl-4-aminobenzylalcohol

CAS-No.	159858-22-7
Formula	$C_{33}H_{39}N_5O_6$
Mol. weight	601,29 g/mol



ADC1000 Fmoc-Val-Cit-PAB-PNP

9-Fluorenylmethyloxycarbonyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)carbonate

CAS-No.	863971-53-3
Formula	$C_{40}H_{42}N_6O_{10}$
Mol. weight	766,80 g/mol



ADC1240 Fmoc-Val-Cit-PAB-NMeCH$_2$CH$_2$NMe-Boc

9-Fluorenylmethyloxycarbonyl-valyl-citrullyl-4-aminobenzyloxycarbonyl-((t-buytl methyl(2-methylamino)ethyl)carbamate)



CAS-No.	1802297-96-6
Formula	$C_{43}H_{57}N_7O_9$
Mol. weight	815,95 g/mol

References:

- *Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αVβ3. A. R. M. Dias, A. Pina, A. Dal Corso, D. Arosio, L. Belvisi, L. Pignataro, M. Caruso, C. Gennari;* ***Chem. Eur. J.*** *2017;* ***23(58)****: 14410-14415. https://doi.org/10.1002/chem.201703093*
- *Synthesis and Biological Evaluation of RGD Peptidomimetic–Paclitaxel Conjugates Bearing Lysosomally Cleavable Linkers. A. D. Corso, M. Caruso, L. Belvisi, D. Arosio, U. Piarulli, C. Albanese, F. Gasparri, A. Marsiglio, F. Sola, S. Troiani, B. Valsasina, L. Pignataro, D. Donati, C. Gennari;* ***Chem. Eur. J.*** *2015;* ***21(18)****: 6921-6929. https://doi.org/10.1002/chem.201500158*
- *Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatible Anticancer Prodrugs for Enhanced Drug Release. F. M. H. de Groot, W. J. Loos, R. Koekkoek, L. W. A. van Berkom, G. F. Busscher, A. E. Seelen, C. Albrecht, P. Bruijn, H. W. Scheeren;* ***J. Org. Chem.*** *2001;* ***66(26)****: 8815-8830. https://doi.org/10.1021/jo0158884*

ADC1100 MC-Val-Cit-PAB

6-maleimidohexanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)



CAS-No.	159857-80-4
Formula	$C_{28}H_{40}N_6O_7$
Mol. weight	572,65 g/mol

ADC1110 MC-Val-Cit-PAB-PNP

6-maleimidohexanoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate



CAS-No.	159857-81-5
Formula	$C_{35}H_{43}N_7O_{11}$
Mol. weight	737,76 g/mol

Reference:

- *Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. D. Mondal, J. Ford, K. G. Pinney;* ***Tetrahedron Lett.*** *2018;* ***59(40)****: 3594-3599. https://doi.org/10.1016/j.tetlet.2018.08.021*

back to content ↑

Product details

ADC1200 Mal-PEG(4)-Val-Cit-PAB

maleimido-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

CAS-No. 2055041-39-7
Formula $C_{33}H_{50}N_6O_{11}$
Mol. weight 706,78 g/mol



Reference:

→ *In Vivo Antitumor Activity of a Novel Acetazolamide–Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas. S. Cazzamalli, E. Figueras, L. Pethő, A. Borbély, C. Steinkühler, D. Neri, N. Sewald;* ***ACS Omega*** *2018;* ***3(11)****: 14726-14731. https://doi.org/10.1021/acsomega.8b02350*

Product details

ADC1220 Mal-beta-Ala-PEG(4)-Val-Cit-PAB

maleimido-beta-alanyl-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl alcohol)

CAS-No. 1949793-41-2
Formula $C_{36}H_{55}N_7O_{12}$
Mol. weight 777,86 g/mol



ADC1230 Mal-beta-Ala-PEG(4)-Val-Cit-PAB-PNP

maleimido-beta-alanyl-tetraethyleneglycol-propanoyl-valyl-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

CAS-No. 2003260-12-4
Formula $C_{43}H_{58}N_8O_{16}$
Mol. weight 942,96 g/mol



ADC1480 Azido-cyclobutane-1,1-dicarboxamide-Cit-PAB

3-azidopropyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{22}H_{32}N_8O_5$
Mol. weight 488,54 g/mol



ADC1490 Azido-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP

3-azidopropyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{29}H_{35}N_9O_9$
Mol. weight 653,64 g/mol



ADC1500 Propargyl-cyclobutane-1,1-dicarboxamide-Cit-PAB

propargyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{22}H_{29}N_5O_5$
Mol. weight 443,50 g/mol



ADC1510 Propargyl-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP

propargyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{29}H_{32}N_6O_9$
Mol. weight 608,60 g/mol



ADC1520 DBCO-cyclobutane-1,1-dicarboxamide-Cit-PAB

dibenzoazacyclooctyne-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl alcohol)

Formula $C_{37}H_{40}N_6O_6$
Mol. weight 664,75 g/mol



ADC1530 DBCO-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP

dibenzoazacyclooctyne-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

Formula $C_{44}H_{43}N_7O_{10}$
Mol. weight 829,85 g/mol



ADC1460 Mal-cyclobutane-1,1-dicarboxamide-Cit-PAB

5-maleimidopentyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl alcohol)

CAS-No. 1799663-03-8
Formula $C_{28}H_{38}N_6O_7$
Mol. weight 570,64 g/mol



ADC1470 Mal-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP

5-maleimidopentyl-cyclobutane-1,1-dicarboxamide-citrullyl-(4-aminobenzyl)-(4-nitrophenyl)-carbonate

CAS-No. 2204228-34-0
Formula $C_{35}H_{41}N_7O_{11}$
Mol. weight 735,74 g/mol



back to content ↑

Reference:

→ *Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity. B. Wei, J. Gunzner-Toste, H. Yao, T. Wang, J. Wang, Z. Xu, J. Chen, J. Wai, J. Nonomiya, S. Ping Tsai, J. Chuh, K. R. Kozak, Y. Liu, S. Yu, J. Lau, G. Li, G. D. Phillips, D. Leipold, A. Kamath, D. Su, K. Xu, C. Eigenbrot, S. Steinbacher, R. Ohri, H. Raab, L. R. Staben, G. Zhao, J. A. Flygare, T. H. Pillow, V. Verma, L. A. Masterson, P. W. Howard, B. Safina;* ***J. Med. Chem.*** *2018;* ***61(3)****: 989-1000. https://doi.org/10.1021/acs.jmedchem.7b01430*

3.3. β-Glucuronide Enzymatically Cleavable Linkers

As an extension of the linkerology® toolbox, the design of linkers with improved stability during systemic circulation is highly desired. As the drug-releasing lysosomal enzyme β-glucuronidase is abundantly present within lysosomes and overexpressed in some tumor types but low outside cells, β-glucuronic acid-based linkers provide the potential for high ADC stability in the systemic circulation and selective intracellular drug release. Especially for ADCs based on highly hydrophobic drugs, the incorporation of the highly hydrophilic β-glucuronides may circumvent the tendency of aggregation. For example, a drug-linker consisting of a β-glucuronide linked to auristatin MMAF was prepared. Rat plasma stability analysis revealed an extrapolated half-life of 81 days, compared with about six days for the corresponding valine-citrulline dipeptide-linked MMAF.

Interested in β-Glucuronide Enzymatically Cleavable Linkers?

Please contact our Custom Synthesis for more details.





References:

→ *Expanded Utility of the β-Glucuronide Linker: ADCs That Deliver Phenolic Cytotoxic Agents; S. C. Jeffrey, J. De Brabander, J. Miyamoto, P. D. Senter;* ***ACS Med. Chem. Lett.*** *2010;* ***1****: 277-280. https://doi.org/10.1021/ml100039h*

→ *Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates; S. C. Jeffrey, J. B. Andreyka, S. X. Bernhardt, K. M. Kissler, T. Kline, J. S. Lenox, R. F. Moser, M. T. Nguyen, N. M. Okeley, I. J. Stone, X. Zhang, P. D. Senter;* ***Bioconjugate Chem.*** *2006;* ***17****: 831-840. https://doi.org/10.1021/bc0600214*

→ *Linker Technologies for Antibody–Drug Conjugates; B. Nolting;* ***Antibody-Drug Conjugates L. Ducry*** *2013;* ***1045****: 71-100. https://doi.org/10.1007/978-1-62703-541-5_5*

3.4. Disulfide-Based (Self-Immolative) Linkers

Another chemically labile linkage extensively exploited in the development of antibody-drug conjugates are disulfides. They are stable at physiological pH and are designed to release the drug upon internalization inside cells. The cytosol provides a significantly more reducing environment compared to the extracellular milieu and the presence of cytoplasmic thiol cofactor, such as reduced glutathione (GSH). Additionally, the intracellular enzyme protein disulfide isomerase, or similar enzymes capable of cleaving disulfide bonds, may also contribute to the preferential cleavage of disulfide bonds inside cells. GSH is reported to be present in cells in the concentration range of 0.5-10 mM, compared with a significantly lower concentration of GSH or cysteine in plasma at approximately 5 µM. This is especially true for tumor cells, where irregular blood flow leads to a hypoxic state, resulting in enhanced activity of reductive enzymes and therefore in even higher glutathione concentrations.



Fig. 19: The stability of disulfide linkers can be finetuned by neighboring methylation.

The stability of disulfide bridges can be fine-tuned by adjacent residues (*Fig. 19*). Methyl groups are bulky enough to have a significant influence on the thermodynamic stability of the disulfide bridge. While one additional methyl group already enhances the stability drastically, two methyl groups make the disulfide bond practically stable towards reductive cleavage. A methylation number of three or four will completely lock the disulfide bridge towards further modifications. As the direct conjugation of cleavable triggers to bioactive agents through disulfide bridges suffers from ineffective cleavage in case of bulky moieties and resulting steric hindrance as well as restricted possibilities for trigger-drug combinations, disulfide based self-immolative linkers (DSILs) provide a robust strategy for selective activation upon disulfide cleavage in the reductive cytoplasmic milieu. Disulfide-based self-immolative linkers benefit of the reversibility of disulfide-bond formation. Upon oxidation, free thiols form less nucleophilic disulfide bonds, preventing self-immolative fragmentation. However, this process can be reversed in the presence of reducing agents, such as GSH. Those specifications allow for sufficient stability in the extracellular milieu but spontaneous self-immolative reaction within the cytosol upon GSH-mediated disulfide cleavage. Variations in the linker's chemical composition (disulfide ethoxycarbonyl (SSE) vs. disulfide benzyloxycarbonyl (SSB)) result in chemically tunable kinetics of the self-immolative cleavage due to different response rates towards GSH, showing higher rates for SSB-based DSILs compared to SSE-based ones (*Fig. 20*). Thus, the choice of the linker allows for fine-tuning of the cleavage speed and payload release.



Fig. 20: Disulfide-based self-immolative linkers either based on an intramolecular cyclization cascade mechanism or on an 1,6-elimination.

back to content ↑

Product details

HNN1090 N_3-Cystamine*HCl

Azido-cystamine hydrochloride

CAS-No. 1807512-40-8 net
Formula $C_4H_{10}N_4S_2$*HCl
Mol. weight 178,28*36,45 g/mol



HAA2255 N_3-Cystamine-Suc-OSu

4-(2-((2-Azidoethyl)disulfanyl)ethylamino)-4-oxobutanoic acid succinimidyl ester

CAS-No. 1987341-40-1
Formula $C_{12}H_{17}N_5O_5S_2$
Mol. weight 375,42 g/mol



BNN1170 Boc-Cystamine

2-(t-Butyloxycarbonylamino)ethyldithio-2'-ethylamine

CAS-No. 485800-26-8
Formula $C_9H_{20}N_2O_2S_2$
Mol. weight 252,40 g/mol



BNN1063 Boc-Cystamine*HCl

2-(t-Butyloxycarbonylamino)ethyldithio-2'-ethylamine hydrochloride

CAS-No. 93790-49-9
Formula $C_9H_{20}N_2O_2S_2$*HCl
Mol. weight 252,40*36,45 g/mol



BAA2180 Boc-Cystamine-Suc-OH

4-(2-((2-t-Butyloxycarbonylaminoethyl)disulfanyl) ethylamino)-4-oxobutanoic acid

CAS-No. 946849-79-2
Formula $C_{13}H_{24}N_2O_5S_2$
Mol. weight 352,47 g/mol



RL-3370 Fmoc-Cystamine*HCl

2-((9-Fluorenylmethyloxycarbonylamino)ethyl)disulfanyl-(2-aminoethane) hydrochloride

CAS-No. 2576471-32-2 net
Formula $C_{19}H_{22}N_2O_2S_2$*HCl
Mol. weight 374,52*36,45 g/mol



RL-3310 Fmoc-Cystamine-Suc

4-(2-((2-(9-Fluorenylmethyloxycarbonylamino)ethyl) disulfanyl)ethylamino)-4-oxobutanoic acid



CAS-No. 946849-80-5
Formula $C_{23}H_{26}N_2O_5S_2$
Mol. weight 474,59 g/mol

FAA5550 Fmoc-L-Cys(Alloc-L-Cys-OAll)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-S-(N-alpha-allyloxycarbonyl)-L-cysteine allyl ester)-L-cysteine



Formula $C_{28}H_{30}N_2O_8S_2$
Mol. weight 586,68 g/mol

FAA5560 Fmoc-L-Cys(Alloc-L-2Abu-OAll)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-S-(N-alpha-allyloxycarbonyl)-L-2-aminobutyric allyl ester)-L-cysteine



CAS-No. 1309975-45-8
Formula $C_{29}H_{32}N_2O_8S$
Mol. weight 568,64 g/mol

RL-3320 Azido-SS-COOH

3-((2-(5-azidopentanamido)ethyl)disulfanyl)propanoic acid



Formula $C_{10}H_{18}N_4O_3S_2$
Mol. weight 306,40 g/mol

RL-3330 Alkyne-SS-COOH

3-((2-pent-4-ynamidoethyl)disulfanyl)propanoic acid



CAS-No. 2279938-29-1
Formula $C_{10}H_{15}NO_3S_2$
Mol. weight 261,36 g/mol

RL-3340 DBCO-SS-COOH

3-((3-(3-(azadibenzocyclooctyn-1-yl)-3-oxopropylamino)-3-oxopropyl)disulfanyl)propanoic acid



Formula $C_{24}H_{24}N_2O_4S_2$
Mol. weight 468,59 g/mol

back to content ↑

Product details

RL-2190 Boc-SS-COOH

3-((2-(tert-butoxycarbonylamino)ethyl)disulfanyl) propanoic acid

CAS-No. 485800-27-9
Formula $C_{10}H_{19}NO_4S_2$
Mol. weight 281,39 g/mol



RL-2200 Fmoc-SS-COOH

3-((2-(((9H-fluoren-9-yl)methoxy)carbonylamino)ethyl) disulfanyl)propanoic acid

CAS-No. 864235-83-6
Formula $C_{20}H_{21}NO_4S_2$
Mol. weight 403,52 g/mol



RL-2220 Stable Disulfide Linker

2-((2-aminoethyl)disulfanyl)-2-methylpropanoic acid

CAS-No. 144700-80-1
Formula $C_6H_{13}NO_2S_2$
Mol. weight 195,30 g/mol



RL-2810 Boc-AEDI-OH

2-((2-(t-Butyloxycarbonylamino)ethyl)disulfa-nyl)-2-methylpropanoic acid

CAS-No. 144700-78-7
Formula $C_{11}H_{21}NO_4S_2$
Mol. weight 295,42 g/mol



RL-2800 Fmoc-AEDI-OH

2-((2-((9-Fluorenylmethyloxycarbonyl)amino)ethyl) disulfanyl)-2-methylpropanoic acid

CAS-No. 1823244-38-7
Formula $C_{21}H_{23}NO_4S_2$
Mol. weight 417,54 g/mol



RL-3500 OPSS-OpNC

2-(2-Pyridithio)ethyl-*p*-nitrophenylcarbonate

CAS-No. 874302-76-8
Formula $C_{14}H_{12}N_2O_5S_2$
Mol. weight 352,38 g/mol



RL-3510 Boc-NH-SS-OH

2-((2-(t-Butyloxycarbonylamino)ethyl)disulfaneyl) ethan-1-ol

CAS-No. 877864-07-8
Formula $C_9H_{19}NO_3S_2$
Mol. weight 253,38 g/mol



RL-3520 Boc-NH-SS-OpNC

2-((2-(t-Butyloxycarbonylamino)ethyl)disulfaneyl) ethan-1-yl *p*-nitrophenylcarbonate

CAS-No. 2040301-00-4
Formula $C_{16}H_{22}N_2O_7S_2$
Mol. weight 418,48 g/mol



RL-3530 Fmoc-NH-SS-OH

2-((2-((9-Fluorenylmethyloxycarbonyl)amino)ethyl) disulfaneyl)ethan-1-ol

Formula $C_{19}H_{21}NO_3S_2$
Mol. weight 375,50 g/mol



RL-3540 Fmoc-NH-SS-OpNC

2-((2-((9-Fluorenylmethyloxycarbonyl)amino)ethyl) disulfaneyl)ethan-1-yl *p*-nitrophenylcarbonate

Formula $C_{26}H_{24}N_2O_7S_2$
Mol. weight 540,61 g/mol



RL-3550 OPSS-Bzl-OpNC

(4-(pyridin-2-yldisulfaneyl)benzyl) *p*-nitrophenylcarbonate

CAS-No. 1151989-04-6
Formula $C_{19}H_{14}N_2O_5S_2$
Mol. weight 414,45 g/mol



RL-3560 Boc-NH-SS-Bzl-OH

4-((2-(t-Butyloxycarbonylamino)ethyl)disulfaneyl) benzylalcohol

Formula $C_{14}H_{21}NO_3S_2$
Mol. weight 315,45 g/mol



back to content ↑

Product details

RL-3570 Boc-NH-SS-Bzl-OpNC

4-((2-(t-Butyloxycarbonylamino)ethyl)disulfaneyl) benzyl *p*-nitrophenylcarbonate



Formula	$C_{21}H_{24}N_2O_7S_2$
Mol. weight	480,55 g/mol

RL-3580 Fmoc-NH-SS-Bzl-OH

4-((2-((9-Fluorenylmethyloxycarbonyl)amino)ethyl) disulfaneyl)benzylalcohol



CAS-No.	2064282-26-2
Formula	$C_{24}H_{23}NO_3S_2$
Mol. weight	437,57 g/mol

Find Biotin linkers with disulfide bridge in our Biotinylation brochure or visit our website.



Product details

RL-3300 Biotin-SS-COOH



3-((2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)ethyl)disulfanyl)propanoic acid

CAS-No. 104582-29-8
Formula $C_{15}H_{25}N_3O_4S_3$
Mol. weight 407,57 g/mol

RL-3820 OPSS-PAB-OpNC



2-(pyridin-2-yldisulfaneyl)ethyl (4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate

CAS-No. 2362536-70-5
Formula $C_{22}H_{19}N_3O_7S_2$
Mol. weight 501,53 g/mol

RL-3850 OPSS-Bzl-PAB-OpNC



4-(pyridin-2-yldisulfaneyl)benzyl (4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)carbamate

Formula $C_{27}H_{21}N_3O_7S_2$
Mol. weight 563,60 g/mol

PEG8100 Biotin-PEG(4)-SS-Azide



N-(2-((3-((3-azidopropyl)amino)-3-oxopropyl)disulfaneyl)ethyl)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxapentadecan-15-amide

CAS-No. 1260247-52-6
Formula $C_{29}H_{52}N_8O_8S_3$
Mol. weight 736,96 g/mol

PEG8110 Biotin-PEG(4)-SS-Alkyne



N-(2-((3-oxo-3-(prop-2-ynylamino)propyl)disulfanyl)ethyl)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxapentadecan-15-amide

CAS-No. 1260247-54-8
Formula $C_{29}H_{49}N_5O_8S_3$
Mol. weight 691,92 g/mol

back to content ↑

Product details

PEG8120 Biotin-PEG(4)-SS-DBCO

N-(2-((3-(3-(azadibenzocyclooctyn-1-yl)-3-oxopropylamino)-3-oxopropyl)disulfanyl)ethyl)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-3,6,9,12-tetrao xapentadecan-15-amide



Formula $C_{44}H_{60}N_6O_9S_3$
Mol. weight 913,18 g/mol

PEG8090 Biotin-PEG(4)-SS-COOH

9,25-dioxo-29-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-12,15,18,21-tetraoxa-4,5-dithia-8,24-diazanonacosan-1-oic acid



CAS-No. 1380166-80-2
Formula $C_{26}H_{46}N_4O_9S_3$
Mol. weight 654,86 g/mol

LS-3570 Biotin-SS-Tyramide

N-(2-((3-(4-hydroxyphenethylamino)-3-oxopropyl) disulfanyl)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanamide



CAS-No. 678975-20-7
Formula $C_{23}H_{34}N_4O_4S_3$
Mol. weight 526,74 g/mol

LS-3930 Biotin-PEG(4)-SS-Tyramide

N-(2-((3-(4-hydroxyphenethylamino)-3-oxopropyl)disulfanyl)ethyl)-1-(5-(2-oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxapentadecan-15-amide



Formula $C_{34}H_{55}N_5O_9S_3$
Mol. weight 774,02 g/mol

LS-3960 Tyramide-SS-amine*HCl

3-((2-aminoethyl)disulfanyl)-N-(4-hydroxyphenethyl) propanamide hydrochloride



Formula $C_{13}H_{20}N_2O_2S_2$*HCl
Mol. weight 300,44*36,45 g/mol

LS-4010 Tyramide-SS-COOH

3-((3-(4-hydroxyphenethylamino)-3-oxopropyl)disulfanyl)propanoic acid



Formula $C_{14}H_{19}NO_4S_2$
Mol. weight 329,43 g/mol

References:

- *Labeling Carboxyl Groups of Surface-Exposed Proteins Provides an Orthogonal Approach for Cell Surface Isolation; N. E. Ozkan Kucuk, E. Sanal, E. Tan, T. Mitchison, N. Ozlu;* ***J Proteome Res*** *2018;* ***17****: 1784-1793. https://doi.org/10.1021/acs.jproteome.7b00825*
- *Development of trifunctional probes for glycoproteomic analysis; C. S. Tsai, P. Y. Liu, H. Y. Yen, T. L. Hsu, C. H. Wong;* ***Chem Commun*** *2010;* ***46****: 5575-7. https://doi.org/10.1039/c0cc00345j*
- *Fluorometric assay for tissue transglutaminase-mediated transamidation activity; C. Gnaccarini, W. Ben-Tahar, W. D. Lubell, J. N. Pelletier, J. W. Keillor;* ***Bioorg Med Chem*** *2009;* ***17****: 6354-9. https://doi.org/10.1016/j.bmc.2009.07.031*
- *Convenient synthesis of photoaffinity probes and evaluation of their labeling abilities; T. Kan, Y. Kita, Y. Morohashi, Y. Tominari, S. Hosoda, T. Tomita, H. Natsugari, T. Iwatsubo, T. Fukuyama;* ***Org Lett*** *2007;* ***9****: 2055-8. https://doi.org/10.1021/ol070376i*
- *Facile synthesis toward the construction of an activity probe library for glycosidases; T. H. Shie, Y. L. Chiang, J. J. Lin, Y. K. Li, L. C. Lo;* ***Carbohydr Res*** *2006;* ***341****: 443-56. https://doi.org/10.1016/j.carres.2005.12.005*
- *A simple photo-affinity labeling protocol; H.-y. Li, Y. Liu, K. Fang, K. Nakanishi;* ***Chemical Communications*** *1999;* ***365-366****. https://doi.org/10.1039/a809507h*
- *Linker Technologies for Antibody–Drug Conjugates; B. Nolting;* ***Antibody-Drug Conjugates L. Ducry*** *2013;* ***1045****: 71-100. https://doi.org/10.1007/978-1-62703-541-5_5*
- *Disulfide-Based Self-Immolative Linkers and Functional Bioconjugates for Biological Applications; Z. Deng, J. Hu, S. Liu;* ***Macromol Rapid Commun*** *2020;* ***41****: e1900531. https://doi.org/10.1002/marc.201900531.*
- *Reduction-Triggered Transformation of Disulfide-Containing Micelles at Chemically Tunable Rates; Z. Deng, S. Yuan, R. X. Xu, H. Liang, S. Liu;* ***Angew. Chem. Int. Ed.*** *2018;* ***57****: 8896-8900. https://doi.org/10.1002/anie.201802909*
- *Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity; T. Suma, J. Cui, M. Müllner, S. Fu, J. Tran, K. F. Noi, Y. Ju, F. Caruso;* ***J. Am. Chem. Soc.*** *2017;* ***139****: 4009-4018. https://doi.org/10.1021/jacs.6b11302*
- *Engineering Intracelular Delivery Nanocarriers and Nanoreactors from Oxidation-Responsive Polymersomes via Synchronized Bilayer Cross-Linking and Permeabilizing Inside Live Cells; Z. Deng, Y. Qian, Y. Yu, G. Liu, J. Hu, G. Zhang, S. Liu;* ***J. Am. Chem. Soc.*** *2016;* ***138****: 10452-10466. https://doi.org/10.1021/jacs.6b04115*

back to content ↑

3.5. pH-sensitive Self-Immolative Linkers

By design, acid-labile linkers are intended to remain stable while circulating in plasma at neutral conditions (pH 7.3. to 7.5). This stability allows conjugates to reach and accumulate at their target cells safely. Once internalized, the mildly acidic pH of the endosomal (pH 5.0-6.5) or lysosomal (pH 4.5-5.0) compartments of the cell induces hydrolysis of the pH-sensitive linkers, releasing the payload (*Fig. 21*). Due to the acidic microenvironment of solid tumors, this cleavage mechanism has been proven to be equally effective against targets that suffer from poor internalization. With a smartly chosen payload, an ADC can even exert its effect on antigen-negative tumor cells present in the vicinity of antigen-positive cells through bystander killing, a feature that renders pH-sensitive linkers (*Fig. 22*) a valuable option in the ADC toolbox.



Fig. 21: pH Values of organelles and compartments in mammalian cells.



Fig. 22: pH-induced cleaving mechanism.

References:

- → *A versatile acid-labile linker for antibody drug conjugates; M. C. Finniss, K. S. Chu, C. J. Bowerman, J. C. Luft, Z. A. Haroon, J. M. DeSimone;* ***Med. Chem. Commun.*** *2014;* ***5****: 1355-1358. https://doi.org/10.1039/C4MD00150H*
- → *Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy; Y. Wang, S. Fan, D. Xiao, F. Xie, W. Li, W. Zhong, X. Zhou;* ***Cancers*** *2019;* ***11(7)****: 957. https://doi.org/10.3390/cancers11070957*
- → *Acid-labil Linkers; E.A. Savoy, F.P. Olatunji. H. Yoon, N. Mesbahi, J.R. Knight, C.E. Berkman; in Chemical Linkers in Antibody-Drug Conjugates (ADCs); edited by Floris van Delft, John M. Lambert.* ***Royal Society of Chemistry*** *2022; ISSN 2041-3203*

Product details

ADC1640 Mal-PEG(2)-DipSi-PHB-PNP



4-(((2-(2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethoxy) ethoxy)diisopropylsilyl)oxy)benzyl (4-nitrophenyl) carbonate

CAS-No.	2410780-45-7
Formula	$C_{28}H_{34}N_2O_{10}Si$
Mol. weight	586,67 g/mol

ADC1650 Mal-Pen-O-DipSi-PHB-PNP



4-((((5-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)pentyl) oxy)diisopropylsilyl)oxy)benzyl (4-nitrophenyl) carbonate

Formula	$C_{29}H_{36}N_2O_9Si$
Mol. weight	584,70 g/mol

3.6. Dde-Based Linkers

The Dde [N-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl] protecting group is commonly utilized to protect the sidechain amine groups of lysine, ornithine, 2,4-diaminobutyric acid, and 2,3-Diaminopropionic acid. Dde shows orthogonal cleavage conditions to Fmoc (piperidine or DBU) and *t*Bu (TFA) deprotecting protocols and is stable to denaturing washing conditions, while allowing for a mild and selective removal in the presence of other protecting groups using a buffered aqueous solution of hydrazine or hydroxylamine, thus representing a versatile tool for the site-specific modification of peptides. Advantageously, the cleavage can be followed spectrophotometrically since the reaction product of Dde with hydrazine is a chromophoric derivative.

Placing Dde as one terminal group of a linker and a functional group prone for conjugation as the other, or using Dde as the central connective portion of a linker, allows for the creation of new bifunctional linkers that can be selectively and temporarily attached to:

- Appropriately modified biomolecules for binding to streptavidin (with terminal biotin) (*Fig. 23* (A)), or conjugation to any solid supports, e.g. *via* Click reaction (*Fig. 23* (B)).
- Solubilizing tags, e.g. hexa-lysine ("helping-hand linkers", *Fig. 23* (C)), oligo-arginine, PEGs (*Fig. 23* (D)) or other hydrophilic groups improving solubility of hydrophobic peptides or other compounds when being attached to either the N-terminus or any lysine side chain within a peptide sequence.
- Dyes and any other conjugate for monitoring, diagnostics, targeting or other purposes.

back to content ↑



Fig. 23: Dde-based linkers can be utilized for various applications: Attachment of a cleavable biotin tag to proteins for catch-and-release affinity purification over Streptavidin beads (A), reversible labeling or conjugation to other biomolecules, or reversible immobilization on solid supports via Click chemistry (B), temporary attachment of solubilizing tags like oligo-lysine (C) or PEGs (D).

Dde/ivDde linkers are implemented in simple and nearly quantitative steps:

1. Orthogonal deprotection of lysine residues in a peptide or N-terminus or any other amino function of a hydrophobic compound.
2. On-resin incorporation of the linker.
3. Fmoc-SPPS elongation.
4. Cleavage of the peptide from the resin and removal of all side chain protecting groups.
5. The tagged peptide can be separated from truncated sequences.
6. In-solution cleavage using mild aqueous hydrazine to cleave the Dde linker after purification, streptavidin attachment, NCL-based assembly or another reaction step. The cleavage can be monitored spectroscopically as the resulting pyrazole shows a strong absorption at 290 nm.

Dde/ivDde becomes particularly useful for handling and purification of insoluble and aggregation-prone peptides, as any appropriate solubilizing promoting group can be attached to create so-called “helping-hand” linkers that can be removed in a traceless manner (*Fig. 24*).



Fig. 24: Dde-based "helping-hand" linkers improve the solubility and allow for the purification of hydrophobic peptides. Removal of the handle can be easily monitored spectroscopically at 290 nm.

back to content ↑

Procedure for Removing Helping-Hands from Peptides (adapted from Jacobsen *et al.*, *J Am Chem Soc* 2016):

10 mL of 2 M hydrazine stock solution (pH 7.5) is being prepared as follows:

1. Weigh 5.7 g Guanidinium chloride and 75 mg DTT into 15 mL Falcon tube.
2. Add 1 mL of 1 M NaH_2PO_4.
3. Add 2 mL of 10 M hydrazine in water.
4. Add 0.5 mL of 12 M HCl.
5. Dissolve solution by thorough vortexing.
6. Adjust pH to 7.5 by adding concentrated HCl.
7. Fill to a final volume of 10 mL with water.
8. Filter solution using 0.2 µm syringe filter.

Cleavage of the helping-hand can be triggered by equivolume addition of 2 M hydrazine stock solution into the solution of the peptide. After adding the hydrazine solution, subtle adjustment may be necessary to achieve a final solution pH of 7.5. The reaction is normally completed within minutes. Deprotection can be monitored spectrophotometrically at 290 nm.

Despite its widespread use, the biotinylation of proteins for subsequent purification *via* Streptavidin beads bears certain hurdles, e.g. concerning the removal of the proteins from the beads due to the strong binding. One possible improvement is represented by the use of appropriately derivatized Dde-linkers. The connection of such a bifunctional linker with a biotin moiety on the one end, and a clickable group (alkyne, e.g. DBCO) or tyramide on the other, allows for the selective attachment to appropriately modified biomolecules, as well as the mild release of captured proteins from the beads after purification (*Fig. 25*).



Fig. 25: Biotinylation of an azide-bearing glycoprotein using Click chemistry, followed by purification of the labelled protein over Streptavidin beads, release of the protein by hydrazinolysis of the Dde-group, and analysis of the isolated glycoprotein (adapted from Griffin et al. Mol. Biosys. 2016).

Aside from the commonly used cleavage solution for Dde consisting of 2% hydrazine monohydrate in H_2O, the following procedure may be used in order to ensure full orthogonality between Dde and Fmoc.

Selective Removal of Dde/ivDde using hydroxylamine (adapted from Díaz-Mochón *et al., Org. Lett.* 2004):

1.25 g (1.80 mmol) of $NH_2OH{\cdot}HCl$ and 0.918 g (1.35 mmol) of Imidazole were suspended in 5 mL NMP, and the mixture sonicated until complete dissolution. This solution can be stirred for at least 2 weeks at -20 °C. Just before reaction, five volumes of this solution were diluted with one volume of alternatively DCM or DMF.

Product details

LS-4020 Biotin-Dde

2-(1-hydroxy-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentylidene)-5,5-dimethylcyclohexane-1,3-dione



CAS-No.	194038-08-9
Formula	$C_{18}H_{26}N_2O_4S$
Mol. weight	366,48 g/mol

LS-4000 Biotin-Dde-Tyramide

2-(1-(4-hydroxyphenethylamino)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentylidene)-5,5-dimethylcyclohexane-1,3-dione



Formula	$C_{26}H_{35}N_3O_4S$
Mol. weight	485,64 g/mol

PEG8130 Biotin-PEG(4)-Dde-Tyramide

N-(15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-18-(4-hydroxyphenyl)-3,6,9,12-tetraoxa-16-azaoctadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide



Formula	$C_{34}H_{56}N_4O_9S$
Mol. weight	732,93 g/mol

PEG7960 Biotin-PEG(4)-Dde-N_3

N-(19-azido-15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3,6,9,12-tetraoxa-16-azanonadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide



CAS-No.	1802907-93-2
Formula	$C_{32}H_{53}N_7O_8S$
Mol. weight	695,87 g/mol

back to content ↑

Product details

PEG7970 Biotin-PEG(4)-Dde-Picolyl-N_3

N-(6-(azidomethyl)pyridin-3-yl)-15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-1-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)-3,6,9,12-tetraoxa-16-azanona decan-19-amide



CAS-No.	2055048-42-3
Formula	$C_{38}H_{57}N_9O_9S$
Mol. weight	815,98 g/mol

PEG7980 Biotin-PEG(4)-Dde-Alkyne

N-(15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3,6,9,12-tetraoxa-16-azanonadec-18-ynyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide



CAS-No.	1802908-00-4
Formula	$C_{32}H_{50}N_4O_8S$
Mol. weight	650,83 g/mol

PEG8140 Biotin-PEG(4)-Dde-DBCO

N-(15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-19-oxo-19-(azadibenzocyclooctyn-1-yl)-3,6,9,12-tetraoxa-16-azanonadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl) pentanamide



CAS-No.	1807512-43-1
Formula	$C_{47}H_{61}N_5O_9S$
Mol. weight	872,08 g/mol

RL-3280 N_3-Pen-Dde

2-(5-azido-1-hydroxypentylidene)-5,5-dimethylcyclohexane-1,3-dione



CAS-No.	1867129-38-1
Formula	$C_{13}H_{19}N_3O_3$
Mol. weight	265,31 g/mol

RL-3290 N_3-Pen-Dtpp

5-(5-azido-1-hydroxypentylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione



CAS-No.	1867129-42-7
Formula	$C_{11}H_{15}N_5O_4$
Mol. weight	281,27 g/mol

The Dde derived linker might cleave under mildly acidic and even neutral conditions in the one or the other case. The DTPM derived linker is totally stable under acidic conditions as well as to a wide range of chemical treatments, including particularly harsh sodium methoxide-based deacetylation of chemically introduced glycans.

Reference:

→ *Combining triazole ligation and enzymatic glycosylation on solid phase simplifies the synthesis of very long glycoprotein analogues; M. Galibert, V. Piller, F. Piller, V. Aucagne, A. F. Delmas;* ***Chem. Sci.*** *2015;* ***6****: 3617-3623. https://doi.org/10.1039/c5sc00773a*

Product details

FAA8115 Fmoc-L-Lys(Pentynoyl-DIM)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-[1-(4,4-dimethyl-2,6- dioxocyclohexylidene)pent-4-yn-1-yl]-L-lysine



CAS-No.	2408993-33-7
Formula	$C_{34}H_{38}N_2O_6$
Mol. weight	570,69 g/mol

FAA8145 Fmoc-L-Lys(N_3-Aca-DIM)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-[6-azido-1-(4,4-dimethyl-2,6- dioxocyclohexylidene)hexyl]-L-lysine



CAS-No.	2408993-39-3
Formula	$C_{35}H_{43}N_5O_6$
Mol. weight	629,76 g/mol

RL-3260 Fmoc-Aca-DIM

6-((9-Fluorenylmethyl)oxycarbonylamino)-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-hexan-1-ol



CAS-No.	2379561-08-5
Formula	$C_{29}H_{33}NO_5$
Mol. weight	475,58 g/mol

RL-3270 Fmoc-AEEP-DIM

3-(2-(2-(9-Fluorenylmethyl)oxycarbonylaminoethoxy) ethoxy)-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-propan-1-ol



CAS-No.	1988771-96-5
Formula	$C_{30}H_{35}NO_7$
Mol. weight	521,60 g/mol

RL-3470 Fmoc-AEEP-DMB

(9-Fluorenylmethyloxycarbonyl)amino-PEG(2)-Dtpp



Formula	$C_{28}H_{31}N_3O_8$
Mol. weight	537,57 g/mol

back to content ↑

Product details

DAA1016 Dde-O_2Oc-OH

8-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-amino]-3,6-dioxaoctanoic acid, {2-[2-(Dde-amino) ethoxy]ethoxy}acetic acid



CAS-No.	1263045-93-7
Formula	$C_{16}H_{25}NO_6$
Mol. weight	327,37 g/mol

PEG8150 Fmoc-PEG(4)-Dde

1-(9H-Fluorenylmethyloxycarbonylamino)-15-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3,6,9,12-tetraoxapentadecyl-15-ol



CAS-No.	2093409-87-9
Formula	$C_{34}H_{43}NO_9$
Mol. weight	609,71 g/mol

BAA1191 Boc-L-Dab(Dde)-OH

N-alpha-t-Butyloxycarbonyl-N-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-L-2,4-diaminobutyric acid



CAS-No.	1263045-50-6
Formula	$C_{19}H_{30}N_2O_6$
Mol. weight	382,46 g/mol

BAA1171 Boc-D-Dab(Dde)-OH

N-alpha-t-Butyloxycarbonyl-N-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-D-2,4-diaminobutyric acid



CAS-No.	1263046-41-8
Formula	$C_{19}H_{30}N_2O_6$
Mol. weight	382,46 g/mol

BAA1193 Boc-L-Dap(Dde)-OH

N-alpha-t-Butyloxycarbonyl-N-beta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-L-2,3-diaminopropionic acid



CAS-No.	1263045-09-5
Formula	$C_{18}H_{28}N_2O_6$
Mol. weight	368,43 g/mol

BAA1176 Boc-D-Dap(Dde)-OH

N-alpha-t-Butyloxycarbonyl-N-beta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl]-D-2,3-diaminopropionic acid



Formula	$C_{18}H_{28}N_2O_6$
Mol. weight	368,43 g/mol

DAA1011 Dde-L-Dap(Aloc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-beta-allyloxycarbonyl-L-2,3-diaminopropionic acid

CAS-No. 1263045-89-1 net
Formula $C_{17}H_{24}N_2O_6$
Mol. weight 352,39 g/mol



DAA1005 Dde-D-Dap(Aloc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-beta-allyloxycarbonyl-D-2,3-diaminopropionic acid

CAS-No. 1263046-79-2
Formula $C_{17}H_{24}N_2O_6$
Mol. weight 352,39 g/mol



DAA1012 Dde-L-Dap(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-beta-(9-fluorenylmethyloxycarbonyl)-L-2,3-diaminopropionic acid

CAS-No. 1263046-98-5
Formula $C_{28}H_{30}N_2O_6$
Mol. weight 490,56 g/mol



DAA1006 Dde-D-Dap(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-beta-(9-fluorenylmethyloxycarbonyl)-D-2,3-diaminopropionic acid

CAS-No. 1263046-87-2
Formula $C_{28}H_{30}N_2O_6$
Mol. weight 490,56 g/mol



DAA1009 Dde-L-Dab(Aloc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-gamma-allyloxycarbonyl-L-2,4-diaminobutyric acid

Formula $C_{18}H_{26}N_2O_6$
Mol. weight 366,42 g/mol



DAA1003 Dde-D-Dab(Aloc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-gamma-allyloxycarbonyl-D-2,4-diaminobutyric acid

CAS-No. 1263046-79-2
Formula $C_{18}H_{26}N_2O_6$
Mol. weight 366,42 g/mol



back to content ↑

Product details

DAA1010 Dde-L-Dab(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylide-ne)ethyl-N-gamma-(9-fluorenylmethyloxycarbo-nyl)-L-2,4-diaminobutyric acid

CAS-No.	1263045-85-7
Formula	$C_{29}H_{32}N_2O_6$
Mol. weight	504,59 g/mol



DAA1004 Dde-D-Dab(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylide-ne)ethyl-N-gamma-(9-fluorenylmethyloxycarbo-nyl)-D-2,4-diaminobutyric acid

CAS-No.	1263046-84-9
Formula	$C_{29}H_{32}N_2O_6$
Mol. weight	504,59 g/mol



BAA1197 Boc-L-Orn(Dde)-OH

N-alpha-t-Butyloxycarbonyl-N-delta-[1-(4,4-di-methyl-2,6-dioxocyclohex-1-ylidene)ethyl]-L-ornithine

CAS-No.	1272755-14-2
Formula	$C_{20}H_{32}N_2O_6$
Mol. weight	396,49 g/mol



DAA1001 Dde-L-Orn(Aloc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-delta-allyloxycarbonyl-L-ornithine

CAS-No.	1423017-98-4
Formula	$C_{19}H_{28}N_2O_6$
Mol. weight	380,44 g/mol



DAA1002 Dde-L-Orn(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-delta-(9-fluorenylmethyloxycarbonyl)-L-ornit-hine

CAS-No.	1423017-87-1
Formula	$C_{30}H_{34}N_2O_6$
Mol. weight	518,62 g/mol



BAA1286 Boc-L-Lys(Dde)-OH*DCHA

N-alpha-t-Butyloxycarbonyl-N-epsilon-(4,4-di-methyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-lysine dicyclohexylamine

CAS-No.	444795-66-8 net
Formula	$C_{21}H_{34}N_2O_6$*$C_{12}H_{23}N$
Mol. weight	410,51*181,32 g/mol



BAA1287 Boc-L-Lys(ivDde)-OH

N-alpha-t-Butyloxycarbonyl-N-epsilon-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-lysine

CAS-No. 862847-44-7
Formula $C_{24}H_{40}N_2O_6$
Mol. weight 452,6 g/mol



BAA5010 Boc-D-Lys(ivDde)-OH

N-alpha-t-Butyloxycarbonyl-N-epsilon-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-D-lysine

CAS-No. 1301706-85-3
Formula $C_{24}H_{40}N_2O_6$
Mol. weight 452,6 g/mol



DAA1013 Dde-L-Lys(Aloc)-OH*DCHA

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-epsilon-allyloxycarbonyl-L-lysine dicyclohexylamine

CAS-No. 264230-73-1 net
Formula $C_{20}H_{30}N_2O_6*C_{12}H_{23}N$
Mol. weight 394,47*181,32 g/mol



DAA1007 Dde-D-Lys(Aloc)-OH*DCHA

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-epsilon-allyloxycarbonyl-D-lysine dicyclohexylamine

CAS-No. 1272754-85-4 net
Formula $C_{20}H_{30}N_2O_6*C_{12}H_{23}N$
Mol. weight 394,47*181,32 g/mol



DAA1014 Dde-L-Lys(Boc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-epsilon-t-butyloxycarbonyl-L-lysine

CAS-No. 1189586-14-8
Formula $C_{21}H_{34}N_2O_6$
Mol. weight 410,51 g/mol



DAA1015 Dde-L-Lys(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-epsilon-(9-fluorenylmethyloxycarbonyl)-L-lysine

CAS-No. 156648-40-7
Formula $C_{31}H_{36}N_2O_6$
Mol. weight 532,64 g/mol



back to content ↑

Product details

DAA1017 Dde-D-Lys(Fmoc)-OH

N-alpha-(4-4-Dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-N-epsilon-(9-fluorenylmethyloxycarbonyl)-D-lysine

CAS-No. 1301706-71-7
Formula $C_{31}H_{36}N_2O_6$
Mol. weight 532,64 g/mol



DAA1018 ivDde-L-Dap(Fmoc)-OH

N-alpha-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-N-beta-(9-fluorenylmethyloxycarbonyl)-L-2,3-diaminopropionic acid

CAS-No. 2389078-71-9
Formula $C_{31}H_{36}N_2O_6$
Mol. weight 532,63 g/mol



DAA1019 ivDde-L-Lys(Fmoc)-OH

N-alpha-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-N-epsilon-(9-fluorenylmethyloxycarbonyl)-L-lysine

CAS-No. 1446752-60-8
Formula $C_{34}H_{42}N_2O_6$
Mol. weight 574,71 g/mol



DAA1030 ivDde-D-Lys(Fmoc)-OH

N-alpha-[(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-N-epsilon-(9-fluorenylmethyloxycarbonyl)-D-lysine

CAS-No. 2308529-94-2
Formula $C_{34}H_{42}N_2O_6$
Mol. weight 574,71 g/mol



DAA1020 Dde-L-Met-OH

N-?alpha-[1-?(4,?4-?dimethyl-?2,?6-?dioxocyclohexylidene?)?ethyl]?-L-methionine

CAS-No. 1435266-87-7
Formula $C_{15}H_{23}NO_4S$
Mol. weight 313,13 g/mol



FAA8690 Fmoc-Aeg(Dde)-OH

(9-Fluorenylmethyloxycarbonyl)-N-(2-((1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)amino)ethyl) glycine

Formula $C_{29}H_{32}N_2O_6$
Mol. weight 504,58 g/mol



FAA8815 Fmoc-L-Abu(3-Dde-amino)-OH (2S,3S)

2-(Fmoc-amino)-3-(Dde-amino)butanoic acid (2S,3S)

Formula $C_{29}H_{32}N_2O_6$
Mol. weight 504,58 g/mol



FAA1462 Fmoc-L-Dap(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-beta-[(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl]-2,3-diaminopropionic acid

CAS-No. 247127-51-1
Formula $C_{28}H_{30}N_2O_6$
Mol. weight 490,56 g/mol



FAA1476 Fmoc-D-Dap(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-beta-[(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl]-D-2,3-diaminopropionic acid

CAS-No. 210830-03-8
Formula $C_{28}H_{30}N_2O_6$
Mol. weight 490,56 g/mol



FAA1464 Fmoc-L-Dap(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-beta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-2,3-diaminopropionic acid

CAS-No. 607366-20-1
Formula $C_{31}H_{36}N_2O_6$
Mol. weight 532,64 g/mol



FAA1478 Fmoc-D-Dap(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-beta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-D-2,3-diaminopropionic acid

CAS-No. 1228900-15-9
Formula $C_{31}H_{36}N_2O_6$
Mol. weight 532,64 g/mol



FAA1365 Fmoc-L-Dab(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-L-2,4-diaminobutyric acid

CAS-No. 235788-61-1
Formula $C_{29}H_{32}N_2O_6$
Mol. weight 504,59 g/mol



back to content ↑

Product details

FAA1318 Fmoc-D-Dab(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-D-2,4-diaminobutyric acid

CAS-No. 596797-14-7
Formula $C_{29}H_{32}N_2O_6$
Mol. weight 504,59 g/mol



FAA1458 Fmoc-L-Dab(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-2,4-diaminobutyric acid

CAS-No. 607366-21-2
Formula $C_{32}H_{38}N_2O_6$
Mol. weight 546,67 g/mol



FAA1473 Fmoc-D-Dab(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-gamma-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-D-2,4-diaminobutyric acid

CAS-No. 872169-32-9
Formula $C_{32}H_{38}N_2O_6$
Mol. weight 546,67 g/mol



FAA1502 Fmoc-L-Orn(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-delta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl]-L-ornithine

CAS-No. 269062-80-8
Formula $C_{30}H_{34}N_2O_6$
Mol. weight 518,62 g/mol



FAA2090 Fmoc-D-Orn(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-delta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl]-D-ornithine

CAS-No. 1419640-31-5
Formula $C_{30}H_{34}N_2O_6$
Mol. weight 518,62 g/mol



FAA1503 Fmoc-L-Orn(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-delta[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-ornithine

CAS-No. 1198321-33-3
Formula $C_{33}H_{40}N_2O_6$
Mol. weight 560,7 g/mol



FAA1493 Fmoc-D-Orn(ivDde)-OH.solv.

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-delta-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-D-ornithine.solv.



CAS-No.	1272754-86-5
Formula	$C_{33}H_{40}N_2O_6$
Mol. weight	560,7 g/mol

FAA1390 Fmoc-L-Lys(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl-L-lysine



CAS-No.	150629-67-7
Formula	$C_{31}H_{36}N_2O_6$
Mol. weight	532,64 g/mol

FAA1486 Fmoc-D-Lys(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-[(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene) ethyl]-D-lysine



CAS-No.	333973-51-6
Formula	$C_{31}H_{36}N_2O_6$
Mol. weight	532,64 g/mol

FAA1488 Fmoc-D-Lys(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-D-lysine



CAS-No.	1272755-33-5
Formula	$C_{34}H_{42}N_2O_6$
Mol. weight	574,72 g/mol

FAA1500 Fmoc-L-Lys(ivDde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-epsilon-[1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl]-L-lysine



CAS-No.	204777-78-6
Formula	$C_{34}H_{42}N_2O_6$
Mol. weight	574,72 g/mol

FAA1401 Fmoc-L-MeLys(Dde)-OH

N-alpha-(9-Fluorenylmethyloxycarbonyl)-N-alpha-methyl-N-epsilon-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-lysine



CAS-No.	1428229-84-8
Formula	$C_{32}H_{38}N_2O_6$
Mol. weight	546,67 g/mol

back to content ↑

References:

- → *Synthesis of hydrophobic insulin-based peptides using a helping hand strategy; M. M. Disotuar, M. E. Petersen, J. M. Nogueira, M. S. Kay, D. H. Chou;* ***Org Biomol Chem*** *2019;* ***17****: 1703-1708. https://doi.org/10.1039/c8ob01212a*
- → *Chemical synthesis of Shiga toxin subunit B using a next-generation traceless "helping hand" solubilizing tag; J. M. Fulcher, M. E. Petersen,R. J. Giesler, Z. S. Cruz, D. M. Eckert, J. N. Francis, E. M. Kawamoto, M. T. Jacobsen, M. S. Kay;* ***Org Biomol Chem*** *2019;* ***17****: 10237-10244. https://doi.org/10.1039/c9ob02012h*
- → *Mapping the Binding Site of BMS-708163 on gamma-Secretase with Cleavable Photoprobes; N. Gertsik, C. W. Am Ende, K. F. Geoghegan, C. Nguyen, P. Mukherjee, S. Mente, U. Seneviratne, D. S. Johnson Y. M. Li;* ***Cell Chem Biol*** *2017;* ***24****: 3-8. https://doi.org/10.1016/j.chembiol.2016.12.006*
- → *A Helping Hand to Overcome Solubility Challenges in Chemical Protein Synthesis; M. T. Jacobsen, M. E. Petersen, X. Ye, M. Galibert, G. H. Lorimer, V. Aucagne, M. S. Kay;* ***J Am Chem Soc*** *2016;* ***138****: 11775-82. https://doi.org/10.1021/jacs.6b05719*
- → *Compounds and methods for purifying peptides produced by solid phase peptide synthesis; Aucagne V., Delmas A.; CNRS; U.S. Patent No. 9,073,969, 2015*
- → *Cleavable trifunctional biotin reagents for protein labelling, capture and release; Y. Yang, S. H. Verhelst;* ***Chem Commun*** *2013;* ***49****: 5366-8. https://doi.org/10.1039/c3cc42076k*
- → *Investigation on the stability of the Dde protecting group used in peptide synthesis: migration to an unprotected lysine; K. Augustyns, W. Kraas, G. Jung;* ***J Pept Res*** *1998;* ***51****: 127-33. https://doi.org/10.1111/j.1399-3011.1998.tb00630.x*
- → *Full Orthogonality between Dde and Fmoc: The Direct Synthesis of PNA-Peptide Conjugates; J. J. Díaz-Mochón, L. Bialy, M. Bradley;* ***Org. Lett.*** *2004;* ***7****: 1127-1129. https://doi.org/10.1021/ol049905y*

4. Trifunctional Linkers

Product details

AAA2190 DAPOA*DCHA

2-(1,3-diazidopropan-2-yloxy)acetic acid dicyclohexylamine

CAS-No. 2389064-43-9 net
Formula $C_5H_8N_6O_3$*$C_{12}H_{23}N$
Mol. weight 200,16*181,32 g/mol



FAA7570 Fmoc2-DAPOA

2-((1,3-bis((9-fluorenylmethyloxycarbonyl)amino)propan-2-yl)oxy)acetic acid

CAS-No. 688350-01-8
Formula $C_{35}H_{32}N_2O_7$
Mol. weight 592,64 g/mol



RL-2710 DACN(Tos,Ns)

N-(o-nitrobenzenesulfonyl)-N'-(*p*-toluenesulfonyl)-4,8-diazacyclononyne

CAS-No. 1797508-58-7
Formula $C_{20}H_{21}N_3O_6S_2$
Mol. weight 463,53 g/mol



RL-2720 DACN(Tos,Suc-OH)

N-succinoyl-N'-(*p*-toluenesulfonyl)-4,8-diazacyclononyne

CAS-No. 2109751-68-8
Formula $C_{18}H_{22}N_2O_5S$
Mol. weight 378,44 g/mol



RL-2730 DACN(Tos_2)

N,N'-bis(*p*-toluenesulfonyl)-4,8-diazacyclononyne

CAS-No. 1797508-57-6
Formula $C_{21}H_{24}N_2O_4S_2$
Mol. weight 432,56 g/mol



back to content ↑

Product details

RL-3600 DACN(Ms)*HCl

N-(Mesyl)-4,8-diazacyclononyne hydrochloride

CAS-No.	2331322-16-6
Formula	$C_8H_{14}N_2O_2S$*HCl
Mol. weight	202,27*36,46 g/mol



RL-3610 DACN(Ms,Ns)

N-(Mesyl)-N'-(2-nosyl)-4,8-diazacyclononyne

CAS-No.	2411082-25-0
Formula	$C_{14}H_{17}N_3O_6S_2$
Mol. weight	387,43 g/mol



RL-3630 DACN(Tos,Mal)

N-(maleimidobutyryl)-N'-(*p*-toluenesulfonyl)-4,8-diazacyclononyne

CAS-No.	2411082-28-3
Formula	$C_{22}H_{25}N_3O_5S$
Mol. weight	443,52 g/mol



RL-2725 DACN(Tos,Suc-NHS)

N-(succinoyl-NHS ester)-N'-(*p*-toluenesulfonyl)-4,8-diazacyclononyne

CAS-No.	2411082-26-1
Formula	$C_{22}H_{25}N_3O_7S$
Mol. weight	475,52 g/mol



RL-2735 DACN(Tos)*HCl

N-(*p*-toluenesulfonyl)-4,8-diazacyclononyne hydrochloride

CAS-No.	2331322-18-8
Formula	$C_{14}H_{18}N_2O_2S$*HCl
Mol. weight	278,37*36,46 g/mol



For various functional group conjugation please inquire with our Custom Synthesis Service.

5. Cross-Linkers for other Bio Applications

5.1. Substrates for Fusion (Halo/Snap/Clip)-Tagged Proteins

Site-specific protein labeling is a versatile tool for studying protein function and interaction in living cells. Various peptide-based protein tags have been developed. Herein, we are focusing on HaloTag®, SNAP-Tag® and CLIP-Tag™, as well as corresponding substrates offered by Iris Biotech. Those labeling systems enable the specific, covalent attachment of in principle any molecule of choice to a protein of interest.

The HaloTag® (*Fig. 26*) is a 33 kDa self-labeling protein tag derived from the haloalkane dehalogenase DhaA from *Rhodococcus rhodochrous*. Its active site reacts in a nucleophilic attack with chloroalkane linker substrates to form an irreversible bond in the case of the mutated enzyme. The chloroalkane linker can easily be functionalized with a label of choice, e.g. with a fluorophore or biotin. For the wild-type enzyme, this intermediate would be hydrolyzed, leading to the regeneration of the enzyme.



Fig. 26: Schematic illustration of the HaloTag® reaction

The SNAP-tag® (*Fig. 27*) is a 20 kDa self-labeling protein tag based on a modified form of the human O_6-alkyl-guanine-DNA-alkyltransferase (hAGT), a DNA repair enzyme. A cysteine residue within the SNAP-tag® undergoes an irreversible reaction with synthetic O_6-benzylguanine (BG) derivatives, resulting in a covalent thioether bond. The BG moiety can easily be further functionalized with a label of choice, e.g. fluorophore, biotin, generally without affecting the reaction of the substrate with the SNAP-tag®.



Fig. 27: Schematic illustration of the SNAP-tag® reaction

The CLIP-tag™ (*Fig. 28*) (20 kDa) is a modified version of the SNAP-tag, engineered to react with benzylcytosine (BC) instead of benzylguanine (BG). Thus, properties are similar. CLIP-tag™- and SNAP-tag®-fused proteins can be labeled simultaneously in the same cells.



Fig. 28: Schematic illustration of the CLIP-tag™ reaction

back to content ↑

Table summarizing main properties of HaloTag®, SNAP-tag® and CLIP-tag™.

	HaloTag	SNAP-tag	CLIP-tag
Origin	Haloalkane dehalogenase *(Rhodococcus rhodochrous)*	Human O_6-alkylguanine-DNA-alkyltransferase	Human O_6-alkylguanine-DNA-alkyltransferase
Reactivity	Chloroalkane derivatives	O_6-benzylguanine derivatives	Benzylcytosine derivatives
Length	297 amino acids	182 amino acids	182 amino acids
Molecular Weight	33.6 kDa	19.4 kDa	19.4 kDa

Iris Biotech offers a Biotin- (RL-3860) as well as an ICG-functionalized (RL-3830) SNAP-tag® substrate, as well as the corresponding CLIP-tag™ suitable (RL-3840, RL-3870) derivatives. Biotinylated proteins can for example be selectively isolated based on the high affinity towards avidin representing a useful tool for purification, immobilization, and labeling. Indocyanine green (ICG) is a near-infrared fluorescence imaging dye (absorption maximum 800 nm + slight absorption in the visible range; emission maximum 810 nm) approved by the FDA.

As substrates for the HaloTag® various products are offered, e.g. suitable for further functionalization *via* Click Chemistry.

You could not find the derivative you are looking for?

Please inquire for a Custom Synthesis!

Product details

RL-3180 Halo-PEG(2)-Suc

4-((2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl) amino)-4-oxobutanoic acid



CAS-No.	1488363-39-8
Formula	$C_{14}H_{26}ClNO_5$
Mol. weight	323,81 g/mol

RL-3640 Halo-PEG(5)-azide

1-azido-21-chloro-3,6,9,12,15-pentaoxahenicosane



CAS-No. 1261238-21-4
Formula $C_{16}H_{32}ClN_3O_5$
Mol. weight 381,90 g/mol

RL-3670 Halo-DBCO

N-[2-[2-[(6-chlorohexyl)oxy]ethoxy]ethyl]-gamma-oxo-dibenz[b,f]azocine-5(6H)-butanamide



CAS-No. 1808119-16-5
Formula $C_{29}H_{35}ClN_2O_4$
Mol. weight 511,06 g/mol

RL-3860 Biotin-SNAP

N-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)-6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)hexanamide



CAS-No. 471918-16-8
Formula $C_{29}H_{39}N_9O_4S$
Mol. weight 609,75 g/mol

RL-3690 Halo-PEG(4)-NH_2*HCl

18-Chloro-3,6,9,12-tetraoxa-octadecan-1-amine hydrochloride



CAS-No. 1261238-20-3
Formula $C_{14}H_{30}ClNO_4$*HCl
Mol. weight 311,85*36,46 g/mol

RL-3700 Halo-PEG(2)-Azide

1-Azido-12-chloro-3,6-dioxadodecane



CAS-No. 2568146-55-2
Formula $C_{10}H_{20}ClN_3O_2$
Mol. weight 249,74 g/mol

RL-3710 Halo-PEG(4)-Azide

1-Azido-18-chloro-3,6,9,12-tetraoxaoctadecane



Formula $C_{14}H_{28}ClN_3O_4$
Mol. weight 337,85 g/mol

back to content ↑

Product details

RL-3830 ICG-SNAP

4-(2-((1E,3E,5E,7E)-7-(3-(6-((4-(((2-amino-9H-purin-6-yl) oxy)methyl)benzyl)amino)-6-oxohexyl)-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimeth yl-1H-benzo[e]indol-3-ium-3-yl) butane-1-sulfonate



Formula	$C_{58}H_{62}N_8O_5S$
Mol. weight	983,25 g/mol

RL-3840 ICG-CLIP

4-(2-((1E,3E,5E,7E)-7-(3-(6-((4-(((4-aminopyrimidin-2-yl) oxy)methyl)benzyl)amino)-6-oxohexyl)-1,1-dimethyl-1,3-dihydro-2H-benzo[e]indol-2-ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-1H-benzo[e]indol-3-ium-3-yl) butane-1-sulfonate



Formula	$C_{57}H_{62}N_6O_5S$
Mol. weight	943,22 g/mol

RL-3680 Halo-PEG(2)-NH_2*HCl

12-Chloro-3,6-dioxa-dodecan-1-amine hydrochloride



CAS-No.	1035373-85-3
Formula	$C_{10}H_{22}ClNO_2$*HCl
Mol. weight	223,74*36,46 g/mol

RL-3870 Biotin-Clip

N-(4-(((4-aminopyrimidin-2-yl)oxy)methyl)benzyl)-6-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d] imidazol-4-yl)pentanamido)hexanamide



CAS-No.	1004524-73-5
Formula	$C_{28}H_{39}N_7O_4S$
Mol. weight	569,73 g/mol

References:

- → *Site-specific protein labeling with SNAP-Tags; N. B. Cole;* ***Curr Protoc Protein Sci.*** *2013;* ***73(30)****: 1-30. https://doi.org/10.1002/0471140864.ps3001s73*
- → *A general method for the covalent labeling of fusion proteins with small molecules in vivo; A. Keppler, S. Gendrezig, T. Gronemeyer, H. Pick, H. Vogel, K. Johnsson;* ***Nat. Biotechnol.*** *2003;* ***21****: 86-89. https://doi.org/10.1038/nbt765*
- → *HaloTag: A Novel Protein Labeling Technology for Cell Imaging and Protein Analysis; g: v: Los; L. P. Encell, M. G. McDougall, D. D. Hartzell, N. Karassina, C. Zimprich, M. G. Wood, R. Learish, R. F. Ohana, M. Urh, D. Simpson, J. Mendez, K. Zimmerman, P. Otto, G. Vidugiris, J. Zhu, A. Darzins, D. H. Klaubert, R. F. Bulleit, K. V. Wood;* ***ACS Chem. Biol.*** *2008;* ***3(6)****: 373-382. https://doi.org/10.1021/cb800025k*
- → *Directed evolution of O6-alkylguanine-DNA alkyltransferase for efficient labeling of fusion proteins with small molecules in vivo; A. Juillerat, T. Gronemeyer, A. Keppler, S. Gendreizig, H. Pick, H. Vogel, K. Johnsson;* ***Chem. Biol.*** *2003;* ***10(4)****: 313-317. https://doi.org/10.1016/s1074-5521(03)00068-1*

- *Site-specific, Covalent Labeling of Recombinant Antibody Fragments via Fusion to an Engineered Version of 6-O-Alkylguanine DNA Alkyltransferase; F. Kampmeier, M. Ribbert, T. Nachreiner, S. Dembski, F. Beaufils, A. Brecht, S. Barth;* ***Bioconjugate Chem.*** *2009;* ***20(5)****: 1010-1015. https://doi.org/10.1021/bc9000257*
- *SNAP-Tag Technology: A Useful Tool to Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments; J. Niesen, M. Sack, M. Seidel, R. Fendel, S. Barth, R. Fischer, C. Stein;* ***Bioconjugate Chem.*** *2016;* ***27(8)****: 1931-1941. https://doi.org/10.1021/acs.bioconjchem.6b00315*
- *The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. Boudewijn E. Schaafsma MD, J. Sven D. Mieog MD, Merlijn Hutteman MSc, Joost R. van der Vorst MD, Peter J.K. Kuppen PhD, Clemens W.G.M. Lwik PhD, John V. Frangioni MD, PhD, Cornelis J.H. van de Velde MD, PhD, Alexander L. Vahrmeijer MD PhD;* ***Surg. Oncol.*** *2011;* ***104****: 323-332. https://doi.org/10.1002/jso.21943*
- *Degradation kinetics of indocyanine green in aqueous solution. Vishal Saxena, Mostafa Sadoqi, Jun Shao;* ***J. Pharm. Sci.*** *2003;* ***92****: 2090-2097. https://doi.org/10.1002/jps.10470*
- *Stability assessment of indocyanine green within dextran-coated mesocapsules by absor- bance spectros-copy. Mohammad Abbas Yaseen; Jie Yu; Michael S. Wong; Bahman Anvari;* ***Journal of Biomedical Optics*** *2007;* ***12(6)****: 064031. https://doi.org/10.1117/1.2821423*
- *Imaging proteins inside cells with fluorescent tags; G. Crivat, J. W. Taraska;* ***Trends Biotechnol*** *2012;* ***30(1)****: 8-16. https://doi.org/10.1016/j.tibtech.2011.08.002*
- *Visualizing Biochemical Activities in Living Cells through Chemistry; L. Reymond, G. Lukinavicius, K. Umezawa, D. Maurel, M. A. Brun, A. Masharina, K. Bojkowska, B. Mollwitz, A. Schena, R. Griss, K. Johnsson;* ***CHIMICA Int. J. Chem.*** *2011;* ***65(11)****: 868-871. https://doi.org/10.2533/chimia.2011.868.*
- *Cell Penetration Profiling Using the Chloroalkane Penetration Assay; L. Peraro, K. L. Deprey, M. K. Moser, Z. Zou, H. L. Ball, B. Levine, J. A. Kritzer;* ***J. Am. Chem. Soc.*** *2018;* ***140(36)****: 11360-11369. https://doi.org/10.1021/jacs.8b06144*
- *HaloTag technology: a versatile platform for biomedical applications; C. G. England, H. Luo, W. Cai;* ***Bioconjug Chem*** *2015;* ***26****: 975-86. https://doi.org/10.1021/acs.bioconjchem.5b00191*
- *HaloTag: a novel protein labeling technology for cell imaging and protein analysis; G. V. Los, L. P. Encell, M. G. McDougall, D. D. Hartzell, N. Karassina, C. Zimprich, M. G. Wood, R. Learish, R. F. Ohana, M. Urh, D. Simpson, J. Mendez, K. Zimmerman, P. Otto, G. Vidugiris, J. Zhu, A. Darzins, D. H. Klaubert, R. F. Bulleit, K. V. Wood;* ***ACS Chem Biol*** *2008;* ***3****: 373-382. https://doi.org/10.1021/cb800025k*
- *Self-labelling enzymes as universal tags for fluorescence microscopy, super-resolution microscopy and electron microscopy; V. Liss, B. Barlag, M. Nietschke, M. Hensel;* ***Scientific Reports*** *2016; 5. https://doi.org/10.1038/srep17740*
- *Snap-, CLIP- and Halo-Tag Labelling of Budding Yeast Cells; F. Stagge, G. Y. Mitronova, V. N. Belov, C. A. Wurm, S. Jakobs; PLoS ONE 8(10): e78745. https://doi.org/10.1371/journal.pone.0078745*

5.2. Specific His-Tag Acylation

Product details

RL-3010 N_3Ac-OPhOMe

4-Methoxyphenyl 2-azidoacetate

CAS-No.	2546513-31-7
Formula	$C_9H_9N_3O_3$
Mol. weight	207,19 g/mol



back to content ↑

Product details

RL-3100 Biotin-AEEA-OPhOMe



2-(2-(2-(Biotinamido)ethoxy)ethoxy)acetic acid 4-methoxyphenyl ester

CAS-No.	2546513-67-9
Formula	$C_{23}H_{33}N_3O_7S$
Mol. weight	495,59 g/mol

A methodology for highly selective N-terminal chemical acylation of expressed proteins. This 4-methoxyphenyl ester selectively adds to Gly-His-tags of proteins, while it does not react with epsilon amino functions of surface accessible lysines. Therefore, it expresses a unique possibility to label proteins regioselectively at the Gly-His-tag position, enabling a wide application for chemical biology and biopharmaceuticals (*Fig. 29*)



Fig. 29: 4-Methoxyphenyl 2-azidoacetate binds specifically to the N-terminus of the His-tag while other amino functions, e.g., from lysine side chains, remain untouched.

General Conjugation Protocol:

A 35 µM solution of GH_6-protein in 200 mM HEPES buffer at pH 7.5 is incubated with 40 equiv. of azidoacetyl 4-methoxyphenylester for 24 h at 4 °C. The formation of the mono-functionalized product can be observed by ESI-MS and can reach 70% to 90% conversion. A higher conversion rate can be achieved by the addition of two aliquots of 10 equiv. of the acylating agent in the course of the next 48 h.



Fig. 30: Imidazole rings of neighboring histidines in aHis-tag catalyze acylation of the N-terminus of glycinevia a base catalyzed mechanism.

Mechanistic studies indicate that the very high selectivity of the His-tag acylation is based on specific base catalysis, in which a His side-chain assists deprotonation during the direct acylation of the Gly α-amine (*Fig. 30*). The ester preferentially reacts with assistance from His side-chain imidazoles since they are not protonated (pK_a ~ 6.0) at the pH of the reaction, in contrast to the N-terminal α-amine (pK_a~ 7.6-8.0) and Lys side-chains (pK_a ~ 10.5). The presenceof the additional five His residues in the His-tag may serve to modulate the basicity of the imidazole nitrogen of the catalytic residue. A recent study has shown that the pK_a values of individual His side-chains in a His_6-tag span arange from 4.8-7.5

Reference:

→ *Selective N-terminal acylation of peptides and proteins with a Gly-His tag sequence; M. C. Martos-Maldonado, C. T. Hjuler, K. K. Sorensen, M. B. Thygesen, J. E. Rasmussen, K. Villadsen, S. R. Midtgaard, S. Kol, S. Schoffelen, K. J. Jensen;* ***Nat Commun*** *2018;* ***9****: 3307. https://doi.org/10.1038/s41467-018-05695-3*

5.3. Bifunctional Protein Cross-Linkage

Product details

RL-2770 BSSS

Bis(sulfosuccinimidyl) suberate sodium salt

CAS-No.	82436-77-9
Formula	$C_{16}H_{18}N_2Na_2O_{14}S_2$
Mol. weight	572,43 g/mol



This molecule (*Fig. 31*) carries amino reactive sulfo-NHS esters on both ends and is a water-soluble, homo-bi functionalprotein cross-linker (spacer length: 11.4 Å). Due to its water solubility, conjugation reactions can conveniently take place at physiological conditions. This 8-atom spacer is non-cleavable and the molecule is not cell membrane permeable. It can be used to prepare antibody-protein conjugates, for crosslinking cell surface proteins, and for covalently binding an antibody to an immobilized Protein A or Protein G resin.



Fig. 31: BSSS can be used for cross-linkage of different biomolecules.

General BSSS Cross-Linking Protocol:

1. Allow *vial* of BSSS to fully equilibrate to ambient temperature before opening to prevent condensation inside the *vial* (BSSS is moisture-sensitive).
2. Immediately before use, prepare a 50 mM solution of BSSS, by dissolving 10 mg BSSS in 350 mL of 25 mM sodium phosphate, pH 7.4 (do not use amine containing buffers for the conjugation reaction).
3. Add BSSS solution (20-fold excess cross-linker to protein) to the protein sample so that the final concentration is between 0.5 to 5 mM.
4. Allow the sample to react at room temperature for 45 minutes to 1 hour. Allow slightly longer if reaction must be done on ice (the reaction rate is only slightly slower at low temperatures).
5. Quench any unreacted BSSS with 25 mM to 60 mM Tris and allow to react for 10-15 minutes at room temperature.
6. Desalt sample to remove unreacted BSSS, i.e., by gel filtration, dialysis, etc.

back to content ↑

References:

- → *Isotope-tagged cross-linking reagents. A new tool in mass spectrometric protein interaction analysis; D. R. Muller, P. Schindler, H. Towbin, U. Wirth, H. Voshol, S. Hoving, M. O. Steinmetz;* ***Anal Chem*** *2001;* ***73****: 1927-34. https://doi.org/10.1021/ac001379a*
- → *The Golgi-associated hook3 protein is a member of a novel family of microtubule-binding proteins; J. H. Walenta, A. J. Didier, X. Liu, H. Kramer;* ***J Cell Biol*** *2001;* ***152****: 923-34. https://doi.org/10.1083/jcb.152.5.923*
- → *Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells; B. K. Law, A. Chytil, N. Dumont, E. G. Hamilton, M. E. Waltner-Law, M. E. Aakre, C. Covington, H. L. Moses;* ***Mol Cell Biol*** *2002;* ***22****: 8184-98. https://doi.org/10.1128/mcb.22.23.8184-8198.2002*
- → *Chemical cross-linking and mass spectrometry for mapping three-dimensional structures of proteins and protein complexes; A. Sinz;* ***J Mass Spectrom*** *2003;* ***38****: 1225-37. https://doi.org/10.1002/jms.559*
- → *Mapping low-resolution three-dimensional protein structures using chemical cross-linking and Fourier transform ion-cyclotron resonance mass spectrometry; G. H. Dihazi, A. Sinz;* ***Rapid Commun Mass Spectrom*** *2003;* ***17****: 2005-14. https://doi.org/10.1002/rcm.1144*
- → *Mapping the topology and determination of a low-resolution three-dimensional structure of the calmodulin-melittin complex by chemical cross-linking and high-resolution FTICRMS: direct demonstration of multiple binding modes; D. M. Schulz, C. Ihling, G. M. Clore, A. Sinz;* ***Biochemistry*** *2004;* ***43****: 4703-15. https://doi.org/10.1021/bi036149f*
- → *Selective inactivation of adrenomedullin over calcitonin gene-related peptide receptor function by the deletion of amino acids 14-20 of the mouse calcitonin-like receptor; D. Koller, L. M. Ittner, R. Muff, K. Husmann, J. A. Fischer, W. Born;* ***J Biol Chem*** *2004;* ***279****: 20387-91. https://doi.org/10.1074/jbc.M313058200*
- → *Mactinin, a fragment of cytoskeletal alpha-actinin, is a novel inducer of heat shock protein (Hsp)-90 mediated monocyte activation; S. D. Luikart, A. Panoskaltsis-Mortari, T. Hinkel, R. T. Perri, K. Gupta, T. R. Oegema, P. Gupta;* ***BMC Cell Biol*** *2009;* ***10****: 60. https://doi.org/10.1186/1471-2121-10-60*
- → *The program for processing newly synthesized histones H3.1 and H4; E. I. Campos, J. Fillingham, G. Li, H. Zheng, P. Voigt, W. H. Kuo, H. Seepany, Z. Gao, L. A. Day, J. F. Greenblatt, D. Reinberg;* ***Nat Struct Mol Biol*** *2010;* ***17****: 1343-51. https://doi.org/10.1038/nsmb.1911*
- → *Sar1 assembly regulates membrane constriction and ER export; K. R. Long, Y. Yamamoto, A. L. Baker, S. C. Watkins, C. B. Coyne, J. F. Conway, M. Aridor;* ***J Cell Biol*** *2010;* ***190****: 115-28. https://doi.org/10.1083/jcb.201004132*
- → *Mps1 directs the assembly of Cdc20 inhibitory complexes during interphase and mitosis to control M phase timing and spindle checkpoint signaling; J. Maciejowski, K. A. George, M. E. Terret, C. Zhang, K. M. Shokat, P. V. Jallepalli;* ***J Cell Biol*** *2010;* ***190****: 89-100. https://doi.org/10.1083/jcb.201001050*
- → *Protection against protein aggregation by alpha-crystallin as a mechanism of preconditioning; J. E. Ferns, C. S. Theisen, E. E. Fibuch, N. W. Seidler;* ***Neurochem Res*** *2012;* ***37****: 244-52. https://doi.org/10.1007/s11064-011-0601-4*
- → *Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis; N. Rahimi, K. Rezazadeh, J. E. Mahoney, E. Hartsough, R. D. Meyer;* ***Mol Biol Cell*** *2012;* ***23****: 1646-56. https://doi.org/10.1091/mbc.E11-11-0934*
- → *TWEAK-independent Fn14 self-association and NF-kappaB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain; S. A. Brown, E. Cheng, M. S. Williams, J. A. Winkles;* ***PLoS One*** *2013;* ***8****: e65248. https://doi.org/10.1371/journal.pone.0065248*
- → *ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia; S. Demajo, I. Uribesalgo, A. Gutierrez, C. Ballare, S. Capdevila, M. Roth, J. Zuber, J. Martin-Caballero, L. Di Croce;* ***Oncogene*** *2014;* ***33****: 5501-10. https://doi.org/10.1038/onc.2013.501*
- → *Ubiquitin Associates with the N-Terminal Domain of Nerve Growth Factor: The Role of Copper(II) Ions; V. Lanza, A. Travaglia, G. Malgieri, R. Fattorusso, G. Grasso, G. Di Natale, V. Zito, G. Arena, D. Milardi, E. Rizzarelli;* ***Chemistry*** *2016;* ***22****: 17767-17775. https://doi.org/10.1002/chem.201603650*
- → *Potentiation of Surface Stability of AMPA Receptors by Sulfhydryl Compounds: A Redox-Independent Effect by Disrupting Palmitoylation; J. Han, H. Zhang, S. Wang, J. Zhou, Y. Luo, L. H. Long, Z. L. Hu, F. Wang, J. G. Chen, P. F. Wu;* ***Neurochem Res*** *2016;* ***41****: 2890-2903. https://doi.org/10.1007/s11064-016-2006-x*

→ *Dramatic Domain Rearrangements of the Cyanobacterial Orange Carotenoid Protein upon Photoactivation; H. Liu, H. Zhang, G. S. Orf, Y. Lu, J. Jiang, J. D. King, N. R. Wolf, M. L. Gross, R. E. Blankenship;* ***Biochemistry*** *2016;* ***55****: 1003-9. https://doi.org/10.1021/acs.biochem.6b00013*

→ *Nuclear Speckle-related Protein 70 Binds to Serine/Arginine-rich Splicing Factors 1 and 2 via an Arginine/Serine-like Region and Counteracts Their Alternative Splicing Activity; C. H. Kim, Y. D. Kim, E. K. Choi, H. R. Kim, B. R. Na, S. H. Im, C. D. Jun;* ***J Biol Chem*** *2016;* ***291****: 6169-81. https://doi.org/10.1074/jbc.M115.689414*

→ *PGL germ granule assembly protein is a base-specific, single-stranded RNase; S. T. Aoki, A. M. Kershner, C. A. Bingman, M. Wickens, J. Kimble;* ***Proc Natl Acad Sci U S A*** *2016;* ***113****: 1279-84. https://doi.org/10.1073/pnas.1524400113*

5.4. Proteolysis Targeting Chimeras (PROTACs®)

Targeted protein degradation (*Fig. 32*) *via* proteolysis-targeting chimeras (PROTACs) is an emerging attempt to cure diseases caused by the irregular expression of certain disease-causing proteins. Such protein degraders act as bifunctional linkers and allow to feed the protein of interest (POI) to the cell's Ubiquitin-Proteasome system, thus, to eliminate the malexpressed proteins. These PROTACs consist of three components: one ligand with high affinity for E3 ubiquitin ligase, another one with high affinity for the protein of interest (POI) and an appropriate cross-linker joining both ligands. This linker can also be used to increase the solubility, if needed, e.g. by incorporation of PEGs. The resulting proximity of both, the recruited POI and the E3 ligase, allows the polyubiquitination of the POI by the E3 associated E2 enzyme. This leads to a labeling of the POI for degradation through the proteasome.

Mode of action:

1. A cross-linker unites the POI ligand and E3 ligase ligand = PROTAC.
2. The three-component PROTAC recruits the POI and the E2-associated E3 ligase *via* the respective ligands = Ternary complex.
3. Several Ubiquitins are added to Lys residues of the POI = Polyubiquitination.
4. The ubiquitinated POI is degraded by the proteasome.



Fig. 32: Targeted protein degradation via proteolysis-targeting chimeras.

back to content ↑

To construct a suitable PROTAC, we provide a variety of E_3 ubiquitin ligase ligands in combination with linkers of various length and an elective amino-, carboxyl-, click- or thiol-reactive end (“Partial PROTACs”).

E3-Ligase Ligands & Negative Controls

Product details

PTC1000 Pomalidomide

1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline,

CAS-No. 19171-19-8
Formula $C_{13}H_{11}N_3O_4$
Mol. weight 273,24 g/mol



PTC1010 N-Methylated pomalidomide

4-Amino-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione

CAS-No. 1352827-50-9
Formula $C_{14}H_{13}N_3O_4$
Mol. weight 287,27 g/mol



PTC1020 Lenalidomide

1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole

CAS-No. 191732-72-6
Formula $C_{13}H_{13}N_3O_3$
Mol. weight 259,26 g/mol



PTC1030 (±)-Thalidomide

(±)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione

CAS-No. 50-35-1
Formula $C_{13}H_{10}N_2O_4$
Mol. weight 258,23 g/mol



PTC1040 (S,R,S)-AHPC hydrochloride

(2S,4R)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

CAS-No. 1448189-80-7
Formula $C_{22}H_{30}N_4O_3S$*xHCl
Mol. weight 430,56 (free base) g/mol



PTC1050 (S,S,S)-AHPC hydrochloride

(2S,4S)-1-((S)-2-Amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

CAS-No.	2115897-23-7
Formula	$C_{22}H_{30}N_4O_3S$*xHCl
Mol. weight	430,56 (free base) g/mol



PTC1060 VH298

(2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

CAS-No.	2097381-85-4
Formula	$C_{27}H_{33}N_5O_4S$
Mol. weight	523,65 g/mol



PTC1070 Nimbolide

CAS-No.	25990-37-8
Formula	$C_{27}H_{30}O_7$
Mol. weight	466,52 g/mol



PTC1080 Nutlin-3

(±)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one

CAS-No.	548472-68-0
Formula	$C_{30}H_{30}Cl_2N_4O_4$
Mol. weight	581,49 g/mol



PTC1090 Nutlin-3a

(-)-4-(4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl) piperazin-2-one

CAS-No.	675576-98-4
Formula	$C_{30}H_{30}Cl_2N_4O_4$
Mol. weight	581,49 g/mol



back to content ↑

E3-Ligase Ligands & Negative Controls

Product details

PTC1100 Pomalidomide-C3-COOH

4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)butanoic acid

CAS-No.	2225940-47-4
Formula	$C_{17}H_{17}N_3O_6$
Mol. weight	359,33 g/mol



PTC1110 Pomalidomide-C6-COOH

7-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)heptanoic acid

CAS-No.	2225940-50-9
Formula	$C_{20}H_{23}N_3O_6$
Mol. weight	401,41 g/mol



PTC1120 Pomalidomide-C9-COOH

10-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindo-lin-4-yl)amino)decanoic acid

CAS-No.	2243000-24-8
Formula	$C_{23}H_{29}N_3O_6$
Mol. weight	443,5 g/mol



PTC1130 Pomalidomide-PEG2-butyl COOH

7-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindo-lin-4-yl)amino)-2-oxoethoxy)ethoxy)heptanoic acid

Formula	$C_{24}H_{29}N_3O_9$
Mol. weight	503,5 g/mol



PTC1140 Pomalidomide-PEG6-butyl COOH

1-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)-1-oxo-3,6,9,12,15,18-hexaoxapentacosan-25-oic acid

Formula	$C_{32}H_{45}N_3O_{13}$
Mol. weight	679,71 g/mol



PTC1150 Pomalidomide-PEG1-COOH

3-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)propanoic acid

CAS-No.	2139348-60-8
Formula	$C_{18}H_{19}N_3O_7$
Mol. weight	389,36 g/mol



PTC1160 Pomalidomide-PEG2-COOH

3-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)propanoic acid

CAS-No.	2140807-17-4
Formula	$C_{20}H_{23}N_3O_8$
Mol. weight	433,42 g/mol



PTC1170 Pomalidomide-PEG3-COOH

3-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoic acid

CAS-No.	2138440-82-9
Formula	$C_{22}H_{27}N_3O_9$
Mol. weight	477,46 g/mol



PTC1180 Pomalidomide-PEG4-COOH

1-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid

CAS-No.	2138440-81-8
Formula	$C_{24}H_{31}N_3O_{10}$
Mol. weight	521,52 g/mol



PTC1190 Pomalidomide-PEG5-COOH

1-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxaoctadecan-18-oic acid

CAS-No.	2139348-63-1
Formula	$C_{26}H_{35}N_3O_{11}$
Mol. weight	565,57 g/mol



PTC1200 Pomalidomide-PEG6-COOH

1-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid

CAS-No.	2225148-49-0
Formula	$C_{28}H_{39}N_3O_{12}$
Mol. weight	609,62 g/mol



back to content ↑

Product details

PTC1220 (S,R,S)-AHPC-PEG2-butyl COOH

(S,R,S)-AHPC-2-2-6-acid, 7-(2-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)heptanoic acid



Formula $C_{33}H_{48}N_4O_8S$
Mol. weight 660,82 g/mol

Carboxy Reactive Partial PROTACs

Product details

PTC1230 Pomalidomide-PEG1-NH_2 hydrochloride

2-(2-Aminoethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide hydrochloride



Formula $C_{17}H_{18}N_4O_6$*xHCl
Mol. weight 374,35 (free base) g/mol

PTC1240 Pomalidomide-PEG2-NH_2 hydrochloride

2-(2-(2-Aminoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide hydrochloride



Formula $C_{19}H_{22}N_4O_7$*xHCl
Mol. weight 418,40 (free base) g/mol

PTC1250 Pomalidomide-PEG3-NH_2 hydrochloride

2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide hydrochloride



Formula $C_{21}H_{26}N_4O_8$*xHCl
Mol. weight 462,45 (free base) g/mol

PTC1260 Pomalidomide-PEG4-NH_2 hydrochloride

14-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxatetradecanamide hydrochloride



Formula $C_{23}H_{30}N_4O_9$*xHCl
Mol. weight 506,41 (free base) g/mol

PTC1270 Pomalidomide-PEG5-NH_2 hydrochloride

17-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaheptadecanamide hydrochloride

Formula $C_{25}H_{34}N_4O_{10}$*xHCl
Mol. weight 550,56 (free base) g/mol



PTC1280 Pomalidomide-PEG6-NH_2 hydrochloride

20-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15,18-hexaoxaicosanamide hydrochloride

Formula $C_{27}H_{38}N_4O_{11}$*xHCl
Mol. weight 594,61 (free base) g/mol



PTC1290 Pomalidomide-C_6-PEG3-butyl-NH_2 hydrochloride

6-(2-(2-((6-Aminohexyl)oxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide

Formula $C_{29}H_{42}N_4O_8$*xHCl
Mol. weight 574,67 (free base) g/mol



PTC1300 Pomalidomide-PEG6-butyl-NH_2 hydrochloride

4-Amino-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin

Formula $C_{31}H_{46}N_4O_{11}$*xHCl
Mol. weight 650,72 (free base) g/mol



PTC1310 (S,R,S)-AHPC-PEG1-NH_2 hydrochloride

(2S,4R)-1-((S)-2-(2-(2-Aminoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

Formula $C_{26}H_{37}N_5O_5S$*xHCl
Mol. weight 531,67 (free base) g/mol



PTC1320 (S,R,S)-AHPC-PEG2-NH_2 hydrochloride

(2S,4R)-1-((S)-2-(2-(2-(2-Aminoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride

CAS-No. 2097973-72-1
Formula $C_{28}H_{41}N_5O_6S$*xHCl
Mol. weight 575,72 (free base) g/mol



back to content ↑

Product details

PTC1330 (S,R,S)-AHPC-PEG3-NH_2 hydrochloride

(2S,4R)-1-((S)-14-Amino-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride



CAS-No.	2097971-11-2
Formula	$C_{30}H_{45}N_5O_7S$*xHCl
Mol. weight	619,77 (free base) g/mol

PTC1340 (S,R,S)-AHPC-PEG4-NH_2 hydrochloride

(2S,4R)-1-((S)-17-Amino-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride



CAS-No.	2010159-57-4
Formula	$C_{32}H_{49}N_5O_8S$*xHCl
Mol. weight	663,83 (free base) g/mol

Click Reactive Partial PROTACs

Product details

PTC1350 (S,R,S)-AHPC-PEG5-NH_2 hydrochloride

(2S,4R)-1-((S)-20-Amino-2-(tert-butyl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride



Formula	$C_{34}H_{53}N_5O_9S$*xHCl
Mol. weight	707,88 (free base) g/mol

PTC1360 (S,R,S)-AHPC-PEG6-NH_2 hydrochloride

(2S,4R)-1-((S)-23-Amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride



Formula	$C_{36}H_{57}N_5O_{10}S$*xHCl
Mol. weight	751,93 (free base) g/mol

PTC1370 (S,R,S)-AHPC-PEG2-butyl-NH_2 hydrochloride

(2S,4R)-1-((S)-2-(2-(2-((6-Aminohexyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula	$C_{32}H_{49}N_5O_6S$*xHCl
Mol. weight	631,83 (free base) g/mol

PTC1380 (S,R,S)-AHPC-C_6-PEG3-butyl-NH_2 hydrochloride

(2S,4R)-1-((S)-22-Amino-2-(tert-butyl)-4-oxo-10,13,16-trioxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula $C_{38}H_{61}N_5O_7S$*xHCl
Mol. weight 731,99 (free base) g/mol

PTC1390 (S,R,S)-AHPC-PEG6-butyl-NH_2 hydrochloride

(2S,4R)-1-((S)-27-Amino-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azaheptacosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula $C_{40}H_{65}N_5O_{10}S$*xHCl
Mol. weight 808,04 (free base) g/mol

PTC1400 Pomalidomide-PEG1-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3-(prop-2-yn-1-yloxy)propanamide



Formula $C_{19}H_{17}N_3O_6$
Mol. weight 383,35 g/mol

PTC1410 Pomalidomide-PEG2-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3-(2-(prop-2-yn-1-yloxy)ethoxy)propanamide



Formula $C_{21}H_{21}N_3O_7$
Mol. weight 427,41 g/mol

PTC1420 Pomalidomide-PEG3-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)propanamide



Formula $C_{23}H_{25}N_3O_8$
Mol. weight 471,46 g/mol

PTC1430 Pomalidomide-PEG4-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-4,7,10,13-tetraoxahexadec-15-ynamide



Formula $C_{25}H_{29}N_3O_9$
Mol. weight 515,51 g/mol

back to content ↑

Product details

PTC1440 Pomalidomide-PEG5-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindo-lin-4-yl)-4,7,10,13,16-pentaoxanonadec-18-ynamide

Formula $C_{27}H_{33}N_3O_{10}$
Mol. weight 559,57 g/mol



PTC1450 Pomalidomide-PEG6-Alkyne

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindo-lin-4-yl)-4,7,10,13,16,19-hexaoxadocos-21-ynamide

Formula $C_{29}H_{37}N_3O_{11}$
Mol. weight 603,62 g/mol



PTC1460 (S,R,S)-AHPC-PEG1-Alkyne

(2S,4R)-1-((S)-3,3-Dimethyl-2-(3-(prop-2-yn-1-yloxy) propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthia-zol-5-yl)benzyl)pyrrolidine-2-carboxamide

Formula $C_{28}H_{36}N_4O_5S$
Mol. weight 540,67 g/mol



PTC1470 (S,R,S)-AHPC-PEG2-Alkyne

(2S,4R)-1-((S)-3,3-Dimethyl-2-(3-(2-(prop-2-yn-1-yloxy) ethoxy)propanamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Formula $C_{30}H_{40}N_4O_6S$
Mol. weight 584,73 g/mol



PTC1480 (S,R,S)-AHPC-PEG3-Alkyne

(2S,4R)-1-((S)-2-(tert-Butyl)-4-oxo-7,10,13-trioxa-3-aza-hexadec-15-ynoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

CAS-No. 2374122-30-0
Formula $C_{32}H_{44}N_4O_7S$
Mol. weight 628,78 g/mol



PTC1490 (S,R,S)-AHPC-PEG4-Alkyne

(2S,4R)-1-((S)-2-(tert-Butyl)-4-oxo-7,10,13,16-tetraoxa-3-azanonadec-18-ynoyl)-4-hydroxy-N-(4-(4-methylthia-zol-5-yl)benzyl)pyrrolidine-2-carboxamide

Formula $C_{34}H_{48}N_4O_8S$
Mol. weight 672,83 g/mol



PTC1500 (S,R,S)-AHPC-PEG5-Alkyne

(2S,4R)-1-((S)-2-(tert-Butyl)-4-oxo-7,10,13,16,19-pentaoxa-3-azadocos-21-ynoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Formula $C_{36}H_{52}N_4O_9S$
Mol. weight 716,88 g/mol



PTC1510 (S,R,S)-AHPC-PEG6-Alkyne

(2S,4R)-1-((S)-2-(tert-Butyl)-4-oxo-7,10,13,16,19,22-hexaoxa-3-azapentacos-24-ynoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide

Formula $C_{38}H_{56}N_4O_{10}S$
Mol. weight 760,94 g/mol



PTC1520 Pomalidomid- PEG1-N_3

2-(2-Azidoethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide

CAS-No. 2133360-04-8
Formula $C_{17}H_{16}N_6O_6$
Mol. weight 400,35 g/mol



PTC1530 Pomalidomid- PEG2-N_3

2-(2-(2-Azidoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide

CAS-No. 2267306-14-7
Formula $C_{19}H_{20}N_6O_7$
Mol. weight 444,4 g/mol



PTC1540 Pomalidomid- PEG3-N_3

2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide

CAS-No. 2267306-15-8
Formula $C_{21}H_{24}N_6O_8$
Mol. weight 488,45 g/mol



PTC1550 Pomalidomid-PEG2-butyl-N_3

2-(2-((6-Azidohexyl)oxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide

Formula $C_{23}H_{28}N_6O_7$
Mol. weight 500,5 g/mol



back to content ↑

Product details

PTC1560 Pomalidomid-C6-PEG3-butyl-N_3

6-(2-(2-((6-Azidohexyl)oxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide



CAS-No. 2300178-66-7
Formula $C_{29}H_{40}N_6O_8$
Mol. weight 600,66 g/mol

PTC1570 Pomalidomid-C6-PEG1-C3-PEG1-butyl-N_3

6-((5-((6-Azidohexyl)oxy)pentyl)oxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide



Formula $C_{30}H_{42}N_6O_7$
Mol. weight 598,69 g/mol

PTC1580 Pomalidomid-PEG6-butyl-N_3

4-azido-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15,18-hexaoxatetracosanamide



Formula $C_{31}H_{44}N_6O_{11}$
Mol. weight 676,71 g/mol

PTC1590 (S,R,S)-AHPC-PEG1-N_3

(2S,4R)-1-((S)-2-(2-(2-Azidoethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No. 2101200-09-1
Formula $C_{26}H_{35}N_7O_5S$
Mol. weight 557,67 g/mol

PTC1600 (S,R,S)-AHPC-PEG2-N_3

(2S,4R)-1-((S)-2-(2-(2-(2-Azidoethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No. 2010159-45-0
Formula $C_{28}H_{39}N_7O_6S$
Mol. weight 601,72 g/mol

PTC1610 (S,R,S)-AHPC-PEG3-N_3

(2S,4R)-1-((S)-14-azido-2-(tert-butyl)-4-oxo-6,9,12-trioxa-3-azatetradecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No. 1797406-80-4
Formula $C_{30}H_{43}N_7O_7S$
Mol. weight 645,77 g/mol

Thiol Reactive Partial PROTACs

Product details

PTC1620 (S,R,S)-AHPC-PEG4-N_3

(2S,4R)-1-((S)-17-Azido-2-(tert-butyl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	1797406-81-5
Formula	$C_{32}H_{47}N_7O_8S$
Mol. weight	689,82 g/mol

PTC1630 (S,R,S)-AHPC-PEG5-N_3

(2S,4R)-1-((S)-20-Azido-2-(tert-butyl)-4-oxo-6,9,12,15,18-pentaoxa-3-azaicosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula	$C_{34}H_{51}N_7O_9S$
Mol. weight	733,88 g/mol

PTC1640 (S,R,S)-AHPC-PEG6-N_3

(2S,4R)-1-((S)-23-Azido-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azatricosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	2086298-71-5
Formula	$C_{36}H_{55}N_7O_{10}S$
Mol. weight	777,93 g/mol

PTC1650 (S,R,S)-AHPC-PEG2-butyl-N_3

(2S,4R)-1-((S)-2-(2-(2-((6-Azidohexyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula	$C_{32}H_{47}N_7O_6S$
Mol. weight	657,82 g/mol

PTC1660 (S,R,S)-AHPC-C_6-PEG3-butyl-N_3

(2S,4R)-1-((S)-22-Azido-2-(tert-butyl)-4-oxo-10,13,16-trioxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	2300155-90-0
Formula	$C_{38}H_{59}N_7O_7S$
Mol. weight	757,98 g/mol

back to content ↑

Product details

PTC1670 (S,R,S)-AHPC-C_6-PEG1-C_3-PEG1-butyl-N_3

(2S,4R)-1-((S)-2-(6-((5-((6-Azidohexyl)oxy)pentyl)oxy) hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula	$C_{39}H_{61}N_7O_6S$
Mol. weight	756,01 g/mol

PTC1680 (S,R,S)-AHPC-PEG6-butyl-N_3

(2S,4R)-1-((S)-27-Azido-2-(tert-butyl)-4-oxo-6,9,12,15,18,21-hexaoxa-3-azaheptacosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



Formula	$C_{40}H_{63}N_7O_{10}S$
Mol. weight	834,03 g/mol

PTC1690 Pomalidomid-PEG2-butyl-I

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-2-(2-((6-iodohexyl)oxy)ethoxy)acetamide



CAS-No.	1835705-72-0
Formula	$C_{23}H_{28}IN_3O_7$
Mol. weight	585,39 g/mol

PTC1700 Pomalidomid-C6-PEG3-butyl-I

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6-(2-(2-((6-iodohexyl)oxy)ethoxy)ethoxy) hexanamide



CAS-No.	1835705-70-8
Formula	$C_{29}H_{40}IN_3O_8$
Mol. weight	685,55 g/mol

PTC1710 Pomalidomid-C6-PEG1-C3-PEG1-butyl-I

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-6-((5-((6-iodohexyl)oxy)pentyl)oxy)hexanamide



CAS-No.	1835705-76-4
Formula	$C_{30}H_{42}IN_3O_7$
Mol. weight	683,57 g/mol

PTC1720 Pomalidomid-PEG6-butyl-I

N-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-24-iodo-3,6,9,12,15,18-hexaoxatetracosanamide



CAS-No.	1835705-74-2
Formula	$C_{31}H_{44}IN_3O_{11}$
Mol. weight	761,6 g/mol

PTC1730 (S,R,S)-AHPC-PEG2-butyl-Cl

(2S,4R)-1-((S)-2-(2-(2-((6-Chlorohexyl)oxy)ethoxy) acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	1835705-57-1
Formula	$C_{32}H_{47}ClN_4O_6S$
Mol. weight	651,26 g/mol

PTC1740 (S,R,S)-AHPC-PEG6-butyl-Cl

(2S,4R)-1-((S)-2-(tert-Butyl)-27-chloro-4-oxo-6,9,12,15,18,21-hexaoxa-3-azaheptacosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	1835705-59-3
Formula	$C_{40}H_{63}ClN_4O_{10}S$
Mol. weight	827,47 g/mol

PTC1750 (S,R,S)-AHPC-C6-PEG3-butyl-Cl

(2S,4R)-1-((S)-2-(tert-Butyl)-22-chloro-4-oxo-10,13,16-trioxa-3-azadocosanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	1835705-55-9
Formula	$C_{38}H_{59}ClN_4O_7S$
Mol. weight	751,42 g/mol

PTC1760 (S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl-Cl

(2S,4R)-1-((S)-2-(6-((5-((6-Chlorohexyl)oxy)pentyl)oxy) hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide



CAS-No.	1835705-61-7
Formula	$C_{39}H_{61}ClN_4O_6S$
Mol. weight	749,44 g/mol

In addition to these pre-designed building blocks, we offer custom synthesis of your required ligand-linker combination (*Fig. 33*) or “complete PROTAC”. This allows to design a library of slightly different PROTACs in order to find the best combination for your application, as even small changes in ligands and cross-linkers might affect the efficiency of the formation of the ternary complex.

back to content ↑



Fig. 33: Possibilities of PROTAC design. Above displayed options for linker constructs can be conjugated to substrates of the protein of interest, in order to create the desired PROTAC®.

References:

- → *Bifunctional Molecules beyond PROTACs; S. J. Conway;* ***J. Med. Chem.*** *2020;* ***63****: 2802-2806. https://doi.org/10.1021/acs.jmedchem.0c00293*
- → *Targeted protein degradation by PROTACs; T. K. Neklesa, J. D. Winkler, C. M. Crews;* ***Pharmacol Ther*** *2017;* ***174****: 138-144. https://doi.org/10.1016/j.pharmthera.2017.02.027*
- → *Targeted Protein Degradation: from Chemical Biology to Drug Discovery; P. M. Cromm, C. M. Crews;* ***Cell Chem Biol*** *2017;* ***24****: 1181-1190. https://doi.org/10.1016/j.chembiol.2017.05.024*
- → *Targeted Protein Degradation by Small Molecules; D. P. Bondeson, C. M. Crews;* ***Annu Rev Pharmacol Toxicol*** *2017;* ***57****: 107-123. https://doi.org/10.1146/annurev-pharmtox-010715-103507*
- → *Small-Molecule PROTACS: New Approaches to Protein Degradation; M. Toure, C. M. Crews;* ***Angew Chem Int Ed*** *2016;* ***55****: 1966-73. https://doi.org/10.1002/anie.201507978*
- → *Impact of linker length on the activity of PROTACs; K. Cyrus, M. Wehenkel, E. Y. Choi, H. J. Han, H. Lee, H. Swanson, K. B. Kim;* ***Mol Biosyst*** *2011;* ***7****: 359-64. https://doi.org/10.1039/c0mb00074d*
- → *Development of potent monoclonal antibody auristatin conjugates for cancer therapy; S. O. Doronina, B. E. Toki, M. Y. Torgov, B. A. Mendelsohn, C. G. Cerveny, D. F. Chace, R. L. DeBlanc, R. P. Gearing, T. D. Bovee, C. B. Siegall, J. A. Francisco, A. F. Wahl, D. L. Meyer, P. D. Senter;* ***Nat Biotechnol*** *2003;* ***21****: 778-84. https://doi.org/10.1038/nbt832*
- → *A versatile acid-labile linker for antibody–drug conjugates; M. C. Finniss, K. S. Chu, C. J. Bowerman, J. C. Luft, Z. A. Haroon, J. M. DeSimone;* ***Med. Chem. Commun.*** *2014;* ***5****: 1355-1358. https://doi.org/10.1039/c4md00150h*
- → *Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia; P. R. Hamann, L. M. Hinman, I. Hollander, C. F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H. R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D. A. Flowers, I. Bernstein;* ***Bioconjug Chem*** *2002;* ***13****: 47-58. https://doi.org/10.1021/bc010021y*
- → *Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy; S. J. Moon, S. V. Govindan, T. M. Cardillo, C. A. D'Souza, H. J. Hansen, D. M. Goldenberg;* ***J Med Chem*** *2008;* ***51****: 6916-26. https://doi.org/10.1021/jm800719t*
- → *Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy; Y. Wang, S. Fan, D. Xiao, F. Xie, W. Li, W. Zhong, X. Zhou;* ***Cancers (Basel)*** *2019;* ***11****: 957. https://doi.org/10.3390/cancers11070957*

Please contact us for Custom Synthesis of the PROTAC® linker fragment of your choice or complete functional PROTAC®.

Notes

back to content ↑

Notes

back to content ↑

Code of Conduct

As business activity of Iris Biotech GmbH impacts people's lives and health, it must be operated in ethical and correct manner and act with integrity and responsibility. To ensure high ethical standards and fair business practices, Iris Biotech GmbH applies an integrated policy known as its Code of Conduct.

In 2001 Iris Biotech GmbH was founded just at the beginning of the Biotech movement and the first remarkable breakthrough of biotech pharma products. Although the biotech field is rather young compared to other industries we believe on long-term business, a good partnership between our business partners and Iris Biotech GmbH and a good reputation. It is our duty as well as our responsibility to maintain and to extend this over the next generations – based on the principles of an honourable and prudent tradesman which based upon the concept of honourable entrepreneurship.

This Code of Conduct has been developed following the "Voluntary Guidelines for Manufacturers of Fine Chemical Intermediates and Active Ingredients" issued by AIME (Agrochemical & Intermediates Manufacturers in Europe) and the requirements of some of our business associates.

Iris Biotech GmbH commits to hold this Code of Conduct and to include and apply its principles in the management system and the company policies.

Ethics

Iris Biotech GmbH undertakes business in an ethical manner and acts with integrity. All corruption, extortion and embezzlement are prohibited. We do not pay or accept bribes or participate in other illegal inducements in business or government relationships. We conduct our business in compliance with all applicable anti-trust laws. Employees are encouraged to report concerns or illegal activities in the workplace, without threat of reprisal, intimidation or harassment.

Labour

Iris Biotech GmbH is committed to uphold the human rights of workers and to treat them with dignity and respect. Child labour, workplace harassment, discrimination, and harsh and inhumane treatment are prohibited. Iris Biotech GmbH respects the rights of the employees to associate freely, join or not join labour unions, seek representation and join workers' councils. Employees are paid and their working timetable is established according to applicable wage and labour laws. Employees are able to communicate openly with management regarding working conditions without threat of reprisal, intimidation or harassment.

General Policies

Contracts and Secrecy Agreements are binding and the confidential information received is only used for intended purposes. Clear management and organizational structures exist to provide efficient normal working and to address problems quickly. Know-how is protected and intellectual property isrespected.

Health and Safety

Iris Biotech GmbH provides a safe and healthy working environment to the employees and protects them from overexposure to chemical and physical hazards. Products are produced, stored and shipped under the guidelines of the relevant chemical and safety legislation. Risks and emergency scenarios are identified and evaluated, and their possible impact is minimized by implementing emergency plans and written procedures. Safety information regarding hazardous materials is available to educate, train and protect workers from hazards. Preventive equipment and facilities maintenance is performed at suitable periods to reduce potential hazards. Employees are regularly trained in health and safety matters and are informed about product properties and risk classification when it is required.

Environment

Iris Biotech GmbH operates in an environmentally responsible and efficient manner, minimizing adverse impacts on the environment. Waste streams are managed to ensure a safe handling, movement, storage, recycling and reuse, before and after being generated. Systems to prevent and mitigate accidental spills and releases to the environment are in place. All required environmental permits and licenses are obtained and their operational and reporting requirements are complied with.

Production and Quality Management

A quality management system following the Good Distribution Practices (GDP rules) of Active Pharmaceutical Ingredients is established covering all the aspects of the worldwide distribution of products. Regular audits are performed to evaluate the efficiency and fulfilling of the quality system. Process controls to provide reproducible product quality are established. There are preventive maintenance procedures to ensure plant reliability and the lowest risk of failure. Staff is trained periodically about GMP and GDP rules. Procedures are established and installations are designed to avoid cross contamination. Batch and analytical records are kept for inspection and audit purposes for suitable periods according guidelines.

Research and Development

Research and development staff education is appropriate to their functional activity and they are trained to develop, optimize and scale-up the processes. Intellectual property is respected and know-how protected. Development of manufacturing processes reflects the principles of the Green Chemistry according to the American Chemical Society Green Chemistry Institute. Animal testing is not used unless alternatives are not scientifically valid or accepted by regulators. If animal testing is carried out, animals are treated so that pain and stress are minimized.

back to content ↑

Terms and Conditions of Sales

All orders placed by a buyer are accepted and all contracts are made subject to the terms which shall prevail and be effective notwithstanding any variations or additions contained in any order or other document submitted by the buyer. No modification of these terms shall be binding upon Iris Biotech GmbH unless made in writing by an authorised representative of Iris Biotech GmbH.

Placing of Orders

Every order made by the buyer shall be deemed an offer by the buyer to purchase products from Iris Biotech GmbH and will not be binding on Iris Biotech GmbH until a duly authorised representative of Iris Biotech GmbH has accepted the offer made by the buyer. Iris Biotech GmbH may accept orders from commercial, educational or government organisations, but not from private individuals and Iris Biotech GmbH reserves the right to insist on a written order and/or references from the buyer before proceeding.

There is no minimum order value. At the time of acceptance of an order Iris Biotech GmbH will either arrange prompt despatch from stock or the manufacture/acquisition of material to satisfy the order. In the event of the latter Iris Biotech GmbH will indicate an estimated delivery date. In addition to all its other rights Iris Biotech GmbH reserves the right to refuse the subsequent cancellation of the order if Iris Biotech GmbH expects to deliver theproduct on or prior to the estimated delivery date. Time shall not be of the essence in respect of delivery of the products. If Iris Biotech GmbH is unable to deliver any products by reason of any circumstances beyond its reasonable control („Force Majeure“) then the period for delivery shall be extended by the time lost due to such Force Majeure. Details of Force Majeure will be forwarded by Iris Biotech GmbH to the buyer as soon as reasonably practicable.

Prices, Quotations and Payments

Prices are subject to change. For the avoidance of doubt, the price advised by Iris Biotech GmbH at the time of the buyer placing the order shall supersede any previous price indications. The buyer must contact the local office of Iris Biotech GmbH before ordering if further information is required. Unless otherwise agreed by the buyer and Iris Biotech GmbH, the price shall be for delivery ex-works. In the event that the buyer requires delivery of the products otherwise than ex-works the buyer should contact the local office of Iris Biotech GmbH in order to detail its requirements. Iris Biotech GmbH shall, at its discretion, arrange the buyer‘s delivery requirements including, without limitation, transit insurance, the mode of transit (Iris Biotech GmbH reserves the right to vary the mode of transit if any regulations or other relevant considerations so require) and any special packaging requirements (including cylinders). For the avoidance of doubt all costs of delivery and packaging in accordance with the buyer‘s requests over and above that of delivery in standard packaging ex-works shall be for the buyer‘s account unless otherwise agreed by both parties. Incoterms 2020 shall apply. Any tax, duty or charge imposed by governmental authority or otherwise and any other applicable taxes, duties or charges shall be for the buyer‘s account. Iris Biotech GmbH may, on request and where possible, provide quotations for multiple packs or bulk quantities, and non-listed items. Irrespective of the type of request or means of response all quotations must be accepted by the buyer without condition and in writing before an order will be accepted by Iris Biotech GmbH. Unless agreed in writing on different terms, quotations are valid for 30 days from the date thereof. Payment terms are net 30 days from invoice date unless otherwise agreed in writing. Iris Biotech GmbH reserves the right to request advance payment at its discretion. For overseas transactions the buyer shall pay all the banking charges of Iris Biotech GmbH. The buyer shall not be entitled to withhold or set-off payment for the products for any reason whatsoever. Government/

Corporate Visa and MasterCard (and other such credit cards) may be accepted on approved accounts for payment of the products. Personal credit cards are not acceptable. Failure to comply with the terms of payment of Iris Biotech GmbH shall constitute default without reminder. In these circumstances Iris Biotech GmbH may (without prejudice to any other of its rights under these terms) charge interest to accrue on a daily basis at the rate of 2% per month from the date upon which payment falls due to the actual date of payment (such interest shall be paid monthly). If the buyer shall fail to fulfil the payment terms in respect of any invoice of Iris Biotech GmbH Iris Biotech GmbH may demand payment of all outstanding balances from the buyer whether due or not and/or cancel all outstanding orders and/or decline to make further deliveries or provision of services except upon receipt of cash or satisfactory securities. Until payment by the buyer in full of the price and any other monies due to Iris Biotech GmbH in respect of all other products or services supplied or agreed to be supplied by Iris Biotech GmbH to the buyer (including but without limitation any costs of delivery) the property in the products shall remain vested in Iris Biotech GmbH.

Shipping, Packaging and Returns

The buyer shall inspect goods immediately on receipt and inform Iris Biotech GmbH of any shortage or damage within five days. Quality problems must be notified within ten days of receipt. Goods must not be returned without prior written authorisation of Iris Biotech GmbH. Iris Biotech GmbH shall at its sole discretion replace the defective products (or parts thereof) free of charge or refund the price (or proportionate price) to buyer. Opened or damaged containers cannot be returned by the buyer without the written prior agreement of Iris Biotech GmbH. In the case of agreed damaged containers which cannot be so returned, the buyer assumes responsibility for the safe disposal of such containers in accordance with all applicable laws.

Product Quality, Specifications and Technical Information

Products are analysed in the Quality Control laboratories of Iris Biotech GmbH's production partners by methods and procedures which Iris Biotech GmbH considers appropriate. In the event of any dispute concerning reported discrepancies arising from the buyer's analytical results, determined by the buyer's own analytical procedures, Iris Biotech GmbH reserves the right to rely on the results of own analytical methods of Iris Biotech GmbH. Certificates of Analysis or Certificates of Conformity are available at the discretion of Iris Biotech GmbH for bulk orders but not normally for prepack orders. Iris Biotech GmbH reserves the right to make a charge for such certification. Specifications may change and reasonable variation from any value listed should not form the basis of a dispute. Any supply by Iris Biotech GmbH of bespoke or custom product for a buyer shall be to a specification agreed by both parties in writing. Technical information, provided orally, in writing, or by electronic means by or on behalf of Iris Biotech GmbH, including any descriptions, references, illustrations or diagrams in any catalogue or brochure, is provided for guidance purposes only and is subject to change.

Safety

All chemicals should be handled only by competent, suitably trained persons, familiar with laboratory procedures and potential chemical hazards. The burden of safe use of the products of Iris Biotech GmbH vests in the buyer. The buyer assumes all responsibility for warning his employees, and any persons who might reasonably be expected to come into contact with the products, of all risks to person and property in any way connected with the products and for instructing them in their safe handling and use. The buyer also assumes the responsibility for the safe disposal of all products in accordance with all applicable laws.

back to content ↑

Uses, Warranties and Liabilities

All products of Iris Biotech GmbH are intended for laboratory research purposes and unless otherwise stated on product labels, in the catalogue and product information sheet of Iris Biotech GmbH or in other literature furnished to the buyer, are not to be used for any other purposes, including but not limited to use as or as components in drugs for human or animal use, medical devices, cosmetics, food additives, household chemicals, agricultural or horticultural products or pesticides. Iris Biotech GmbH offers no warranty regarding the fitness of any product for a particular purpose and shall not be responsible for any loss or damage whatsoever arising there from. No warranty or representation is given by Iris Biotech GmbH that the products do not infringe any letters patent, trademarks, registered designs or other industrial rights. The buyer further warrants to Iris Biotech GmbH that any use of the products in the United States of America shall not result in the products becoming adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act (or such equivalent legislation in force in the buyer‘s jurisdiction) and shall not be materials which may not, under sections 404, 505 or 512 of the Act, be introduced into interstate commerce. The buyer acknowledges that, since the products of Iris Biotech GmbH are intended for research purposes, they may not be on the Toxic Substances Control Act 1976 („TSCA“) inventory. The buyer warrants that it shall ensure that the products are approved for use under the TSCA (or such other equivalent legislation in force in the buyer‘s jurisdiction), if applicable. The buyer shall be responsible for complying with any legislation or regulations governing the use of the products and their importation into the country of destination (for the avoidance of doubt to include, without limitation, the TSCA and all its amendments, all EINECS, ELINCS and NONS regulations). If any licence or consent of any government or other authority shall be required for the acquisition, carriage or use of the products by the buyer the buyer shall obtain the same at its own expense and if necessary produce evidence of the same to Iris Biotech GmbH on demand. Failure to do so shall not entitle the buyer to withhold or delay payment. Any additional expenses or charges incurred by Iris Biotech GmbH resulting from such failure shall be for the buyer‘s account. Save for death or personal injury caused by negligence of Iris Biotech GmbH, sole obligation of Iris Biotech GmbH and buyer‘s exclusive remedy with respect to the products proved to the satisfaction of Iris Biotech GmbH to be defective or products incorrectly supplied shall be to accept the return of said products to Iris Biotech GmbH for refund of the actual purchase price paid by the buyer (or proportionate part thereof), or replacement of the defective product (or part thereof) with alternative product. Iris Biotech GmbH shall have no liability to the buyer under or arising directly or indirectly out of or otherwise in connection with the supply of products by Iris Biotech GmbH to the buyer and/or their re-sale or use by the buyer or for any product, process or services of the buyer which in any way comprises the product in contract tort (including negligence or breach of statutory duty) or otherwise for pure economic loss, loss of profit, business, reputation, depletion of brand, contracts, revenues or anticipated savings or for any special indirect or consequential damage or loss of any nature except as may otherwise be expressly provided for in these terms. All implied warranties, terms and representations in respect of the products (whether implied by statute or otherwise) are excluded to the fullest extent permitted by law. The buyer shall indemnify Iris Biotech GmbH for and against any and all losses, damages and expenses, including legal fees and other costs of defending any action, that Iris Biotech GmbH may sustain or incur as a result of any act or omission by the buyer, its officers, agents or employees, its successors or assignees, its customers or all other third parties, whether direct or indirect, in connection with the use of any product. For the avoidance of doubt and in the event that Iris Biotech GmbH supplies bespoke or custom product to the buyer‘s design or specification, this indemnity shall extend to include any claim by a third party that the manufacture of the product for the buyer or the use of the product by the buyer infringes the intellectual property rights of any third party.

General

Iris Biotech GmbH shall be entitled to assign or sub-contract all or any of its rights and obligations hereunder. The buyer shall not be entitled to assign, transfer, sub-contract or otherwise delegate any of its rights or obligations hereunder. Any delay or forbearance by Iris Biotech GmbH in exercising any right or remedy under these terms shall not constitute a waiver of such right or remedy. If any provision of these terms is held by any competent authority to be invalid or unenforceable in whole or in part the validity of the other provisions of these terms and the remainder of the provision in question shall not be affected. These terms shall be governed by German Law and the German Courts shall have exclusive jurisdiction for the hearing of any dispute between the parties save in relation to enforcement where the jurisdiction of the German Courts shall be non-exclusive.

Notes

back to content ↑

Index

Product code	Product name	Page
ADC1580	Azido-cyclobutane-1,1-dicarboxamide-Ala-PAB	51
ADC1590	Azido-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP	51
ADC1480	Azido-cyclobutane-1,1-dicarboxamide-Cit-PAB	57
ADC1490	Azido-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP	57
ADC1330	Azido-PEG(4)-Val-Ala-PAB	46
ADC1340	Azido-PEG(4)-Val-Ala-PAB-PNP	46
ADC1160	Azido-PEG(4)-Val-Cit-PAB	53
ADC1170	Azido-PEG(4)-Val-Cit-PAB-PNP	54
RL-3320	Azido-SS-COOH	62
RL-3100	Biotin-AEEA-OPhOMe	93
RL-3870	Biotin-Clip	91
LS-4020	Biotin-Dde	74
LS-4000	Biotin-Dde-Tyramide	74
PEG7980	Biotin-PEG(4)-Dde-Alkyne	75
PEG8140	Biotin-PEG(4)-Dde-DBCO	75
PEG7960	Biotin-PEG(4)-Dde-N3	74
PEG7970	Biotin-PEG(4)-Dde-Picolyl-N3	75
PEG8130	Biotin-PEG(4)-Dde-Tyramide	74
PEG8110	Biotin-PEG(4)-SS-Alkyne	66
PEG8100	Biotin-PEG(4)-SS-Azide	66
PEG8090	Biotin-PEG(4)-SS-COOH	67
PEG8120	Biotin-PEG(4)-SS-DBCO	67
LS-3930	Biotin-PEG(4)-SS-Tyramide	67
RL-3860	Biotin-SNAP	90
RL-3300	Biotin-SS-COOH	66
LS-3570	Biotin-SS-Tyramide	67
PEG5385	Boc,Z-AEEEE	20
BAA4870	Boc-Aca-Aca-OH	32
RL-2810	Boc-AEDI-OH	63
BNN1170	Boc-Cystamine	61
BNN1063	Boc-Cystamine*HCl	61
BAA2180	Boc-Cystamine-Suc-OH	61
BAA1171	Boc-D-Dab(Dde)-OH	77
BAA1176	Boc-D-Dap(Dde)-OH	77
BAA5010	Boc-D-Lys(ivDde)-OH	80
BNN1016	Boc-DOOA	15
BAA1191	Boc-L-Dab(Dde)-OH	77
BAA1193	Boc-L-Dap(Dde)-OH	77
BAA1286	Boc-L-Lys(Dde)-OH*DCHA	79

Product code	Product name	Page
BAA1287	Boc-L-Lys(ivDde)-OH	80
BAA1197	Boc-L-Orn(Dde)-OH	79
PEG4960	Boc-NH-PEG(2)-N3	14
PEG7870	Boc-NH-PEG(3)-NH2	21
PEG1920	Boc-NH-PEG(4)-COOH	25
PEG7880	Boc-NH-PEG(4)-NH2	24
PEG1915	Boc-NH-PEG(4)-OH	24
RL-3560	Boc-NH-SS-Bzl-OH	64
RL-3570	Boc-NH-SS-Bzl-OpNC	65
RL-3510	Boc-NH-SS-OH	64
RL-3520	Boc-NH-SS-OpNC	64
BAA1485	Boc-O2Oc-O2Oc-OH	23
PEG8080	Boc-O2Oc-OH	16
BAA1466	Boc-O2Oc-OH*DCHA	16
RL-2190	Boc-SS-COOH	63
BNN1028	Boc-TOTA	19
ADC1040	Boc-Val-Ala-PAB	48
ADC1050	Boc-Val-Ala-PAB-PNP	48
ADC1020	Boc-Val-Cit-PAB	55
ADC1010	Boc-Val-Cit-PAB-PNP	55
PEG7860	Boc2-AEEEE	20
PEG7190	Bromoacetamido-PEG(3)-N3	21
RL-2770	BSSS	94
RL-3600	DACN(Ms)*HCl	87
RL-3610	DACN(Ms,Ns)	87
RL-2735	DACN(Tos)*HCl	87
RL-3630	DACN(Tos,Mal)	87
RL-2710	DACN(Tos,Ns)	86
RL-2725	DACN(Tos,Suc-NHS)	87
RL-2720	DACN(Tos,Suc-OH)	86
RL-2730	DACN(Tos2)	86
AAA2190	DAPOA*DCHA	86
ADC1620	DBCO-cyclobutane-1,1-dicarboxamide-Ala-PAB	52
ADC1630	DBCO-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP	52
ADC1520	DBCO-cyclobutane-1,1-dicarboxamide-Cit-PAB	58
ADC1530	DBCO-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP	58
RL-2490	DBCO-mal	37
RL-2500	DBCO-PEG(4)-mal	37
RL-2420	DBCO-PEG(4)-NH2*TFA	28

back to content ↑

Product code	Product name	Page
RL-2510	DBCO-PEG(4)-OH	28
RL-3340	DBCO-SS-COOH	62
RL-2421	DBCO-Sulfo-PEG(4)-NH2	28
DAA1003	Dde-D-Dab(Aloc)-OH	78
DAA1004	Dde-D-Dab(Fmoc)-OH	79
DAA1005	Dde-D-Dap(Aloc)-OH	78
DAA1006	Dde-D-Dap(Fmoc)-OH	78
DAA1007	Dde-D-Lys(Aloc)-OH*DCHA	80
DAA1017	Dde-D-Lys(Fmoc)-OH	81
DAA1009	Dde-L-Dab(Aloc)-OH	78
DAA1010	Dde-L-Dab(Fmoc)-OH	79
DAA1011	Dde-L-Dap(Aloc)-OH	78
DAA1012	Dde-L-Dap(Fmoc)-OH	78
DAA1013	Dde-L-Lys(Aloc)-OH*DCHA	80
DAA1014	Dde-L-Lys(Boc)-OH	80
DAA1015	Dde-L-Lys(Fmoc)-OH	80
DAA1020	Dde-L-Met-OH	81
DAA1001	Dde-L-Orn(Aloc)-OH	79
DAA1002	Dde-L-Orn(Fmoc)-OH	79
DAA1016	Dde-O2Oc-OH	16, 77
BNN1350	DETA(BHH*2HCl)	32
BNN1330	DETA(HBH)*2HCl	31
PEG2145	Dnp-NH-PEG(4)-COOH	25
PEG2150	Dnp-NH-PEG(4)-NHS	26
PEG2035	DOODA	14
BNN1340	DPTA(BHB)*HCl	32
ADC1540	DTM-C6-Val-Ala-PAB	49
ADC1550	DTM-C6-Val-Ala-PAB-PNP	50
RL-2940	Fivemethyl-Lock	7
RL-3260	Fmoc-Aca-DIM	76
RL-2800	Fmoc-AEDI-OH	63
PEG5370	Fmoc-AEEE	19
PEG5380	Fmoc-AEEEE	20
PEG1810	Fmoc-AEEP	18
RL-3270	Fmoc-AEEP-DIM	76
RL-3470	Fmoc-AEEP-DMB	76
FAA8690	Fmoc-Aeg(Dde)-OH	81
RL-3370	Fmoc-Cystamine*HCl	61
RL-3310	Fmoc-Cystamine-Suc	62
FAA1318	Fmoc-D-Dab(Dde)-OH	83
FAA1473	Fmoc-D-Dab(ivDde)-OH	83

Product code	Product name	Page
FAA1476	Fmoc-D-Dap(Dde)-OH	82
FAA1478	Fmoc-D-Dap(ivDde)-OH	82
FAA1486	Fmoc-D-Lys(Dde)-OH	84
FAA1488	Fmoc-D-Lys(ivDde)-OH	84
FAA2090	Fmoc-D-Orn(Dde)-OH	83
FAA1493	Fmoc-D-Orn(ivDde)-OH.solv.	84
FNN1007	Fmoc-DOOA*HCl	15
PEG5180	Fmoc-DOOA-DIG-OH	15
PEG4970	Fmoc-Ebes	18
FAA8815	Fmoc-L-Abu(3-Dde-amino)-OH (2S,3S)	82
FAA5560	Fmoc-L-Cys(Alloc-L-2Abu-OAll)-OH	62
FAA5550	Fmoc-L-Cys(Alloc-L-Cys-OAll)-OH	62
FAA1365	Fmoc-L-Dab(Dde)-OH	82
FAA1458	Fmoc-L-Dab(ivDde)-OH	83
FAA1462	Fmoc-L-Dap(Dde)-OH	82
FAA1464	Fmoc-L-Dap(ivDde)-OH	82
FAA1390	Fmoc-L-Lys(Dde)-OH	84
FAA1500	Fmoc-L-Lys(ivDde)-OH	84
FAA8145	Fmoc-L-Lys(N3-Aca-DIM)-OH	76
FAA8115	Fmoc-L-Lys(Pentynoyl-DIM)-OH	76
FAA1401	Fmoc-L-MeLys(Dde)-OH	84
FAA1502	Fmoc-L-Orn(Dde)-OH	83
FAA1503	Fmoc-L-Orn(ivDde)-OH	83
PEG1805	Fmoc-NH-dPEG(4)-NHNH-Boc	24
PEG4410	Fmoc-NH-dPEG™(4)-NHS	26
PEG7810	Fmoc-NH-dPEG™(4)-TFP	26
PEG4370	Fmoc-NH-PEG(3)-COOH	22
RL-3580	Fmoc-NH-SS-Bzl-OH	65
RL-3530	Fmoc-NH-SS-OH	64
RL-3540	Fmoc-NH-SS-OpNC	64
FAA1787	Fmoc-O2Oc-O2Oc-OH	23
FAA6790	Fmoc-O2Oc-O2Oc-PFP	23
FAA1435	Fmoc-O2Oc-OH	16
FAA6020	Fmoc-O2Oc-PFP	17
PEG8150	Fmoc-PEG(4)-Dde	77
FAA7190	Fmoc-Spr(oNB)-OH	8
FAA7200	Fmoc-Spr(oNv)-OH	8
RL-2200	Fmoc-SS-COOH	63
FNN1011	Fmoc-TOTA*HCl	19
FAA5730	Fmoc-TTD-DIG-OH	15
FAA1568	Fmoc-TTDS-OH	18

Product code	Product name	Page
ADC1060	Fmoc-Val-Ala-PAB	48
ADC1410	Fmoc-Val-Ala-PAB-NMeCH2CH2NMe-Boc	48
ADC1070	Fmoc-Val-Ala-PAB-PNP	48
ADC1030	Fmoc-Val-Cit-PAB	55
ADC1240	Fmoc-Val-Cit-PAB-NMeCH2CH2NMe-Boc	56
ADC1000	Fmoc-Val-Cit-PAB-PNP	55
FAA7570	Fmoc2-DAPOA	86
RL-2950	Fourmethyl-Lock	7
HAA9300	H-Aca-Aca-OH	32
PEG8060	H-O2Oc-O2Oc-O2Oc-O2Oc-OH	23
PEG2770	H-O2Oc-O2Oc-O2Oc-OH	23
PEG1221	H-O2Oc-O2Oc-OH	22
PEG2420	H-O2Oc-OH	15
PEG7940	H-O2Oc-OH*HCl	15
PEG2430	H-O2Oc-OtBu*HCl	16
PEG1375	H2N-dPEG(4)-CO-OtBu	25
PEG1370	H2N-dPEG(4)-COOH	25
PEG1335	H2N-dPEG(4)-NHNH-Boc	24
PEG1365	H2N-PEG(2)-CO-OtBu	13
PEG4980	H2N-PEG(2)-N3*TosOH	14
PEG3060	H2N-PEG(3)-N3	22
PEG1320	H2N-PEG(4)-OH	24
RL-3670	Halo-DBCO	90
RL-3700	Halo-PEG(2)-Azide	90
RL-3680	Halo-PEG(2)-NH2*HCl	91
RL-3180	Halo-PEG(2)-Suc	89
RL-3710	Halo-PEG(4)-Azide	90
RL-3690	Halo-PEG(4)-NH2*HCl	90
RL-3640	Halo-PEG(5)-azide	90
PEG1535	HO-dPEG(4)-CO-OtBu	24
PEG7220	HO-PEG(4)-TFP	25
PEG4885	HOOC-dPEG™(2)-COOH	13
PEG4875	HOOC-dPEG™(3)-COOH	21
PEG4880	HOOC-dPEG™(4)-COOH	25
PEG1970	HS-dPEG(4)-COOH	28
RL-3840	ICG-CLIP	91
RL-3830	ICG-SNAP	91
DAA1030	ivDde-D-Lys(Fmoc)-OH	81
DAA1018	ivDde-L-Dap(Fmoc)-OH	81
DAA1019	ivDde-L-Lys(Fmoc)-OH	81
PTC1020	Lenalidomide	97

Product code	Product name	Page
PEG3590	Lipoamide-dPEG™(4)-OMe	29
MAA1100	Mal-AMCHC-N-Propargylamide	41
MAA5400	Mal-AMCHC-OH	38
MAA1000	Mal-AMCHC-OSu	39
MAA1020	Mal-beta-Ala-OSu	37
ADC1390	Mal-beta-Ala-PEG(4)-Val-Ala-PAB	51
ADC1400	Mal-beta-Ala-PEG(4)-Val-Ala-PAB-PNP	51
ADC1220	Mal-beta-Ala-PEG(4)-Val-Cit-PAB	57
ADC1230	Mal-beta-Ala-PEG(4)-Val-Cit-PAB-PNP	57
RL-2640	Mal-Bu-NHS	37
RL-3400	Mal-CH2CH2-N(Me)-CH2-COOH	41
RL-3450	Mal-CH2CH2-N-(CH2-COOH)2	40
RL-2650	Mal-cHxHx-NHS	39
ADC1560	Mal-cyclobutane-1,1-dicarboxamide-Ala-PAB	52
ADC1570	Mal-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP	52
ADC1460	Mal-cyclobutane-1,1-dicarboxamide-Cit-PAB	58
ADC1470	Mal-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP	58
MAA1060	Mal-D-Dap(Boc)-OH*DCHA	38
ADC1080	Mal-Dap(Boc)-Val-Ala-PAB-PNP	50
PEG1485	mal-dPEG(3)-mal	21
RL-3000	Mal-Et-OH	36
RL-2660	Mal-Hx-NHS	38
MAA1040	Mal-L-Dap(Boc)-OH*DCHA	38
MAA1080	Mal-L-Dap(Boc)-OPfp	38
RL-3430	Mal-N-Boc-Aeg-NHS	40
RL-2780	Mal-NH2*HCl	36
PEG4870	Mal-O2Oc-OH	17
PEG1555	mal-PEG(2)-COOH	14
ADC1640	Mal-PEG(2)-DipSi-PHB-PNP	70
PEG1560	mal-PEG(2)-NHS	14
ADC1370	Mal-PEG(4)-Val-Ala-PAB	51
ADC1200	Mal-PEG(4)-Val-Cit-PAB	57
RL-2670	Mal-Pen-NHS	37
ADC1650	Mal-Pen-O-DipSi-PHB-PNP	70
RL-2680	Mal-PhBu-NHS	40
RL-2690	Mal-PrHx-NHS	38
ADC1270	MC-Val-Ala-PAB	49
ADC1280	MC-Val-Ala-PAB-PNP	49
ADC1100	MC-Val-Cit-PAB	56
ADC1110	MC-Val-Cit-PAB-PNP	56
RL-2310	MeTz-PEG(4)-COOH	29

back to content ↑

Product code	Product name	Page
RL-2340	MeTz-PEG(4)-mal	30, 37
RL-2330	MeTz-PEG(4)-NHS	30
PEG1740	Mmt-S-dPEG(4)-COOH	28
PEG2161	Mtt-NH-PEG(4)-COOH*TEA	26
PEG4650	Mtt-O2Oc-OH*DEA	17
PTC1010	N-Methylated pomalidomide	97
HAA6990	N3-Aca-Aca-OH	32
RL-2980	N3-Aca-OSu	32
PEG7950	N3-AEEA-OK	17
PEG5400	N3-AEEEA*CHA	19
HNN1090	N3-Cystamine*HCl	61
HAA2255	N3-Cystamine-Suc-OSu	61
PEG1400	N3-dPEG(4)-NHS	29
PEG4900	N3-EEEt-OH	19
AAA1960	N3-Hx-OH	33
PEG2790	N3-O2Oc-O2Oc-OH	23
PEG2780	N3-O2Oc-OH*CHA	17
PEG5390	N3-O2Oc-OtBu	17
PEG3760	N3-PEG(3)-OH	22
PEG2345	N3-PEG(4)-COOH	29
PEG5320	N3-PEG(4)-NH2	22
PEG5300	N3-PEG(4)-OH	29
RL-3280	N3-Pen-Dde	75
RL-3290	N3-Pen-Dtpp	75
AAA1970	N3-Pen-OH	33
PEG5000	N3-TFBA-O2Oc	18, 43
BNN1150	N3-TOTA	20
PEG5170	N3-TOTA-Suc	20
RL-3010	N3Ac-OPhOMe	92
PEG4120	NHS-PEG(2)-NHS	13
PEG4130	NHS-PEG(3)-NHS	21
PTC1070	Nimbolide	98
PTC1080	Nutlin-3	98
PTC1090	Nutlin-3a	98
RL-3550	OPSS-Bzl-OpNC	64
RL-3850	OPSS-Bzl-PAB-OpNC	66
RL-3500	OPSS-OpNC	63
RL-3820	OPSS-PAB-OpNC	66
PEG2230	OPSS-PEG(4)-NHS	26
RL-2920	Photo-Benzoic acid	43
RL-2930	Photo-Benzylamine*HCl	43

Product code	Product name	Page
RL-2910	Photo-Butylamine	42
RL-3410	Photo-Click-Heptanoic acid	43
RL-2900	Photo-Hexanoic acid	42
RL-2890	Photo-Pentanoic acid	42
RL-2970	Photo-Trimethyl-Lock	8
PEG5080	Phth-NO-dPEG™(4)-NHS	26
PAA1050	Poc-O2Oc-OH*DCHA	18
PTC1520	Pomalidomid- PEG1-N3	106
PTC1530	Pomalidomid- PEG2-N3	106
PTC1540	Pomalidomid- PEG3-N3	106
PTC1710	Pomalidomid-C6-PEG1-C3-PEG1-butyl-I	109
PTC1570	Pomalidomid-C6-PEG1-C3-PEG1-butyl-N3	107
PTC1700	Pomalidomid-C6-PEG3-butyl-I	109
PTC1560	Pomalidomid-C6-PEG3-butyl-N3	107
PTC1690	Pomalidomid-PEG2-butyl-I	109
PTC1550	Pomalidomid-PEG2-butyl-N3	106
PTC1720	Pomalidomid-PEG6-butyl-I	109
PTC1580	Pomalidomid-PEG6-butyl-N3	107
PTC1000	Pomalidomide	97
PTC1100	Pomalidomide-C3-COOH	99
PTC1110	Pomalidomide-C6-COOH	99
PTC1290	Pomalidomide-C6-PEG3-butyl-NH2 hydrochloride	102
PTC1120	Pomalidomide-C9-COOH	99
PTC1400	Pomalidomide-PEG1-Alkyne	104
PTC1150	Pomalidomide-PEG1-COOH	100
PTC1230	Pomalidomide-PEG1-NH2 hydrochloride	101
PTC1410	Pomalidomide-PEG2-Alkyne	104
PTC1130	Pomalidomide-PEG2-butyl COOH	99
PTC1160	Pomalidomide-PEG2-COOH	100
PTC1240	Pomalidomide-PEG2-NH2 hydrochloride	101
PTC1420	Pomalidomide-PEG3-Alkyne	104
PTC1170	Pomalidomide-PEG3-COOH	100
PTC1250	Pomalidomide-PEG3-NH2 hydrochloride	101
PTC1430	Pomalidomide-PEG4-Alkyne	104
PTC1180	Pomalidomide-PEG4-COOH	100
PTC1260	Pomalidomide-PEG4-NH2 hydrochloride	101
PTC1440	Pomalidomide-PEG5-Alkyne	105
PTC1190	Pomalidomide-PEG5-COOH	100
PTC1270	Pomalidomide-PEG5-NH2 hydrochloride	102
PTC1450	Pomalidomide-PEG6-Alkyne	105
PTC1140	Pomalidomide-PEG6-butyl COOH	99

Product code	Product name	Page
PTC1300	Pomalidomide-PEG6-butyl-NH2 hydrochloride	102
PTC1200	Pomalidomide-PEG6-COOH	100
PTC1280	Pomalidomide-PEG6-NH2 hydrochloride	102
ADC1600	Propargyl-cyclobutane-1,1-dicarboxamide-Ala-PAB	52
ADC1610	Propargyl-cyclobutane-1,1-dicarboxamide-Ala-PAB-PNP	52
ADC1500	Propargyl-cyclobutane-1,1-dicarboxamide-Cit-PAB	58
ADC1510	Propargyl-cyclobutane-1,1-dicarboxamide-Cit-PAB-PNP	58
RL-2220	Stable Disulfide Linker	63
MAA1050	Sulfo-SMCC	39
TCO1050	TCO-PEG(3)-mal	22
TCO1040	TCO-PEG(4)-COOH	27
TCO1010	TCO-PEG(4)-NHS	28
PEG7010	Trt-S-EEE	19
PEG6730	Trt-S-EEEE	21
PEG6710	Trt-S-PEG(4)-COOH*H2O	29
PEG2030	TUDA	14
LS-3960	Tyramide-SS-amine*HCl	67
LS-4010	Tyramide-SS-COOH	67
PTC1060	VH298	98
PEG1495	Z-NH-dPEG(4)-COOH	27
ZAA1186	Z-O2Oc-OH*DCHA	18
PEG1745	Z-TOTA	20

back to content ↑

Get in Contact

Iris Biotech GmbH
Adalbert-Zoellner-Str. 1
95615 Marktredwitz
Germany

+49 (0) 9231 97121-0
+49 (0) 9231 97121-99
info@iris-biotech.de
www.iris-biotech.de

Distribution Partners

The list contains the current distributors of Iris Biotech in different regions of the world. The latest list of distribution partners and contact details is available at: **www.iris-biotech.de/distribution-partner**

China:

Chengdu Yoo Technology Co., Ltd.

Japan:

BizCom Japan, Inc.

Shigematsu & Co., Ltd

Cosmo Bio Co., Ltd.

USA & Canada:

Peptide Solutions LLC

India, Bangladesh, Oman, Sri Lanka, United Arab Emirates:

Sumit Biosciences Pvt Ltd.

Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Brunei, Burma (Myanmar), Laos, Cambodia, Timor-Leste:

SciClix Pte. Ltd.

Empowering Peptide Innovation